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ABSTRACT 
Introduction:  Crohn’s  disease  is  characterised  by  an  abnormal  inflammatory  response 
possibly induced by components of enteric bacteria, in genetically susceptible individuals. 
Mutations in the NOD2 gene are strongly associated with Crohn's disease, although the 
mechanisms by which these mutations cause Crohn’s disease remain unknown. Peripheral 
blood monocytes (PBMC), a key component of the innate immune system, highly express 
NOD2, as do intestinal epithelial Paneth cells. The ligand for NOD2 is Muramyl dipeptide 
(MDP), a component of bacterial peptidoglycan. MDP has been shown to be a powerful 
priming agent for subsequent stimulation by lipopolysaccharide (LPS) in cell lines and this 
effect has been linked to NOD2. Studies of primary mononuclear cells in Crohn’s disease 
comparing the functional effects of the NOD2 mutations had not previously been reported. 
Aims: To determine the effect of inherited mutations in the NOD2 gene on the cellular 
responses  of  freshly  extracted  PBMC  to  MDP  and  other  bacterial  ligands  including 
mycobacteria. To examine the effect of MDP pre treatment ‘priming’ on PBMC responses 
to  subsequent  LPS  stimulation  in  both  normal  and  Crohn’s  disease  affected  patients 
expressing wild type and mutant NOD2 proteins. 
Methods: PBMC from healthy controls (n=12), and Crohn’s disease affected patients who 
were genotypically either wild type (n=12), heterozygous (n=11) or homozygous (n=5) for 
the  common  disease-causing  NOD2  mutations.  PBMC  were  stimulated  with  bacterial 
products  in  vitro,  with  or  without  prior  stimulation  or  ‘priming’  with  MDP.  The 
transcription of selected cytokine genes was determined by real time quantitative RT-PCR 
Results:  MDP  is  a  weak  stimulant  of  inflammatory  responses  in  PBMC  whereas  LPS 
evoked much stronger responses. Responses to MDP were particularly reduced in PBMC 
homozygous  for  the  NOD2  mutations.  Priming  with  MDP  reduced  the  inflammatory 
response of normal PBMC to subsequent LPS stimulation. In PBMC carrying two mutant 
NOD2  alleles  this  modulatory  effect  was  reversed  and  MDP  priming  caused  the 
inflammatory response to be enhanced.  
Conclusion: MDP priming significantly modulates responses of monocytes to LPS. This 
effect is altered in patients with Crohn’s disease – possibly related to mutations in the 
NOD2 gene. This modulatory effect may explain in part the pro-inflammatory consequence 
of  mutations  in  the  NOD2  gene  and  could  provide  mechanistic  understanding  of  how 
mutations in the NOD2 gene may cause Crohn’s disease.   iv 
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Chapter One 
1.0 Introduction 
Inflammatory bowel disease (IBD) is a chronic relapsing, idiopathic inflammatory disorder 
of  the  gastrointestinal  tract.  The  two  main  forms  of  IBD  -  Crohn’s  Disease  (CD)  and 
ulcerative  colitis  (UC)  have  many  similarities,  but  also  several  distinct  clinical  and 
pathological  differences.  The  diagnosis  depends  on  the  aggregate  constellation  of  the 
clinical history, physical findings, endoscopic, radiological, and histological and laboratory 
findings. These features allow a firm diagnosis to be made in the majority of cases. In 10% 
of cases where the inflammation is limited to the colon, they are indistinguishable and are 
categorised as ‘indeterminate colitis’  
 
The incidence of Crohn’s disease has increased rapidly over the last half of the 20
th century 
in  almost  all  western  countries.    The  aetiology  of  Crohn’s  disease  remains  unknown, 
although there is an accumulating body of evidence that strongly suggests that CD develops 
as a consequence of an excessive or unregulated mucosal inflammatory reaction mounted in 
response to components of intestinal microflora (Bouma 2003).  Recently epidemiological 
and linkage studies suggest that genetic factors play a significant role in determining IBD 
susceptibility. Most notable is the identification that individuals carrying mutations in the 
NOD2 gene are predisposed to develop Crohn’s disease (Hugot 2001, Ogura 2001). It is 
postulated that NOD2 proteins, which sense bacterial antigens, play a role in the protective 
immune  responses  against  pathogens  (Inohara  2005).  Nonetheless,  the  reasons  why 
individuals  with  NOD2  mutations  are  predisposed  to  develop  Crohn's  disease  remain 
unknown. 
 
In the present thesis, I will examine the effect of inherited mutations in the NOD2 gene on 
cellular responses to bacterial stimuli. 
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1.1  Crohn’s disease 
Crohn’s disease is an inflammatory disorder affecting any part of the gastrointestinal tract 
from the oropharynx to the perianal area. It is a chronic disorder that is characterised by 
alternating periods of active intestinal inflammation and resolution.  The incidence of CD 
has increased exponentially over the last 4 decades whereas no clear trend is identifiable in 
UC. The most recent measured prevalence of CD was 144 cases per 100,000 in the UK 
(Rubin 2000). Disease incidence is highest in the developed, urbanised countries. CD is 
more common in women than men and shows a bimodal age distribution with a major peak 
at 15-30 years of age, and a lesser one at 60-80 years. (Fellows 1990)  
 
The  clinical  presentation  of  Crohn's  disease  varies  and  depends  on  the  site,  extent  and 
severity of inflammation. The original description of the disease by Crohn, Ginzberg & 
Oppenheimer  in  1932  localised  the  disease  to  the  ileum  (ileitis),  however  the  same 
inflammatory process may involve any part of the gastrointestinal tract, and it preferentially 
affects the terminal ileum, followed by the caecum, peri-anal area and colon (colitis). CD is 
characterised  by  the  presence  of  segments  of  normal  bowel  between  affected  regions, 
known as ‘skip’ lesions. The intersection of linear ulcers with islands of normal mucosa can 
produce  a  classical  ‘cobblestone’  appearance.  The  histology  is  characteristic  with 
transmural dense infiltration of lymphocytes and macrophages and granulomas are present 
in  60%  of  cases.      Due  to  the  transmural  nature  of  the  inflammation,  extra  luminal 
complications  such  as  fistulae,  either  enterocutaneous  or  intestinal  fistulae  that 
communicate with other intestinal and pelvic organs may occur.  
 
The major clinical features of CD are abdominal pain, diarrhoea, anorexia, weight loss & 
fatigue.  The  complications  of  the  disease  are  often  local  resulting  from  intestinal 
inflammation and involvement of adjacent structures leading to intestinal strictures, bowel 
obstruction,  abscess  formation  and  fistula  formation  that  may  communicate  with  other 
intestinal and pelvic organs or develop into enterocutaneous fistula (Keshav 2004) 
 
In IBD, fever, malaise and weight loss may occur due to systemic inflammatory responses, 
and these symptoms are often more severe in patients with Crohn's disease. Extra-intestinal 
manifestations of Crohn's disease include arthralgia and arthritis, pyoderma gangrenosum   3 
and erythema nodosum, and iritis and uveitis. Some of these are related to the underlying 
disease activity. There is currently no curative therapy for Crohn's disease and patients 
usually require long term therapy with immunosuppressive therapy such as Azathioprine, 
Mercaptopurine or Methotrexate to reduce intestinal inflammation. Newer biological drugs 
such as anti-tumour necrosis factor (TNF) antibodies which target the general inflammatory 
cytokine TNFα, are increasingly being used but these too are limited by limited efficacy 
and toxicity.  Surgical treatment is reserved for treating the complications of CD.  
 
1.1.1  Pathogenesis of Crohn's disease 
 
 
The  aetiology  of  Crohn's  disease  remains  unknown.  However  many  investigators 
hypothesise  that  IBD  results  from  an  inappropriate  and  exaggerated  mucosal  immune 
response  to  normal  constituents  of  the  intestinal  microflora  that  is,  in  part,  genetically 
determined (Podolsky 2002, Bouma 2003). In Crohn’s disease, mucosal inflammation is 
mediated by an excessive T helper 1 (TH1)-cell response that is associated with increased 
secretion of interferon γ (IFNγ), tumour necrosis factor α (TNFα) and interleukin-12 (IL-
12) (Bouma 2003).  This contrasts with patients with UC whose mucosa is dominated by 
CD4+ lymphocytes with a typical type 2 helper T cell (TH2) phenotype, characterised by 
the production of transforming growth factor b (TGF-b), interleukin-4 (IL-4), interleukin-5 
(IL-5) and interleukin-13 (IL-13).  
The stereotypical TH1 cytokines activate macrophages which in turn produce interleukin-12 
(IL-12), interleukin-18 (IL-18) and macrophage migration inhibition factor and thus further 
stimulate TH1 in a self sustaining cycle. As importantly, activated macrophages produce a 
potent  mix  of  active  inflammatory  cytokines  including  TNFα,  interleukin-1  (IL-1)  and 
interleukin-6 (IL-6). 
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1.1.2  Murine Models of IBD 
 
An important advance in the study of IBD has been the discovery and analysis of murine 
models of intestinal inflammation which resemble IBD. From these studies Bouma (2003) 
has  proposed  seven  principles  that  are  important  in  understanding  the  pathogenesis  of 
human  IBD.  (Bouma  2003)    The  first  principle  states  that  entirely  different  genetic 
abnormalities can lead to the same clinical features of intestinal inflammation. The second 
principle states that the host genetic background determines the susceptibility to intestinal 
inflammation, even when a major genetic defect that predisposes to inflammation is present 
for example some strains of mice with IL-10 deficiency are highly susceptible to colitis 
whereas others are resistant. (Mahler 2002) 
 
Experimental colitis does not develop when mouse are kept in a germ free environment 
(Sartor  1997).  This  leads  to  the  third  principle  that  states  that  the  normal  mucosal 
microflora is required to establish and maintain the inflammatory response presumed to be 
by  providing  one  or  more  antigens  or  co  factors  that  drive  the  immune  response  in  a 
genetically  susceptible  host.  Despite  an  extensive  search  no  specific  pathogenic  micro 
organisms have been associated with any of the mouse models so far. The fourth principle 
states that experimental inflammation is due to either excessive effector T-cell function or 
deficient regulatory T-cell function. The former possibility is exemplified in mouse models 
where TNF is over produced as a result of a deletion in the AU-rich regulatory elements 
(ARE) (TNF 
ARE mice) (Kontoyiannis 1999). In human Crohn’s Disease, excessive TH1-
cell-mediated inflammation is the best characterised pathophysiologic feature of Crohn's 
disease. It is not clear however whether mucosal inflammation, may also be caused by a 
defect in regulatory T-cell function because it is not possible to measure regulatory cell 
responses with confidence in patients with Crohn’s disease.  
 
The fifth principle states that despite a wide variety of causes, intestinal inflammation is 
either mediated by excessive T helper 1 (TH1)-cell or T helper 2 (TH2)-cell responses. This 
dichotomy  between  TH1  and  TH2  inflammation  is  seen  in  human  IBD  where  the 
histopathological  features  of  Crohn’s  disease  resemble  those  of  experimental  TH1  cell 
mediated colitis, whereas those of UC are most similar to experimental TH2 cell mediated   5 
colitis and the cytokine patterns that are characteristic of these diseases are in accordance 
with these distinct mechanisms. 
 
The sixth principle states that the epithelium of the intestinal mucosa has an essential role 
in the physical separation of potentially stimulating microflora and the reactive cells of the 
mucosal immune system (Podolsky 1999, Hermiston 1995).The effect of the loss of this 
barrier function was clearly shown in mice who developed severe inflammation in areas of 
the intestine where the epithelial cell barrier was disrupted. (Hermiston 1995) 
  
Finally, the seventh principle states that mucosal inflammation can also arise due to specific 
defects  in  the  innate  immune  system  and  genetic  abnormalities  of  innate  immunity 
involving  the  function  of  antigen-presenting  cells,  macrophages,  or  natural  killer  cells. 
(Takeda 1999) In human IBD there is emerging evidence to suggest that defects in innate 
immunity may predispose patients to IBD. Wehkamp and colleagues (2004) have reported 
that expression of the antimicrobial peptides alpha defensin 5 (HD5) and 6 (HD6) is lower 
in patients with Crohn’s disease as compared to patients with ulcerative colitis. In Crohn’s 
disease, HD5 and HD6 expression is especially low in those patients carrying mutations in 
their NOD2 gene.  
 
1.2  The genetic epidemiology of Crohn's disease 
There is compelling epidemiological evidence including racial and ethnic differences in 
disease  prevalence,  and  familial  aggregation  and  twin  studies  suggesting  a  genetic 
contribution to the pathogenesis of Crohn’s disease. Among ethnic groups, in the USA, the 
Ashkenazi Jewish population has the greatest risk of developing IBD compared with non- 
Jewish  Caucasians,  with  an  incidence  rate  2-4  fold  greater  (Roth  1989).  The  lowest 
incidence and prevalence is found in Asian and African populations. (Bonen 2003) 
 
Furthermore  Crohn's  disease  is  known  to  cluster  within  families.  In  population  based 
studies it has been shown that the greatest risk factor for developing Crohn’s disease is 
having other family members with the disease. Indeed both by case control and cohort 
studies the relative risk for Crohn’s disease amongst first degree relatives is a 14 -15 fold   6 
increased risk of developing CD (Orholm 1991, Satsangi 1996). Furthermore it has been 
reported that approximately 75% of multiply affected families with IBD are concordant for 
disease type and site of disease. (Binder 1998)  This further supports the hypothesis of a 
genetic predisposition. 
 
Disease aggregation in families may, however, be due to shared genetic and environmental 
factors. Twin concordance studies therefore, provide stronger evidence to evaluate genetic 
and environmental factors in Crohn's disease. Concordance amongst monozygotic twins for 
Crohn's  disease  ranges  from  42%  to  58%,  whereas  amongst  dizygotic  twins  the 
concordance rate is not significantly different from that for all siblings - 7%. (Tysk 1988, 
Thompson 1996) 
 
Collectively these findings lend compelling support to the inference that susceptibility is 
inherited  and  furthermore  the  absence  of  simple  Mendelian  inheritance  suggests  that 
multiple gene products contribute to a person’s risk of CD.  
 
Over  the  last  two  decades  a  wide  variety  of  candidate  genes  have  been  studied  and 
substantial progress in the search for genetic determinants of IBD susceptibility has been 
made. Using genetic linkage studies and candidate gene association studies at least nine 
IBD susceptibility loci have been identified in the search for genetic determinant of IBD 
susceptibility (Hugot 1996, Satsangi 1996, Cho 1998, Duerr 1998, Ma 1999, Rioux 2000, 
Duerr 2000). These have had varying degrees of replication and statistical support. Whereas 
some loci are specific to either Crohn’s disease (IBD1 on chromosome 16) or ulcerative 
colitis  (IBD2  on  chromosome  12)  others  confer  susceptibility  to  IBD  overall  (IBD3 
chromosome 6) These findings lend support to the idea that CD and Ulcerative Colitis are 
polygenic disorders that share some but not all susceptibility loci.  (Figure 1.1) 
 
In  the  past  year  two  new  single  nuclear  polymorphisms  have  also  been  identified  and 
shown to be associated with Crohn’s Disease - IL23R and ATG16L1 (Duerr 2006 and 
Rioux 2007)  
   7 
 
 
Figure 1.1 Susceptibility loci for inflammatory bowel disease as identified on genome 
scanning Figure adapted from Gaya et al 2006 
 
 
1.2.1  IBD susceptibility loci - The IBD1 locus  
 
In 1996 Hugot and colleagues were the first to identify a gene susceptibility locus in the 
pericentromeric region of Chromosome 16 which these investigators designated as IBD1. 
Widespread  replication  and  confirmation  of  this  linkage  was  soon  obtained  including 
pooled data from 12 centres in the International IBD Genetics Consortium study, which 
provided the strongest evidence for linkage with susceptibility to Crohn’s Disease to this 
region.  (Ohmen  1996,  Brant  1998,  Cavanaugh  1998,  Curran  1998  Annese  1999,  and 
Cavanaugh  2001)  The  evidence  for  linkage  in  this  region  is  now  known  to  be  largely 
accounted for by the NOD2 gene. (See Chapter 1.4) 
  
 
 
 
   8 
1.2.2  The IBD3 locus 
 
The IBD3 locus on Chromosome 6p, encompassing the major histocompatibility complex 
has  been  consistently  implicated  for  both  Crohn’s  disease  and  Ulcerative  Colitis  in  a 
number of linkage studies (Rioux 2000). Subtle changes within or near the peptide binding 
groove  of  the  HLA  class  I  and  II  peptides  encoded  within  this  locus  lead  to  large 
interindividual differences in the capacity to respond to antigens in the acquired immune 
system. Both data from linkage and epidemiologic studies estimate the relative contribution 
of the HLA region to overall genetic risk as 10-33% for Crohn’s disease. Interestingly 
recently the linkage seen at IBD3 has been suggested to be specific to men. (Fisher 2002) 
The specific risk allele or causative gene has thus far not been established. 
 
 
1.2.3  The IBD5 locus  
 
A region of significant linkage at chromosome 5q31-q33 was identified by Rioux (2001) 
and  colleagues.  This  contributes  to  disease  susceptibility  in  patients  with  early  onset 
disease.  This  region  contains  a  number  of  candidate  genes  encoding  immunoregulatory 
cytokines IL-3, IL-4 and IL-5 that may be important in the pathogenesis of Crohn’s disease. 
More  recently  there  are  data  suggesting  that  polymorphisms  in  the  organic  cation 
transporter (OCTN) genes OCTN1 and OCTN2 represent disease-causing mutations within 
the IBD5 locus (Cho 2006). The causative role for these genes however is not yet proven.  
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1.3  Environmental factors in Crohn’s disease pathogenesis  
 
The fact that disease concordance is significantly less than 100% amongst monozygotic 
twins is the most powerful indicator supporting both a genetic and environmental factor in 
the pathogenesis of CD (Bonen 2003). Epidemiological and other evidence has identified a 
number of potentially important environmental factors. 
 
1.3.1  Smoking 
 
Of  the  potentially  relevant  environmental  factors  the  best  established  is  with  tobacco 
exposure or smoking. Smokers are more than twice as likely to develop Crohn’s disease as 
non smokers and smokers are also more likely to have ileal disease than ileocolonic or 
colonic (Loftus 2004). It is an unexplained but intriguing observation that only about 10% 
of patients with UC smoke, compared with 30% of the normal population and 40% of those 
with  Crohn's  disease  (Timmer  1998).  Indeed,  in  siblings,  who  have  a  similar  genetic 
predisposition  to  IBD,  those  who  smoke  tend  to  develop  Crohn’s  disease,  while  non-
smokers get ulcerative colitis. (Bridger 2002) Smoking in Crohn's disease increases the risk 
of relapse, the need for immunosuppressive therapy and of surgery, especially in women 
(Cottone 1994). Furthermore, the natural history of Crohn's disease in patients who stop 
smoking is significantly better than in those who continue (Cosnes 2001).  Interestingly 
there is no association between NOD2 risk allele carriage and smoking status. Multivariate 
analysis suggests that tobacco use, as well as NOD2 risk allele carriage are independent 
risk factors for developing ileal Crohn’s disease. (Brant 2007) 
 
1.3.2  Drugs 
 
Relapse of  IBD may be precipitated by  non-steroidal anti-inflammatory drugs, (Bonner 
2002), and by antibiotics, possibly secondary to adverse changes in enteric flora (Demling 
1994). The latter conclusion is supported by case-control studies in adults and children 
showing an association between the onset of Crohn's disease and previous antibiotic usage 
(Card  2004).  The  oral  contraceptive  pill  has  also  previously  been  associated   10 
epidemiologically with Crohn's disease the risk being associated with duration of usage but 
not the oestrogen content of the preparation (Boyko 1994). 
 
1.3.3  Diet 
 
Because dietary antigens are, next to bacterial antigens, the most common type of luminal 
antigen,  it  is  logical  to  surmise  that  diet  may  be  important  in  the  expression  of  IBD. 
Furthermore differences in diet may explain the differences in IBD incidence in migrant 
populations  and  across  geographic  regions.  However  despite  numerous  studies  no 
consensus has emerged. Studies examining the association between diet and disease are 
difficult to perform due to the propensity for information bias. (Loftus 2004) However the 
most consistent association noted in dietary studies has been the link between high refined 
sugar  and  Crohn’s  disease.  Other  proposed  dietary  triggers  include  particles  such  as 
titanium oxide, aluminosilicates, (Powell 2000) fluoride and cornflakes, but none has yet 
been substantiated. 
 
Patients with active Crohn's disease improve on replacement of ordinary food by a liquid 
formula diet (Fernandez-Benares 1994; Fernandez-Benares 1995; Griffiths 1995), and have 
been reported thereafter to deteriorate on introduction of specific foods (Riordan 1993).  
 
In summary although no individual foods have been identified as universally detrimental to 
patients with Crohn's disease, it is conceivable  that some foods may prove pathogenic, 
through direct adverse effects on mucosal immunity or by modifying luminal gut flora. 
 
1.3.4  Bacteria 
 
The  role  of  bacteria  in  the  pathogenesis  of  Crohn’s  disease  is  of  fundamental  and 
increasingly recognised importance. The normal human intestine is home to more than 400-
500  species  of  bacteria  and  foreign  antigens.  Bacterial  colonization  is  hindered  in  the 
stomach and proximal small intestine, due to the secretion of bile and acid and the normal 
intestinal motility. However the concentration of bacteria rises rapidly in the terminal ileum 
till in the colon it reaches 10
10 to 10 
12   bacteria/g. This antigenic load is separated from the   11 
gut associated lymphoid tissue (GALT) by only a single layer of intestinal epithelium. In 
health the mucosal immune system maintains active tolerance to commensal bacteria and 
food antigens whilst retaining the ability to respond to pathogens. In Crohn’s disease this 
active tolerance is broken down and the inflammation is propagated by the intestinal flora. 
A role for the intraluminal bacteria in disease pathogenesis is suggested by the absence of 
inflammation in various genetic models of colitis when animals are raised in germ free 
conditions. (Fiocchi 1998) Furthermore antibiotic therapies are effective and extensively 
used in the treatment of Crohn’s disease. (Hendrickson 2002) 
 
1.3.4.1    Specific Pathogenic Bacteria 
 
The literature contains many reports proposing an aetiological role for specific infectious 
agents in Crohn’s disease but thus far, despite extensive research there is no compelling 
evidence of a single causative pathogen. 
 
1.3.4.2    Mycobacterium avium subspecies paratuberculosis (MAP) 
Over 20 years ago Mycobacterium avium subspecies paratuberculosis (MAP), a cell wall-
deficient organism was first proposed as a causative agent for Crohn’s disease after being 
isolated  from  CD  tissue.  MAP  is  the  causative  agent  for  Johne’s  disease  a  chronic 
granulomatous ileitis in cattle and sheep which clinically resembles CD. 
The question has recently increased in intensity following the detection of
 the specific DNA 
insertion sequence, IS900 of MAP in 52% of patients with Crohn’s disease compared
 to 2% 
of  ulcerative  colitis  patients  and  5%  of  normal  controls  (Autschbach  2007)    Other 
arguments in favour of MAP being causative in Crohn’s disease are reports of long term 
responses to antimycobacterial
 antibiotic combinations (Gui 1997) and also cultured viable 
M.  paratuberculosis
  in  blood  samples  of  Crohn’s  disease  patients.
  (Naser  2004) 
Furthermore different groups have detected MAP in both the
 food chain
 (Millar 1996) and 
water supply (Mishina 1996) increasing the possibility of MAP being causative in human 
CD.   12 
However there are many flaws in the argument that MAP is pathogenic in CD as well as 
substantial  evidence  that  it  cannot  be  pathogenic.  Firstly  there  is  huge  variability  in 
detection of MAP by PCR and serological testing in CD patients ranging from 0-100% 
(Sartor  2005)  and  secondly  genotypes  of  Crohn’s  disease  MAP  and  bovine  MAP  are 
different (Motiwala 2003). Also importantly a cellular immune response to MAP has not 
been documented in CD patients despite increased serological responses to MAP in the 
same  patients  (Olsen  2001)  Furthermore  the  observation  that  CD  patients  respond  to 
chronic  immunosuppressive  therapies  rather  than  have  a  worsening  of  their  disease 
suggests MAP cannot be causative. Recently Selby and colleagues (Selby 2007) reported 
the results of combination antibiotic therapy for patients with Crohn’s Disease and reported 
that there was no significant difference between treatment and placebo groups after 2 years 
again suggesting that MAP does not play a significant pathogenic role in CD.  
In conclusion existing data do not compellingly implicate MAP as a causal agent in CD 
however neither does it definitively exclude the possibility. (Sartor 2005)  
Two possible options to explain the discrepant findings are that MAP infection could cause 
CD in a subset of patients who are genetically susceptible to it or that alternatively this 
relatively common dietary organism may selectively colonise the ulcerated mucosa of CD 
patients but neither initiate or perpetuate the inflammation. 
1.3.4.3    Adherent invasive Escherichia coli and Yersinia 
 
Adherent invasive Escherichia coli have also been proposed as having a causative role in 
CD. Martin (Martin 2004) identified mucosa-associated E.coli in 43% and intramucosal 
E.coli in 29 % of CD compared to 17% and 9% respectively in control patients.  Yersinia 
enterocolitica and Y. pseudotuberculosis have also been proposed in several studies as the 
cause  of  CD  after  being  demonstrated  in  Crohn’s  disease  lesions  (Lamps  2003).  
Yersiniosis clinically resembles Crohn’s disease making differentiating between these two 
conditions difficult. They both feature ileitis, ileocolitis, erythema nodosum and a reactive 
arthritis. Hugot (Hugot 2003) and colleagues proposed the ‘cold-chain hypothesis’ in 2003 
after recognizing the rise of CD mirrors the rise of refrigeration. The cold chain hypothesis 
suggests  that  psychrotrophic  bacteria  such  as  Yersinia  and  Listeria  species  which  are   13 
capable  of  growing  at  low  temperatures  contribute  to  the  disease.  This  has  yet  to  be 
substantiated. 
 
1.3.4.4    Measles 
 
The association between both measles infection and measles vaccine and the development 
of IBD has received much attention in recent years, both in the scientific and popular press. 
Two  systematic  reviews  (Robertson  2001,  Davis  2001)  however  show  no  positive 
association. 
1.3.4.5    Non-pathogenic bacteria 
 
Recently the focus of research has changed from infectious to commensal bacteria. There is 
a substantial body of evidence demonstrating that the normal enteric flora plays a key role 
in  the  development  of  CD  and  the  search  is  now  on  for  alterations  in  the  endogenous 
microflora which may be involved in initiating or perpetuating inflammation in CD. The 
most convincing data of the importance of gut flora comes from animal models. Taurog and 
colleagues (Taurog 1994) demonstrated that intestinal inflammation fails to develop where 
transgenic rats are kept in a germ free environment though once introduced to normal flora 
colitis rapidly developed. Furthermore the diversion of faecal stream from inflamed bowel 
loops  is  known  to  induce  symptomatic  improvement  in  CD  whilst  restoring  intestinal 
continuity can trigger a recurrence.(D’Haens 1998) Studies of animal models resonate with 
clinical experience. Broad spectrum antibiotics have proven efficacy and are used regularly 
in specific subgroups of patients. 
 
Furthermore changes in the normal bacterial flora have been demonstrated in CD. (Fabia 
1993, Swidsinski 2002) Fabia et al reported radically reduced concentrations of anaerobic 
bacteria and Lactobacillus in active IBD pts whilst Seksik (Seksik 2003) reported that the 
faecal microflora in patients with both active and inactive colonic Crohn’s disease differed 
from the faecal microflora in healthy controls. The two main differences they demonstrated 
were that the patients harboured significantly more enterobacteria and that 30% of their 
faecal bacteria did not belong to the usual dominant groups found in the healthy controls. 
(Seksik 2003) Other studies have demonstrated the presence of an increased number of   14 
surface-adherent  and  intra-  cellular  bacteria  in  the  colonic  epithelium  of  patients  with 
IBD.(Swidsinski  2002,  Darfeuille-Michaud  1998)    It  has  also  interestingly  been 
demonstrated that different bacteria illicit different cytokine  responses from immune or 
intestinal cells. (Borruel 2003)  
 
Furthermore recently probiotics which are live, non-pathogenic bacteria that confer health 
benefits beyond their nutritional value have been used in the experimental treatment of CD. 
Currently  the  beneficial  effect  of  probiotics  is  demonstrated  mainly  in  pouchitis  and 
ulcerative colitis though their efficacy proves the importance of the role of the gut flora. 
Gionchetti (2003) demonstrated that the probiotic VSL#3 was effective in preventing acute 
pouchitis in patients who underwent ileo-anal pouch formation in UC having previously 
reported its use in preventing relapses in chronic relapsing pouchitis. Conversely Prantera 
(2002)  demonstrated  no  benefit  from  Lactobacillus  rhamnosus  CG  in  preventing 
endoscopic  recurrence  of  CD  after  surgery.  These  observations  therefore  support  the 
importance of the role of the gut flora without allowing wide extrapolation. (Marteau 2004) 
In the future it is hopeful that identifying variations in the flora may help in developing new 
treatment strategies. 
 
Finally  the  role  of  bacteria  in  the  pathogenesis  of  CD  is  supported  by  the  finding  of 
increased  intestinal  permeability  in  patients  with  CD  (May  1993).  Increased  intestinal 
permeability has been suggested as an early predisposing factor which may precede the 
development  of  clinical  disease.  (Schmitz  1999)    Recent  data  reporting  an  association 
between  genes  important  in  mucosal  transport  and  integrity  (OCTN  &  DLG5)  further 
support this association 
1.4  Identification of the NOD2 gene 
 
In 1996, Hugot and colleagues, using genetic linkage studies, identified a gene locus on 
chromosome 16q12, named IBD1, which is specifically associated with Crohn's disease 
(Hugot 1996). In 2001, two groups of investigators working independently, identified the 
NOD2 gene within the IBD1 gene locus, and showed that mutations of the NOD2 gene 
were  strongly  associated  with  Crohn's  disease  (Hugot  2001,  Ogura  2001).  Hugot  and 
colleagues (2001) screened 235 Crohn's disease families to identify the NOD2 gene on the   15 
IBD1  locus  using  a  positional-cloning  strategy,  based  on  linkage  analysis  followed  by 
linkage disequilibrium mapping, then on pedigree disequilibrium mapping, and finally on  
extensive  sequence  analysis  of  the  best  candidate  gene.  Three  independent  associations 
with  Crohn's  disease,  a  frameshift  variant  and  two  missense  variants  of  NOD2  were 
identified by this approach. Ogura and colleagues (2001), alternatively identified the NOD2 
gene whilst investigating apoptotic proteins, and intuitively considered NOD2 a candidate 
gene on the IBD1 locus as this gene is located in the peak region of linkage on chromosome 
16. Using the transmission disequilibrium test and case-control analysis, these investigators 
identified a frameshift mutation that is associated with Crohn's disease (Ogura 2001) 
 
Exon number 
 
Protein 
 
Figure 1.2 The genomic structure of the NOD2/CARD 15 gene, showing the location of 
Crohn's disease-associated variants, and predicted protein structural domains. The 
three major coding region polymorphisms Arg702Trp (R702W), Gly908Arg (G908R), and 
Leu1007fsinsC (3020insC) are indicated. All three common variants occur together with a 
background  mutation,  Pro268Ser  (P268S).  CARD:  Caspase-recruitment  domains;  NOD: 
Nucleotide-binding domain; LRR: Leucine rich repeats.    16 
1.4.1  NOD2 Mutations associated with Crohn’s disease 
There  are  three  common  genetic  variants  of  the  NOD2  gene  that  are  associated  with 
Crohn’s  disease.  The  frameshift  mutation,  identified  by  both  Hugot  (2001)  and  Ogura 
(2001), is caused by a single cytosine base insertion in exon 11 at nucleotide position 3020 
(3020insC),  which  results  in  a  frameshift  at  the  second  nucleotide  of  codon  1007,  and 
substitutes proline for leucine in the tenth LRR, followed by a premature stop codon. Hugot 
and  colleagues  (2001)  identified  two  other  single  nucleotide  polymorphisms  (SNP), 
designated with the marker names SNP8 and SNP 12 which are associated with Crohn's 
disease.  SNP8  is  a  point  mutation,  substituting  Cytosine  for  Tryptophan,  at  nucleotide 
position  2104  and  SNP12  is  a  point  mutation,  substituting  Guanine  for  Cytosine,  at 
nucleotide  position  2722.  These  2  mutations  encode  for  amino  acid  substitutions, 
tryptophan substituted for arginine at codon 702 (Arg702Trp) and arginine substituted for 
glycine at codon 908 (Gly908Arg). These three major mutations all occur within or near the 
leucine-rich repeats (LRR)-encoding region of the gene (Figure 1.2). All three common 
variants  occur  together  with  a  background  mutation,  Pro268Ser  (serine  substituted  for 
proline at codon 268). Hugot and colleagues (2001) also described over 30 other much rarer 
amino acid polymorphisms occurring near or within the LRR-encoding region of the gene. 
 
Subsequently,  many  studies  have  consistently  shown  the  presence  of  higher  allelic 
frequencies for Arg702Trp, Gly908Arg, and Leu1007fsinsC in Caucasian Crohn's disease-
affected patients. Economou et al (Economou 2004) published a large meta analysis of 
these studies assessing NOD2 polymorphisms associations with CD and UC. Forty –two 
studies  were  included  and  the  findings  are  summarised  in  Figure  1.3a.  The  strongest 
association is found with Leu1007fsinsC although homozygous carriage of this mutation 
does not always lead to IBD. (Linde 2003) Overall, approximately 8% to 17% of Crohn’s 
disease-affected patients carry two copies of the major NOD2 risk alleles compared to less 
than 1% of the control Caucasian population. About 27% to 32% of Caucasians patients 
carry one copy of these risk alleles compared with about 20% of controls. The 3 risk alleles 
occur in the healthy population in varying frequencies. The genetic association between the 
rarer polymorphisms and Crohn's disease is difficult to ascertain due to the rare occurrence 
of these mutations. In summary heterozygous carriage of a NOD2 risk allele increases risk   17 
of  developing  CD  2-4  fold  whereas  double  dose  carriage  increases  risk  20-40  fold. 
(Cuthbert 2002, Cavanaugh 2002).  
 
 
Figure 1.3a 
Association of individual NOD2 SNPs with Crohn’s Disease expressed as odds ratios 
 
  SNP8 OR (95%CI)  SNP12 OR (95%CI)  SNP13 OR (95%CI) 
Non-Jewish Caucasians 
Jewish Caucasians 
Asians 
2.20 (1.84-2.62) 
1.74 (0.88-3.42) 
Not found 
2.99 (2.38-3.74) 
1.93 (1.23-3.00) 
Not found 
4.09 (3.23-5.18 
2.45 (1.51-3.98) 
Only found in one 
study* 
 * Guo et al, 2004. SNP13 allele frequencies: CD 3.3%, UC 1.3%, controls 0.3%, OR – 
odds ratio, (adapted from Economou et al, 2004).  
 
 
 
Figure 1.3b 
Carriage of NOD2 variant SNP and association with Crohn’s Disease phenotype  
 
Variable  OR (95%CI) 
Dose-response relationship 
Carriage of one allele 
Carriage of two alleles 
CD phenotype 
Familial vs sporadic 
Small bowel affected vs not affected 
Stricturing/stenosing vs other behaviour 
Colonic CD only vs healthy controls  
 
2.39 (2.00-2.86) 
17.1 (10.7-27.2) 
 
1.49 (1.18-1.87) 
2.53 (2.01-3.16) 
1.94 (1.61-2.34) 
1.41 (1.71-1.69) 
 
OR- odds ratio, adapted from Economou et al, 2004 
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1.4.2  Racial and geographical differences in NOD2 genotype expression 
Investigations  into  the  inheritance  of  the  three  common  disease  causing  risk  alleles 
Arg702Trp, Gly908Arg and Leu1007fsinsC in NOD2 associated with susceptibility to CD 
have demonstrated a remarkable amount of heterogeneity across ethnicities and populations 
with even regional differences across Europe. Several authors have previously commented 
on  evidence  for  a  North-South  gradient  in  CD  in  Europe  with  a  higher  incidence  in 
Northern Europe however the frequencies of the NOD2 risk alleles do not underlie this 
gradient. Arnott (2004) reported lower frequencies of the NOD2 risk alleles in Scottish, 
Irish  &  Scandinavian  CD  patients  than  in  English,  Central  Europe  or  North  American 
patients and Vind (2005) compared Danish & Portugese patients and controls and again 
found no evidence to support this hypothesis. 
Increasing  evidence  shows  the  highest  frequencies  of  the  risk  alleles  in  central  and 
Southern Europe. In a comparison of NOD2 allele frequencies in 3575 Caucasian healthy 
individuals from 16 different centres across Europe, North America and Australia Hugot 
(2007) showed the lowest frequencies of the known variants in Australian and Finland 
populations whereas Belgium and Canada had the highest frequency of the known NOD2 
risk alleles. 
In  specific  non-Caucasian  racial  populations,  the  common  NOD2  mutations  show  no 
significant contribution to CD susceptibility. A study by Inoue (2002) showed there were 
no carriers in Japanese and Korean populations for any of the 3 common NOD2 risk alleles 
seen in Caucasian populations amongst 350 CD patients or 292 controls. More recently the 
NOD2 risk alleles have also been found to be absent in the Han-Chinese population.  
Furthermore  carriage  of  the  3  major  NOD2  risk  alleles  is  considerably  lower  amongst 
African–American and Hispanic Crohn’s patients compared with Caucasian CD patients or 
controls. (Cavanaugh 2006) Little information is available from African or South American 
populations  with  the  exception  of  a  recent  report  of  low  NOD2  allele  frequencies  in 
coloured South Africans of Indian descent. (Cavanaugh 2006)  
 
Amongst Caucasians Bonen (2003) reported comparable allele frequencies of the NOD2 
frameshift mutation Leu1007fsinsC in both Jewish (7.3%) and non-Jewish (8.4%) Crohn’s   19 
patients whereas the allele frequency of G908R was significantly higher among Ashkenazi 
Jews (10.2%) compared with non–Jewish CD patients (4.3%).This association has been 
confirmed in other studies. 
In summary the 3 major risk alleles are found primarily in Caucasian CD and in some 
populations the NOD2 risk allele frequencies are high – in up to 50% of CD patients. 
However the incidence of CD in populations with high carrier frequencies of the NOD2 
risk alleles for example Belgium and Canada is remarkably similar to those with lower rates 
suggesting the presence of other genetic susceptibilities. 
 
1.4.3 NOD2 genotype and Crohn's disease phenotype 
 
Crohn's  disease,  a  complex  heterogeneous  disorder,  is  classified  all  be  it  imperfectly 
according  to  the  Vienna  classification.  The  Vienna Classification  was  developed  by  an 
international working party in 1996 and classifies patients according to there categories; 
age of diagnosis, location of disease and disease behaviour. (Appendix B) Age at diagnosis 
is divided into <40 years (A1) and over 40 years (A2) Location of disease is subdivided in 
to terminal ileum (L1), colon (L2), ileocolon (L3) and upper gastrointestinal tract (L4). 
These subgroups apply to the maximal extent of disease prior to the first surgery. Disease 
location is moderately stable in the short term but after 10 years there can be significant 
changes  (Louis  2001).  Finally  disease  behaviour  is  divided  into  inflammatory  (B1), 
stricturing (B2) and penetrating (B3). It is disease behaviour which is the most contentious 
of  the  categories  as  it  has  been  shown  that  46%  of  patients  initially  diagnosed  with 
inflammatory (B1) disease phenotype will go onto develop stricturing or penetrating (B2 or 
B3) within 10 years. (Louis 2001) Accepting these restrictions numerous investigators have 
sought  to  determine  the  association  between  NOD2  genotype  and  Crohn’s  disease 
phenotype. 
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1.4.3.1    Disease location 
Numerous studies have established that mutant NOD2 risk allele carriage is specifically 
associated  with  ileal  disease  (Ahmad  2002,  Cuthbert  2002,  Lesage  2002).  In  European 
patients, the frequency of the NOD2 risk alleles is significantly higher in patients with 
exclusive ileal disease (26.9%), intermediate in those with ileocolitis (19.7%), and lowest in 
those with colonic disease (12.7%) (Cuthbert 2002). Lesage and colleagues (2002) have 
reported that in French patients with Crohn's disease, colonic involvement is significantly 
less  common  in  individuals  carrying  two  copies  of  the  risk  NOD2  alleles  than  in 
individuals carrying wild-type alleles. 
 
This site specific association has also been confirmed in an analysis of American patients 
with Crohn's disease (Brant 2003). Using logistic regression analysis, these investigators 
determined  that  carriage  of  two  NOD2  risk  alleles,  either  homozygous  or  compound 
heterozygous was the strongest predictor of ileal disease. NOD2 mutations were associated 
with a 10-fold risk of developing ileal disease, even after adjusting for the risks associated 
with cigarette smoking and age at diagnosis.  
 
Other studies have also confirmed that the NOD2 variant alleles specifically confer risk for 
ileal  disease.  In  a  recent  meta-analysis,  Economou  and  colleagues  (2004)  assessed  the 
effects of NOD2 variants alleles on Crohn's disease phenotype in non-Jewish Caucasian 
populations,  and  showed  that  the  strongest  genetic  effect  of  NOD2  mutations  was 
predisposition to small bowel disease. This meta-analysis confirmed that the presence of a 
NOD2 risk allele does not confer any increased risk for Crohn's disease when cases with 
only colonic disease are considered. Figure 1.3b 
 
1.4.3.2  Age at diagnosis 
 
Presence of the NOD2 risk alleles is associated with an earlier age of diagnosis in Crohn's 
disease. The disorder is diagnosed on average 3-5 years earlier in European and American 
patients  who  are  homozygous  or  compound  heterozygotes  for  the  NOD2  mutations. 
(Economou 2004)   21 
1.4.3.3    Disease behaviour 
Disease behaviour is the most difficult to study, because as stated previously, it changes 
over time, and a longer duration of inflammation makes it more likely that stricturing or 
penetrating complications will develop in an individual with Crohn's disease. Given this 
caveat, some studies have shown an association between NOD2 variant allele carriage and 
both stricturing and penetrating phenotype. (Lesage 2002, Brant 2003, Heliö 2003) One 
meta-analysis of 13 studies showed that the presence of at least one high-risk variant allele 
increases the risk of stricturing disease 1.9 fold. (Economou 2004) 
 
1.4.3.4   Surgery and Infliximab 
 
Most studies have also shown that in adults the NOD2 variant haplotype does not influence 
the  need  for  surgery  independently  of  disease  location.  (Economou  2004)  However  in 
children carriage of NOD2 mutations does confer an increased risk of need for surgery. 
(Gaya  2006).  Thus  far  pharmacogenetic  studies  assessing  the  usefulness  of  NOD2 
mutations in predicting outcome of treatment with infliximab (anti TNF antibody) have 
found no association between predictive response from infliximab treatment and mutant 
NOD2 carriage. 
 
In conclusion, patients carrying the NOD2 mutations are more likely to have early onset 
disease, terminal ileal involvement, and stricturing disease, all phenotypic characteristics 
initially implicated in Crohn’s initial description of regional enteritis. (Crohn 1932) 
 
 
1.4.4    NOD2 mutations associated with other diseases 
 
Since the association between NOD2 mutations and Crohn's disease was identified, other 
diseases have been associated with mutations in NOD2. The first non-IBD association was 
with a rare disease long known to map to the pericentromeric region of chromosome 16 - 
Blau Syndrome. Blau Syndrome is an autosomal-dominant disorder characterised by skin 
rashes,  uveitis  and  arthritis  with  granulomatous  inflammation.  In  contrast  to  Crohn’s 
Disease mutations that confer susceptibility to Blau syndrome occur in the NOD encoding   22 
region of the NOD2 gene as opposed to the LRR domain linked to CD. (Miceli-Richard 
2001)  Interestingly Early Onset Sarcoid which clinically resembles Blau Syndrome has 
also been recently demonstrated to be associated with NOD2 mutations (Kanazawa 2005) 
 
The second association identified is with gastrointestinal graft-versus-host disease. Holler 
and colleagues (2004) analysed NOD2 mutations in a 169 recipients of allogeneic blood 
stem cell transplantation and their respective donors. The presence of NOD2 mutations in 
either donor or host was associated with a significantly increased frequency of intestinal 
graft-versus-host disease and mortality. Where both donor and recipient carried the NOD2 
mutations mortality was increased from 24% to 60%.  The authors speculate that the NOD2 
mutations  impair  the  microbial  response  of  the  gastrointestinal  epithelium  resulting  in 
septicaemia and multi-organ failure. 
 
There  are  reports  suggesting  an  association  between  carcinoma  and  NOD2  mutations. 
Kurzawski (2004) reported that an association between the Leu1007fsinsC mutation and 
colorectal cancer in a Polish population, and more recently there has been a suggestion that 
the NOD2 risk alleles may be involved in breast cancer in individuals with first degree 
relatives with lung cancer. (Lener 2006) These studies require further validation before an 
association can be confirmed. 
 
A number of autoimmune diseases, for example rheumatoid arthritis and systemic lupus 
erythematosus, have been shown to demonstrate linkage to the pericentromeric region of 
chromosome  16  that  includes  NOD2  and  as  a  result  various  investigators  have  tested 
specific diseases for the common NOD2 mutations (Cavanaugh 2006). Thus far published 
reports suggest that there is no association between NOD2 gene mutations and rheumatoid 
arthritis  (Steer  2003),  systemic  lupus  erythematosus  (Ferreiros-Vidal  2003),  Wegener’s 
granulomatosis  (Newman  2003),  Behcet’s  disease  (Uyar  2004)  or  sarcoidosis  (Martin 
2003) With regard to infectious diseases, no association has been identified between NOD2 
gene mutations and pulmonary tuberculosis (Stockton 2004) and periodontitis (Folwaczny 
2004, Laine 2004),  
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1.5  NOD2 Protein 
1.5.1  The structure of the NOD2 protein 
 
The  NOD2  protein,  comprising  of  1040  amino  acids,  is  composed  of  two  N-terminal 
caspase-recruitment  domains  (CARD)  (residues  28-220)  fused  to  a  centrally  located 
nucleotide  binding  domain  (NBD)  (residues  273-577)  containing  consensus  nucleotide-
binding motifs followed by 10 tandem leucine-rich repeats (LRRs) (residues 744-1020) 
(Figure  1.2).  The  frameshift  mutation  Leu1007fsinsC  encodes  for  a  truncated  NOD2 
protein containing 1007 amino acids, instead of 1040. 
 
The  NOD2  protein  is  a  member  of  a  large  family  of  intracellular  proteins  –  the  NOD 
(nucleotide-binding oligomerization domain) proteins- that are widely distributed in nature 
and includes the resistance (R) proteins in plants that are involved in plant host defence 
against pathogens. (Ogura 2001)  Thus far over 20 NOD containing proteins have been 
identified in humans, nematodes and plants (Inohara 2005). Some of these proteins are 
shown  in  Figure  1.4.  This  family  of  proteins  is  alternatively  classified  as  the 
CATERPILLER family of proteins– a family of proteins that are implicated in intracellular 
recognition of bacterial components (Inohara 2002 & Girardin 2003). CATERPILLER is an 
acronym  for  CARD,  transcription  enhancer,  R  (purine)-binding,  pyrin,  lots  of  leucine 
repeats (Ting 2005). The family also includes the protein NOD1. NOD1 is NOD2’s closest 
relative in mammals and is a ubiquitously expressed protein having a similar structure to 
NOD2 except for a single CARD domain compared to NOD2’s two. 
 
The majority of animal and plant NOD proteins are comprised of three distinct domains: an 
amino-terminal  effector  domain,  a  centrally  located  regulatory  NOD  domain,  and  a 
carboxyl-terminal  LRR  domain.  Structurally  the  NOD2  protein  consists  of  two  amino 
terminal effector domains, known as caspase-recruitment domains (CARD) which mediate 
protein-protein interactions, fused to a centrally located nucleotide binding domain (NBD) 
containing  consensus  nucleotide-binding  motifs  which  mediate  self  –  oligomerization 
required  for  activation,  followed  by  10  tandem  leucine-rich  repeats  (LRRs).  The  LRR 
domain  is  of  particular  importance  as  the  three  common  coding  region  polymorphisms   24 
Arg702Trp, Gly908Arg and Leu1007fsinsC associated with Crohn’s disease occur within 
this domain.  
 
 
 
 
Figure 1.4 The domain structure of the NOD proteins found in humans, nematodes 
and Arabidopsis (plants) share structural homology. Most NOD proteins are composed 
of variable amino-terminal effector-binding domains (EBD), a centrally located nucleotide-
binding oligomerization domain (NOD) that mediates self-oligomerization, and a carboxyl-
terminal  ligand-recognition  domain  (LRD).  The  number  of  leucine-rich  repeats  (LRRs) 
varies in NOD proteins.  Other abbreviations: CARD - caspase-recruitment domain, PYD - 
pyrin domain, BIR-baculoviral inhibitor-of-apoptosis repeat, TIR - Toll interleukin-1 receptor 
domain, Apaf-1 - apoptotic protease activating factor 1. Figure adapted from Inohara (2005)   25 
1.5.1.1    CARD domain 
 
The CARD domains of NOD2 share significant sequence similarity with CARD motifs 
found in a variety of apoptotic signalling molecules, such as CED-4 and APAF-1 (Bertin 
1999). The CARD domain is a protein fold consisting of a tightly packed, six-membered α-
helical  bundle.  The  CARD  motif  functions  as  effector  domains  that  mediate  specific 
homophilic  interactions  with  down-stream  CARD-containing  signalling  molecules.  It  is 
believed that proteins with CARD domains are centrally involved in assembling protein 
complexes that drive activation of either caspases or IκB kinase (IKK) by facilitating close 
proximity  of  the  latter  molecules  (Martin  2001).  Both  the  NOD  proteins,  NOD1  and 
NOD2,  interact  with  RICK  through  homophilic  CARD-CARD  interactions.  RICK 
associates with the γ subunit of IκB kinase (IKKγ) that complexes with IKKα and IKKβ to 
then  induce  the  degradation  of  IκB  which,  subsequently  results  in  NF-κB  activation 
(Inohara 2000). 
 
1.5.1.2    NOD domain 
 
The centrally located nucleotide oligomerization domain (NOD) of NOD2 mediates self-
oligomerization  leading  to  NF-kB  activation.  (Abraham  2006)  The  NOD  region  has 
residues at catalytic sites which are essential for binding and hydrolysis of Mg
2+-ATP or –
GTP,  and  are  predicted  to  share  common  nucleotide  binding  folds  with  ATP-binding 
cassettes  (ABC)  of  members  of  the  ABC  ATPase/GTPase  superfamily  (Inohara  2000). 
Point mutations in the phosphate chain binding site (known as P-loop) are predicted to 
result in loss-of-function of NOD2, since corresponding point mutations in NOD1 P-loop 
result in loss-of-function. (Inohara 1999) 
 
1.5.1.3    LRR domain 
 
The LRR domain of NOD2 is similar to the LRR of Toll like receptors which mediate 
recognition of pathogen-associated molecular patterns (PAMP). Each of the NOD2 LRR’s 
have structural homology to LRR’s of the plant disease resistance (R) proteins, and each   26 
LRR  contains  a  predicted  α  helix  and  β  sheet  sequence  that  is  consistent  with  the 
prototypical horseshoe-shaped structure of R protein LRR’s (Ogura 2003). The LRR’s of 
these  proteins  recognise  distinct  effector  molecules  from  pathogenic  bacteria,  and  it  is 
currently suggested that the NOD2 LRR’s perform a similar function. The NOD- and LRR-
containing  proteins,  however,  are  relatively  abundant  and  functionally  diverse  in 
mammalian  cells,  and  an  interaction  between  the  LRR’s  and  bacterial  products  in 
mammalian cells has thus far not been proven (Beutler 2001).  
 
1.5.2    NOD2 Protein Expression  
1.5.2.1    Monocytes 
The original expression studies by Ogura determined the tissue expression of NOD2 by 
northern blot analysis. They localised NOD2 expression to peripheral blood leukocytes, 
with little or no detectable expression in various other human tissues. This compared to 
NOD1  which  is  present  in  most  tissues.  They  further  fractionated  peripheral  blood 
leukocytes into its granulocytic, monocytic and lymphocytic components and established, 
that NOD2 expression was most abundant in monocytes (Ogura 2001a) Gutierrez went on 
to  demonstrate  by  quantitative  real-time  PCR  analysis  that  NOD2  was  expressed  in
 
monocytes but also granulocytes and dendritic cells and to a lesser extent
 in T lymphocytes. 
(Gutierrez 2002).  
 
 
1.5.2.2   Epithelial Cells 
Following  the  discovery  that  it  is  expressed  constitutively  in  myeloid  cells  other 
investigators  subsequently  showed  that  NOD2  mRNA  was  also  expressed  in  intestinal 
epithelial cells. (Rosenstiel 2003)  NOD2 mRNA and protein expression was upregulated in 
intestinal  epithelial  cells  and  in  primary  colonic  epithelial  cells  by  TNFα  and  γIFN. 
(Rosenstiel 2003) 
 
   27 
1.5.2.3   Paneth Cells 
 
Using in situ hybridisation, immunohistochemistry and laser capture microdissection Lala 
et al demonstrated that NOD2 mRNA and protein is expressed in Paneth cells in the small 
intestine with the greatest intensity being noted in the terminal ileum where Paneth cells are 
most  numerous.  NOD2  expression  was  increased  in  Paneth  Cells  from  patients  with 
inflammatory  bowel  disease  both  in  the  terminal  ileum  and  due  to  the  presence  of 
metaplastic Paneth cells in the colon (Lala  2003, Ogura 2003(a)) (See Section 1.6) 
 
 
1.5.3    NOD2 protein Function –PAMP recognition 
 
It was originally proposed that the NOD2 protein was an intracellular receptor for bacterial 
products, in particular LPS. This hypothesis was correlated with two important findings. 
Toll like receptors also contain LRR’s and are linked to the recognition of pathogen derived 
products, including LPS. Secondly NOD proteins have domains similar to those of plant R 
proteins which are involved in resistance to pathogens therefore the NODs were thought to 
be responsible for the intracellular discrimination of pathogen products, analogous to the 
extracellular  recognition  functions  mediated  through  the  TLR’s.  The  intracellular 
recognition of LPS by the NODs was thought to activate NFkB and other critical innate 
defence mechanisms.  
 
1.5.3.1    Initial Hypothesis of NOD2 function – Receptor for LPS 
 
Inohara and  colleagues  (2001a) initially showed that in NOD2-expressing transfectants, 
NF-κB activation increased in response to LPS stimulation and, to a lesser extent, to PGN 
stimulation (Inohara 2001a). Furthermore they suggested that the LRR motifs was essential 
for enabling the NOD2 protein to respond to LPS, which was consistent with the prevailing 
view that LPS interacts with the LRR domains of R proteins and TLR with subsequent NF-
κB  activation.  (Inohara  2001a)  Interestingly,  in  mammalian  cells  transfected  with  an 
expression plasmid encoding the mutant Leu1007fsinsC-NOD2 protein, LPS induced less 
NF-κB activation and it was therefore postulated that mutant NOD2 proteins fail to mediate   28 
cellular activation in response to LPS (Ogura 2001). Based on these findings, it was widely 
accepted at the time that NOD2 was an intracellular receptor for LPS (Hugot 2001).  
 
NOD2  was  thought  to  be  responsible  for  the  intracellular  discrimination  of  pathogens, 
analogous to the extracellular recognition functions mediated through the TLR’s.  
 
1.5.3.1  .1  Toll like Receptors 
 
Toll like receptors (TLR’s) are a family of pattern recognition receptors that sense motifs 
found  in  microbial  pathogens  called  pathogen  associated  molecular  patterns  (PAMPS). 
TLR’s  detect  microbial  infection  and  initiate  immune  defence  against  pathogens.  The 
majority  of  TLR’s  are  located  on  the  cell  surface. This  is  opposed  to  NOD2  which  is 
expressed intracellularly, within the cytoplasm. Thirteen TLR’s named simply TLR1 to 
TLR13 have been identified in humans and each has a specific well conserved ligand. The 
recognition of PAMPS by toll like receptors leads to the activation of the NF-ĸB signalling 
pathway. 
 
1.5.3.2    NOD2 recognises bacterial Muramyl dipeptide (MDP) 
 
Bonen  and  colleagues  (2003a)  using  HEK293T  transfectants,  first  showed  that 
peptidoglycan (PGN), mediated NOD2-induced cellular activation. Later, two independent 
groups  of  investigators  showed  that  a  component  of  bacterial  PGN,  called  muramyl 
dipeptide  (MDP)  is  the  minimal  component  which  induces  NOD2-mediated  cellular 
activation (Girardin 2003, Inohara 2003).  
 
Girardin and colleagues (2003) showed that purified PGN activates NF-κB in mammalian 
cells  that  were  simultaneously  transfected  with  NOD2  expression  plasmids.  They 
subsequently determined that cellular activation mediated by NOD2 was due to MDP, a 
component  of  gram-positive  and  gram-negative  bacteria.  Using  chemically  synthesised 
MDP they verified that MDP mediates NOD2-induced NF-κB activation. As MDP did not 
induce cellular activation in cells expressing NOD1, TLR1, TLR2 and TLR6, Giardin and   29 
colleagues (2003) described NOD2 as the first protein that mediates cellular activation in 
response to MDP.  
At the same time Inohara and colleagues (2003) using biochemical and functional analyses 
also went on to characterise the bacterial moiety that interacts with NOD2. Their studies 
also demonstrated & confirmed that only MDP specifically induces NOD2-mediated NF-
κB  activation.  Once  activated  by  MDP,  NOD2  activates  downstream  inflammatory 
signalling pathway through RICK. Furthermore they showed that NOD2 mutants associated 
with susceptibility to CD were deficient in their recognition of MDP and particularly those 
homozygous for the frameshift mutation. 
 
1.5.3.2.1 The structure of peptidoglycan (PGN) and muramyl dipeptide (MDP)  
 
 
Peptidoglycan  (PGN)  is  an  essential  and  unique  component  of  bacteria  that  provides 
rigidity and structure to the bacterial cell wall. Virtually all bacteria contain a layer of PGN 
but the amount, location and specific composition vary. (Mcdonald 2005) In gram positive 
bacteria the PGN layer  is a thick layer  and found in association with lipoteichoic acid 
(LTA) whereas in gram negative bacteria it is a thin layer and overlaid by a thick layer of 
Lipopolysaccharide  (LPS).  PGN  is  composed  of  carbohydrate  chains  of  β(1-4)linked, 
alternating  N-acetylglucosamine  and  N-acetylmuramic  acid  sugars  crosslinked  by  short 
peptide chains with alternating L and D amino acids. Two major types of PGN can be 
classified by the nature of the third residue of the stem peptide. In Gram negative bacteria it 
is commonly lysine whereas in Gram positive bacteria it is classically diaminopimelic acid 
(mesoDAP) however there is considerable variation. See Figure 1.5 
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Figure  1.5  The  structure  of  peptidoglycan  showing  the  muropeptides  that  are 
postulated  to  interact  with  NOD2.  Abbreviations:  LTA,  lipoteichoic  acid;  LPS, 
lipopolysaccharide; TA, teichoic acid. Figure from Girardin (2003a) 
 
 
In gram negative bacteria there is a thin layer of peptidoglycan in the periplasmic space 
(left). Cross-linking of two parallel glycan strands through stem peptides occurs at low 
frequency. This cross-linking is made by a direct link between a mesoDAP amino acid and 
the D-Alanine in position four from a peptide anchored on a parallel glycan strand. In 
gram-positive  bacteria,  peptidoglycan  represents  a  thick  structure  that  surrounds  the 
bacterial membrane (right). Glycan strands are generally cross-linked to a high degree. In 
contrast  to  gram-negative  bacteria,  the  cross-linking  requires  additional  bridging  amino 
acids,  for  example,  through  penta-glycine  bridges,  which  are  a  characteristic  of 
Staphylococcus aureus peptidoglycan (shown in the figure). NOD2 ‘senses’ two types of 
muropeptides: GM-Di (GlcNAc-MurNAc-L-Ala-D-Glu, also known as GMDP) present in 
peptidoglycans from gram-negative and gram-positive bacteria, and GM-TriLys (GlcNAc-
MurNAc-L-Ala-D-Glu-L-Lys), a muropeptide found only in peptidoglycans from gram-
positive bacteria. 
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1.5.3.3    NOD2 protein Function - Signalling pathways induced  
1.5.3.3.1   NOD2 induces NF-κ κ κ κB activation  
 
Initially  it  was  presumed  NOD2  would  be  involved  in  apoptosis  but  it  has  since  been 
established that NOD2 associates through its CARD domains with the RICK protein kinase 
leading  to  activation  of  NFκB  and  subsequent  induction  of  genes  encoding  pro-
inflammatory cytokines. Figure 1.6   
 
The  transcription  factor  nuclear  factor-κB  (NF-κB)  is  present  in  the  cytoplasm  in  an 
inactive form, bound to the inhibitory protein IκB (or inhibitor of NF-κB). Phosphorylation 
of IκB, mediated by IκB kinase (IKK) a complex of IKKα, IKKβ, and IKKγ results in 
degradation  of  IκB,  and  translocation  of  NF-κB  to  the  nucleus  where  it  induces  gene 
transcription (Li 2002). NOD2-induced NF-κB activation was inhibited in mammalian cells 
expressing mutant forms of IKKα, IKKβ, IKKγ, and IκBα which indicated that NOD2 acts 
upstream of the IKK complex. This finding was verified by expression studies (Yamaoka 
1998, Inohara 2000). 
 
Further analysis revealed that NOD2 interacts with the RICK protein through its CARD 
domain, upstream of the IKK complex, before inducing NF-κB activation (Inohara 2000). 
Firstly, NOD2-induced NF-κB activation was inhibited in cells expressing mutant RICK 
proteins. Then, the association between NOD2 and RICK proteins was proven in a series of 
transfection experiments using plasmids expressing wild-type or mutant forms of NOD2 
and RICK. The association was only evident between native RICK and wild-type or mutant 
NOD2 protein that contained both CARD domains. Similarly, native NOD2 only interacted 
with either wild-type or mutant RICK proteins containing the CARD domain. In addition, 
NOD2 did not associate with other CARD-containing proteins including Apaf-1, caspase-1 
and procaspase-9, indicating that the NOD2-RICK interaction is specific and mediated by a 
homophilic CARD-CARD interaction (Ogura 2001a). 
 
Ogura and colleagues (2001a) determined the essential motifs from the NOD2 molecule 
required for NF-κB activation by expressing variant NOD2 proteins, genetically engineered   32 
so that they lacked one or more of the major structural motifs, in HEK293T cells. These 
investigations showed that both CARD domains were essential for NF-κB activation, as 
variant proteins containing only one CARD domain, NOD or LRRs motifs could not induce 
cellular activation. In addition, these studies also suggested that the LRR motif may play a 
regulatory role, as engineered NOD2 proteins lacking the LRR motif caused more profound 
activation of NF-κB than wild type protein (Ogura 2001, Bonen  2003a).  
 
Figure  1.6  Extracellular  and  intracellular  signalling  pathways  of  microbial  host 
interactions. Toll like receptors recognise pathogen associated molecular patterns (PAMPS) and 
once  activated  recruit  the  adapter  protein  MyD88  which  is  associated  with  the  interleukin-1   33 
receptor-associated  kinase  (IRAK).  IRAK  is  then  phosphorylated  and  associates  with  TNF-
receptor-associated factor 6 (TRAF6) which leads to the phosphorylation of IκB kinase (IKK) and 
subsequent dissociation of active NFκB and IκB. The active NFκB moves into the nucleus and 
induces the transcription of various pro inflammatory genes. NOD1 and NOD2 acts intracellularly 
as receptors for PAMPS and through CARD-CARD interaction, associates with RICK to induce the 
NFκB signalling cascade. Figure adapted from Bonen & Cho 2003 
1.5.3.3.2  NOD2 interacts with the TAK1 signalling pathway  
 
There  is  emerging  evidence  that  NOD2  activation  of  NF-κB  is  also  dependant  on 
transforming  growth  factor-β-activated  kinase  1  (TAK1)  (Chen  2004).  Transforming 
growth factor (TGF)-β-activated kinase 1  (TAK1), a MAP kinase kinase enzyme is  an 
essential component of the signalling pathways of many inflammatory cytokines. TAK1 is 
required for interleukin (IL)-1, tumour necrosis factor-α, IL-18 and TGF-β- mediated NF-
κB  activation.  (Wang  2001)  Pro  inflammatory  mediators  such  as  IL1  activate  TAK1. 
Activated TAK1 phosphorylates IκB-related kinases which leads to activation of the NFκB 
pathway. 
 
In 2004 Chen and colleagues demonstrated that TAK1 interacts with NOD2 and is required 
for  NOD2  mediated  NF-κB  activation.  Chen  further  established  using  transfected 
HEK293T cells that the dominant negative form of TAK1 abolished muramyl dipeptide 
induced NF-κB activation in NOD2 expressing cells. They then went on to demonstrate 
that  in  RICK-deficient  embryonic  fibroblasts,  NOD2  inhibited  TAK1-induced  NF-κB 
activation, suggesting that NOD2 acts in a reciprocal manner, negatively regulating TAK1-
induced NF-κB activation. They further investigated the interaction between NOD2 and 
TAK1 and suggested that NOD2 interacts with TAK1 through its LRR domain to mediate 
its inhibitory effect on TAK1 induced NF-ĸB activation. Furthermore the wild-type NOD2-
LRR more effectively inhibited TAK1-induced NF-κB activation, than the mutant NOD2 
protein encoded by the 3020insC mutation. (Chen 2004).  
 
There is also evidence that TAK1 plays a key role in innate defence. In 2001 Vidal (Vidal 
2001) isolated drosophila with null mutations in the Drosophila dTAK1 gene that encoded 
dTAK1  a  homolog  of  TAK1.  These  flies  were  viable  and  fertile  but  did  not  produce   34 
antibacterial  peptides  and  were  thus  highly  susceptible  to  gram-negative  bacterial 
infections. These results suggest that TAK1 may mediate interactions between bacterial 
products, inflammatory cytokines and NOD2 thereby offering a mechanistic hypothesis of 
disease pathogenesis in NOD2-affected Crohn's disease. 
 
1.5.3.3.3  Role in apoptosis 
 
Beutler (2001) has suggested that NOD2 may play a role in Crohn's disease-pathogenesis 
through altered regulated of apoptotic pathways. There is, however, no evidence to suggest 
that  over  expression  of  NOD2  induces  apoptosis  in  cell  transfectants,  although  NOD2 
enhances apoptosis induced by caspase-9 expression in these cells (Ogura 2001a). NOD2 
and NOD1 promote activation of caspases, however, and their role in apoptosis needs to be 
evaluated under more physiological conditions including knock-out mice. Indeed, Maeda 
and colleagues (2005) have shown that, in colitis, an increase in apoptotic lamina propria 
macrophages  is  observed  in  NOD2
2939iC  mice,  which  encode  for  a  truncated  protein 
homologous to the Leu1007fsinsC protein. Thus, there remains a possibility that NOD2-
dependent apoptosis plays a role in the development of intestinal inflammation, but this 
remains to be confirmed.  
1.6  Paneth cells 
 
1.6.1  Paneth cell Structure 
 
Paneth  cells,  initially  identified  by  Joseph  Paneth  in  Vienna  in  1888  are  specialised 
epithelial  cells  located  at  the  bases  of  the  crypts  of  Lieberkühn  in  the  small  intestine. 
(Paneth 1888) There are approximately 20 cells per crypt and their exact function remains 
unknown. Paneth cells are essential components of the innate intestinal defences and have 
been proposed to play a regulatory role in intestinal inflammation (Porter 2002, Bevins 
2004). Paneth cells are distributed throughout the length of the small intestine but are most 
numerous in the terminal ileum (Porter 2002). They are not present in the normal colon. 
They are located adjacent to the stem cell zone and are characterised by the presence of 
prominent apical secretory granules. They secrete a variety of antimicrobial
 peptides after 
exposure to bacteria or bacterial products such as LPS or LTA. These include  -defensins   35 
lysozyme, and secretory
 phospholipase A2 (sPLA2), and result in increased concentrations 
of  antimicrobial  products  in  the  intestinal  lumen.  (Ayabe  2000)  These  antimicrobial 
peptides, when released into the gut lumen, are thought to provide protection to the stem 
cells  that  are  found  above  Paneth  cells  in  the  intestinal  crypt.  These  Paneth  cell 
antimicrobials may play a role in the innate immunity of the gastro-intestinal tract (Porter, 
2002) by regulating the composition and number of the intestinal microflora, thus creating 
unfavourable conditions for the growth of pathogenic bacteria. 
 
There is a link between intestinal inflammation
 and Paneth cell number. In mouse models 
of  enteric  infection,
  Paneth  cell  hyperplasia  occurs.  Furthermore  in  mouse  models  of 
ileocolitis there is Paneth cell
 metaplasia, and in inflammatory bowel disease, Paneth cell 
metaplasia
  is  seen  in  the  colon.  More  recently  in  the  context  of  intestinal  disease,  the 
finding  of  the  NOD2  protein  in  Paneth  cells  (Lala  2003,  Ogura  2003)  has  refocused 
attention on Paneth cells and its possible link to the pathogenesis of Crohn’s disease  
 
1.6.2    Paneth Cell function - antimicrobial peptides  
1.6.2.1    Alpha defensin expression 
 
Defensins are small (29-45 amino acids in length) cationic peptides that are divided in to 2 
main families, the α- and β- defensins on the basis of the disulphide bond pairing pattern. 
They are synthesised as precursor polypeptides that are post translationally processed into 
mature active peptides. In man the four neutrophil defensins (HNP1-4) were identified first, 
followed by 2 enteric α-defensins 5 (HD5) and 6 (HD6) which are Paneth cell specific 
(Elphick & Mahida 2005). HD5 and HD6 are potent antimicrobials peptides which are 
likely to confer resistance to infection by intestinal pathogens. They are the most abundant 
antimicrobial peptides found in Paneth cells (Bevins 2004). The α-defensins have a broad 
spectrum of antimicrobial
 activity against Gram positive and Gram negative bacteria, fungi 
and some enveloped viruses. They function
 by the formation of a membrane spanning pore 
that eventually leads to lysis of the cell. (Elphick & Mahida 2005) In normal and Crohn's 
disease-affected terminal ileum, expression of HD5 and HD6 is restricted to Paneth cells. 
(Cunliffe 2001) The expression of both HD-5 and HD-6 is
 increased in the colonic mucosa   36 
of inflammatory bowel disease
 patients through the presence of metaplastic Paneth cells. 
(Lawrance 2001, Fahlgreen 2003) 
 
Mice cryptdin (defensins) concentrations in intestinal crypts are thought to reach over 1000 
times their minimal bactericidal concentrations and thus are thought to create a sterile 
micro-environment to protect the stem cell compartment and also reduce bacterial 
colonisation of the mucosa (Elphick & Mahida 2005) 
1.6.2.2    Secretory phospholipase A2 Group IIA (sPLA2) expression 
 
Secretory phospholipase A2 Group IIA (sPLA2) is another antimicrobial enzyme that is a 
component  of  Paneth  cell  granules  (Nevalainen  1997).  sPLA2  has  been  shown  to  be 
released into the intestinal lumen after stimulation with bacterial products, including LPS 
(Harwig 1995). Furthermore purified murine sPLA2 has been shown to have bactericidal 
activity against Salmonella typhimurium and Listeria monocytogenes (Qu 1996). There is 
increased sPLA2 expression in inflammatory bowel disease. (Lawrance 2001) It’s mode of 
action is to bind and cleave surface phospholipids.  
1.6.2.3    Lysozyme expression 
 
Alexander Fleming first described lysozyme (LZM) in 1922. Lysozyme is an antibacterial 
enzyme  that  is  found  at  significant  concentrations in  many  human  secretions  including 
tears, breast milk, saliva and gastric and small intestinal secretions. (Elphick and Mahida, 
2005)    It  is  expressed  in  the  intestinal  tract  by  gastric  and  pyloric  glands,  duodenal 
Brunner’s glands, mononuclear cells and granulocytes but most strongly by Paneth cells. 
(Stamp 1992) Lysozyme is not expressed in the normal colon but in Ulcerative colitis there 
is  colonic  lysozyme  expression  presumed  to  be  secondary  to  metaplastic  Paneth  Cells. 
(Lawrance  2001)  There  is  no  significant  difference  in  Lysozyme  expression  in  small 
intestinal cells from patients with or without Crohn’s disease (Fahlgren 2003).  Lysozyme 
is an enzyme which cleaves the glycosidic bonds that connects N-acetyl muramic acid to N-
acetylglucosamine and which stabilises Peptidoglycan thereby resulting in bacterial lysis. 
LZM is predominantly active against Gram positive bacteria as Gram negative bacteria 
have an outer membrane which makes them relatively resistant to LZM.    37 
 
Despite its widespread expression its exact function remains unknown. Its importance in 
innate immunity however is suggested by the finding of reduced Lysozyme staining Paneth 
Cells in newborn infants with Necrotising Enterocolitis. (Coutinho 1998) Those authors 
suggest a deficiency of lysozyme, may render the intestine more susceptible to bacterial 
infection and bacterial translocation across the mucosa.  
 
1.6.2.4   Tumour necrosis factor alpha (TNFα α α α) expression 
TNFα is a potent pro-inflammatory cytokine that is postulated to play a key role in the 
pathogenesis of Crohn’s disease (Beutler 1999). TNFα is an important proinflammatory 
cytokine that is found in increased concentrations in the mucosa of patients with Crohn's 
disease  (Reinecker  1993)  and  anti-TNFα  immunotherapy  is  used  currently  as  a  highly 
successful  treatment  for  Crohn’s  Disease  (Targan  1997).  The  role  of  Paneth  cells  is 
therefore made more interesting as these cells were found to express mRNA to the pro-
inflammatory cytokine, TNF-α, in both humans and mice (Keshav 1990)  
 
1.6.3    Paneth Cells and Crohn’s disease 
 
Overall, these results suggest that the expression of Paneth cell products may be regulated 
in inflammatory disease, although the functional consequences  of this  are unknown.  In 
Crohn’s disease, Paneth cells numbers are increased and metaplastic Paneth cells are  a 
feature of Crohn's colitis. There is evidence to suggest that lysozyme and TNFα expression 
is regulated in IBD, although it is unclear if expression of these products is specifically 
regulated in Paneth cells.  
 
NOD2  is  highly  expressed  in  Paneth  cells  and  NOD2  mutations  are  associated  with 
terminal ileal disease. Studies in humans and mice have shown that normal NOD2 function 
is required for optimal defensin expression and therefore impaired defensin expression and 
regulation  may  be  key  features  of  Crohn’s  disease  pathophysiology.  (See  later  1.7.1) 
However  the  degree  to  which  altered  defensin  regulation  alone  can  account  for  the 
development of Crohn’s disease is as yet unclear as spontaneous intestinal disease does not 
develop in the matrilysin knockout
 mice (Matrilysin is a protease which cleaves and thus   38 
activates α defensins in mice) Furthermore Mori-Akiyama (2007) and colleagues recently 
developed the SOX 9 knock out mice which have no functioning Paneth cells and these 
mice were also outwardly normal, of the same weight as healthy controls and fertile. They 
also did not develop spontaneous intestinal disease. 
 
1.7  Effect of Crohn’s Disease associated NOD2 mutations  
 
There is considerable  current interest into the  mechanism whereby an abnormal NOD2 
protein leads to Crohn’s disease. Possible mechanisms involve a defective recognition of 
bacterial products by NOD2 in Paneth cells leading to a dysregulated Paneth cell mediated 
bacterial  response  and  abnormal  microbial  colonisation  of  the  small  bowel  which  may 
provoke chronic inflammation via adaptive immune mechanisms.  
 
1.7.1  Effect of Crohn’s Disease associated NOD2 mutations on Paneth Cell Function 
The  functional  importance  of  defensins  has  been  illustrated  recently  in  a  number  of 
experiments in both mouse and human models. NOD2 deficient mice generated in two 
independent laboratory are outwardly healthy and do not develop histological evidence of 
inflammation after 6 months observation (Kobayashi 2005, Pauleau 2003). However when 
challenged  with  intragastric  Listeria  monocytogenes  the  NOD
-/-  mice  had  greater 
susceptibility to infection as shown by significantly greater numbers of bacteria recovered 
from the liver and spleen compared to wild type controls. Interestingly when challenged 
with  Listeria  monocytogenes  intraperitoneally  or  intravenously  there  was  no  difference 
between  the  NOD2  -/-  mice  and  wild  type  controls.  Furthermore  NOD2  -/-  mice  were 
found to have reduced Paneth cell expression of α-defensins cryptidin 4 and cryptidin 10 
and  this  was  further  reduced  after  intragastric  infection  with  Listeria  monocytogenes 
(Kobayashi 2005). This suggests that a functioning NOD2 plays a key role in mediating 
protection of the intestinal mucosa against bacterial infection possibly by mediating optimal 
defensin response. 
In a further experiment using transgenic mice the functional importance of α- defensins was 
again demonstrated. In transgenic mice which expressed human HD-5 in intestinal Paneth 
cells  Salzmann  and  colleagues  demonstrated  increased  protection
  against  Salmonella   39 
typhimurium. (Salzmann 2003) After lethal oral Salmonella typhimurium challenge there 
was a reduction in the bacterial burden in the intestinal lumen and faeces, reduced bacterial 
translocation  to  the  spleen  and  higher  survival  rates  in  the  HD5  transgenic  mice. 
Interestingly  however  HD5  transgenic  mice  did  not  have  a  survival  advantage  when 
injected intraperitoneally with Salmonella typhimurium, indicating that the effect of HD5 is 
again mediated in the intestinal lumen.   Furthermore using  a matrilysin knockout
 mice 
(matrilysin – a protease which cleaves and thus activates α defensins in mice) Wilson and 
colleagues demonstrated a defect in the microbicidal activity in vivo after oral inoculation 
with Escherichia Coli as evidenced by increased numbers of bacteria in the distal small 
intestine. In addition these knock out mice were more susceptible to invasive pathogens 
such as Salmonella typhimurium, in comparison to wild type mice. (Wilson 1999)  
 
The  majority  of  human  data  comes  from  Wekhamp  and  colleagues  who  originally 
demonstrated that defensins are differentially expressed in Crohn’s
 disease and ulcerative 
colitis.  (Wekhamp  2004)  Following  the  identification  that  Paneth  cells  express  NOD2, 
(Lala  2003)  Wekhamp  hypothesised  that  NOD2  may  regulate  or  influence
  Paneth  cell 
number or Paneth cell defensin expression. They examined 45 Crohn’s disease
 patients (24 
with NOD2 variants and 21 without) and 12
 controls and showed that ileal expression of 
HD-5 and HD-6, but not sPLA2  or lysozyme were diminished in Crohn’s affected ileum, 
and the decrease
 was significantly more pronounced in patients with NOD2 mutations.
 In 
the colon, HD-5, HD-6, and sPLA2 were increased during inflammation
 in wild-type but 
not in NOD2 mutated patients. In both the colon
 and ileum, proinflammatory cytokines and 
lysozyme were unaffected
 by NOD2 status (Wekhamp 2004) 
Wehkamp  concludes  that  as  alpha  defensins  are  important  in  the  mucosal
  antibacterial 
barrier, their diminished expression may explain,
 in part, the bacterial induced mucosal 
inflammation and ileal
 involvement of Crohn’s disease, and that this may be mediated by 
inherited mutations in NOD2.
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1.7.2    Effect  of  Crohn’s  Disease  associated  NOD2  mutations  on  MDP 
mediated cell responses 
1.7.2.1    Transfection Studies  
 
Bonen and colleagues (2003a) showed that PGN-induced cellular activation is diminished 
in mammalian cells expressing mutant NOD2 proteins. Using transfected HEK293T cells 
they  showed  that  NF-κB  activation  was  reduced  or  absent  in  PGN-treated  cells  that 
expressed  mutant  NOD2  proteins.  In  a  similar  way,  Girardin  and  colleagues  (Girardin 
2003) showed that mutant NOD2 proteins do not mediate NF-κB activation in response to 
PGN and MDP stimulation. Both groups showed that no MDP-induced NF-κB activation 
was noted in HEK293T cells expressing the Leu1007fsinsC-encoded NOD2 mutant protein 
whereas lesser degrees of activation were noted in cells expressing the Arg702Trp- and 
Gly908Arg-encoded NOD2 proteins.  
 
Inohara and colleagues (2003) verified this finding in mammalian cells. These investigators 
obtained primary peripheral blood mononuclear cells (PBMC) from healthy volunteers and 
Crohn's  disease  patients  that  were  either  homozygous  or  heterozygous  for  the 
Leu1007fsinsC mutation. Using electrophoretic mobility shift assay and quantitative real-
time PCR, they showed that MDP did not induce NF-κB activation in PBMC which were 
homozygous  for  the  framesfhift  NOD2  mutation.  MDP  did  however  induce  NF-κB 
activation in PBMC from normal controls or patients who were heterozygous for the NOD2 
mutations. This was in contrast to LPS stimulation which induced NF-κB activation in all 
PBMC  regardless  of  NOD2  status,  further  demonstrating  that  NOD2  mediates  the  host 
cellular response to MDP.  
 
Interestingly  all  three  of  the  major  risk  alleles  have  comparable  allele  frequencies  and 
genetic risk for hetereozygotes and homozygotes, but only the Leu1007fsinsC has been 
shown  to  have  complete  loss  of  function  in  transfection  studies  (Inohara  2003,  Bonen 
2003a)  
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1.7.2.2    Murine Studies  
 
The  role  of  MDP  in  the  pathogenesis  of  NOD2-associated  Crohn's  disease  has  been 
examined using mouse studies by two groups - Murray and Maeda (Pauleau 2003, Maeda 
2005).  
 
Murray in his NOD2-/- mice showed reduced secretion of proinflammatory cytokines Il-6, 
IL-12 and TNFα in Bone marrow derived monocytes stimulated with MDP from -/- mice 
compared  to  controls.  (Pauleau  2003)  The  response  to  other  TLR  stimulation  was 
comparable in both -/- and control mice. 
 
Maeda generated mice whose NOD2 encoded for a truncated NOD2 protein lacking the last 
33 amino acids, which is homolog of the human NOD2 protein that is encoded by the 
frameshift mutation. In this model, in contrast to previous studies MDP stimulation caused 
increased  levels  of  NF-κB  activation  in  macrophages  isolated  from  NOD2
2939iC  mice 
relative to macrophages from wild-type mice. Furthermore, the expression of several NF-
κB target genes was increased in MDP-treated NOD2
2939iC macrophages relative to wild-
type  controls  and  MDP  also  induced  increased  secretion  of  IL-1β  from  NOD2
2939iC 
macrophages relative to wild-type controls. (Maeda 2005) 
 
1.7.2.3  Human Studies  
 
Li (Li 2004) first examined the effects of MDP mediated activation on primary peripheral 
mononuclear cells stratified on NOD2 genotype. They demonstrated that by microarray, 
MDP induced a broad array of transcripts, including  IL-1β and IL-8. Furthermore they 
demonstrated a reduced transcriptional response to MDP in mononuclear cells homozygous 
for the frameshift mutation. At low MDP doses (10ng/ml) they observed no induction of 
IL-8  protein  in  all  homozygotes  but  using  higher  doses  of  MDP  (1µg/ml)  only  those 
mononuclear cells homozygous for the frameshift mutation showed no induction of IL-8 
protein. In the same paper Li also went on to demonstrate that in wild type mononuclear 
cells that MDP plus TNFα together causes a synergistic induction of IL-1β secretion and   42 
that  this  is  absent  in  Leu1007fsinsC  homozygotes  despite  marked  induction  of  IL-1β 
mRNA. They suggest that this shows a post –transcriptional dependency on the NOD2 
pathway for IL-1β secretion. 
 
Netea  (Netea  2004)  alternatively  demonstrated  a  defective  release  of  IL-10  from  blood 
mononuclear cells homozygous for the frameshift mutation, after stimulation with TLR2 
ligands  (PGN  and  Pam3Cys-KKKK)  but  not  with  TLR4  ligands  (LPS).  They  also 
demonstrated  decreased  anti  –  inflammatory  cytokine  release  after  stimulation  with 
Bacteroides species and concluded that the resulting pro- inflammatory cytokine bias could 
be responsible for the inflammation seen in Crohn’s disease. 
 
Van  Heel  (van  Heel  2005)  also  analysed  the  cytokine  response  of  peripheral  blood 
mononuclear cells to MDP. They demonstrated that MDP alone induced little TNFα or IL -
1β  but  strong  IL-8  secretion.  Furthermore  they  went  on  to  demonstrate  that  MDP 
substantially upregulated the secretion of TNFα or IL -1β induced by Toll like receptors 2, 
4, 5 and 6. These effects were not seen in mononuclear cells homozygous for the common 
NOD2 mutations. These results will be discussed more fully in Chapter 4.5 
 
1.8     Aims   
 
The  most  intriguing  question  therefore  remains  concerning  the  mechanism  whereby 
mutations  in  the  NOD2  gene  predispose  towards  Crohn’s  disease.  Thus  far  functional 
studies of the NOD2 protein have relied heavily on the use of transfected cell lines and 
murine models. Most of these studies have shown that mutant NOD2 proteins, especially 
those  encoded  by  the  frameshift  mutation,  mediate  a  decreased  NF-κB  response.  Yet 
Crohn’s disease is characterised by increased NF-ĸB activation with downstream effects on 
inflammatory cytokine production. At the time of doing my research the functional effect of 
the  established  NOD2  risk  alleles  had  not  yet  been  examined  in  primary  human 
mononuclear cells. The aim of my research was therefore to study the effect of inherited 
mutations  in  the  NOD2  gene  on  cellular  responses  to  bacterial  stimuli  using  freshly 
extracted primary human monocytes both from healthy controls and from patients with 
Crohn’s disease carrying the common NOD2 gene mutations.    43 
With  the  more  recent  discovery  showing  NOD2  expression  in  Paneth  cells  and  with 
emerging  evidence  that  Paneth  cell  antimicrobial  products  may  be  regulated  in  NOD2 
associated  Crohn’s  disease,  I  investigated  whether  another  Paneth  cell  derived 
antimicrobial enzyme, lysozyme, plays a role in inducing cellular activation in intestinal 
epithelial cells. Most functional studies of NOD2 function have relied on synthetic MDP 
and  PGN  but  in  biological  systems,  muropeptides  (of  which  MDP  is  a  commercially 
available  example)  are  generated  by  the  enzymatic  action  of  lysozyme  on  the  PGN 
component  of  the  bacterial  cell  wall.    I  therefore  wanted  to  investigate  the  effect  of 
lysozyme and lysozyme generated muropeptides from various bacterial species on cellular 
inflammatory responses by measuring the transcriptional activity of specific inflammatory 
cytokines in intestinal epithelial cells. 
 
The  original  hypotheses  were  that  carriage  of  a  mutant  NOD2  gene  would  affect  the 
response of PBMC and Paneth cells to bacterial stimulation. 
 
The specific objectives of this study are: 
 
1.  To  determine  the  effect  of  various  bacterial  antigens  on  inflammatory  cytokine 
expression in PBMC freshly extracted from healthy volunteers and Crohn’s disease 
affected patients carrying wild-type and mutant NOD2 genotypes.  
2.  To examine the effect of MDP pre treatment ‘priming’ on inflammatory responses 
in PBMC extracted from healthy volunteers and Crohn’s disease affected patients 
carrying wild-type and mutant NOD2 genotypes. 
3.  To examine the effect of different mycobacteria stimulation on PBMC extracted 
from healthy volunteers and Crohn’s disease affected patients carrying wild-type 
and mutant NOD2 genotypes.  
4.  To  examine  the  effect  of  lysozyme  generated  muropeptides  on  inflammatory 
responses in intestinal epithelial cells by measuring the transcriptional activity of 
specific inflammatory cytokines. 
5.  To  examine  whether  lysozyme  generated  muropeptides  from  different  bacterial 
species provoked differing effects on inflammatory signalling in intestinal epithelial 
cells. 
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Chapter Two 
2. Materials and Methods 
 
2.1 Materials 
A list of reagents and suppliers is attached - Appendix C 
2.2 Molecular biology Techniques 
2.2.1 Isolation of peripheral blood mononuclear cells (PBMC) 
Reagents:  
1.  Histopaque®  1077:  A  solution  containing  polysucrose  and  sodium  diatrizoate, 
adjusted to a density of 1.077 g/mL. 
2.  Hanks’ balanced salt solutions (HBSS) 
3.  0.5M EDTA 
4.  Macrophage serum free media  
 
Peripheral blood mononuclear cells (PBMC) were harvested, using Ficoll density gradient 
centrifugation. 
 
Method: 
20mls of blood was collected from human healthy volunteers or from patients attending the 
Inflammatory Bowel Disease clinic at the Royal Free Hospital, London. The project was 
approved  by  the  joint  Ethics  Committee  of  the  Royal  Free  Hampstead  NHS  Trust  and 
Royal  Free  and  University  College  Medical  School  (London,  UK).  The  fresh  collected 
blood  was  put  into  anti-coagulant  tubes  containing  K3EDTA  (BD  Diagnostics)  for 
immediate  transfer  to  the  laboratory.  Once  in  the  laboratory  the  whole  blood  was 
transferred to a 50 ml-centrifuge tube and 10ml Hanks’ balanced salt solutions (HBSS) 
(with 2.5mM EDTA to aid cell separation) was added to make a total solution of 30mls. 
This was then very carefully layered onto 15mL Histopaque® 1077 which was in a separate 
50 mL-centrifuge tube, and then centrifuged at 1400 rpm (409 g) for 20 minutes at 20°C 
with the brake off. Following centrifugation, mononuclear cells form a distinct layer at the 
plasma- Histopaque® interface, and red blood cells and neutrophils form a pellet at the   45 
base of the tube. The layer of mononuclear cells was then carefully aspirated and placed in 
fresh 50 mL-centrifuge tubes. HBSS was added to make the final volume 50 mL, and the 
samples were centrifuged at 1400 rpm (409g) for 10 minutes at 4°C with the brakes on. 
After discarding the supernatant containing contaminating platelets, the PBMC pellet was 
re-suspended in 50 mL HBSS, and centrifuged at 1200 rpm (301 g) for  a further 7 minutes 
at 4°C with the brakes on. This wash in 50mL HBSS was repeated twice more, to remove 
contaminating platelets. A final wash was then performed in 5mls Macrophage serum free 
media  and  following  that  final  wash,  the  PBMC  were  suspended  in  3mls  Macrophage 
serum  free  media  and  counted  using  an  improved  Neubauer  counting  chamber.  The 
monocytes were then suspended, at a concentration of 2 x 10
6 cells/ml, and 2mls put into 
each well of a 6 well plate and incubated at 37°C in a 5% CO2, 95% air atmosphere. This 
gave a total of 4 x 10
6 cells well. 
 
2.2.2  Bacterial stimulation of PBMC 
Reagents 
 
1.  Muramyl diPeptide (MDP) N-acetylmuramyl-L-alanyl-D-isoglutamine 
2.  Peptidoglycan (PGN) micrococcus luteus Sigma-Aldrich – category number 53243, 
staphylococcus aureus Sigma-Aldrich – category number 77140 
3.  Lipopolysaccharide (LPS)  
4.  Sonicated Mycobacteria vaccae (Strain NCTC11659 and Mycobacteria tuberculosis 
(Strain H37RV) gift of Dr Sanjay Lala  
 
After being incubated at 37°C in a 5% CO2, 95% air atmosphere for one hour the 4 x 10
6 
PBMC in each well were stimulated with the appropriate bacterial stimuli. The bacterial 
stimuli was diluted into the correct concentration in warmed Macrophage serum free media 
before being added to the PBMC at time zero. Each well finally contained 4 x 10
6 cells in 3 
ml of Macrophage serum free media. The 6 well plates containing the PBMC and bacterial 
stimuli were then incubated at 37°C in a 5% CO2, 95% air atmosphere for a further 1,2,4 or 
6  hours  depending  on  the  experiment.  At  harvesting,  the  PBMC  were  recovered  by 
aspiration and mechanical scraping to ensure that both adherent  and non-adherent cells 
were obtained. For RNA extraction, the recovered PBMC were lysed in Trizol® reagent.   46 
2.2.3 RNA extraction 
Reagents: 
1.  Trizol® reagent 
2.  Isopropanol 
3.  70% ethanol 
4.  Nuclease-free water/ DEP-C Water 
5.  Chloroform 
 
Method: 
RNA  extraction  from  intestinal  epithelial  cells  and  peripheral  blood  mononuclear  cells 
(PBMC) was performed using Trizol® reagent. For RNA extraction from PBMC cultured 
in 6-well plates, the culture medium containing non-adherent lymphocytes was transferred 
to clean microfuge tubes and centrifuged at 13 000 rpm (16 100 g) for 5 minutes at 4°C. 
This supernatant was then stored at -20°C for future protein analysis. 600 µL Trizol reagent 
was added to each well and after agitation the solution transferred to a clean microfuge 
tube. The remaining adherent mononuclear cells in the 6-well culture plates were lysed 
using  a  further  400  µL  Trizol,  and  this  solution  was  added  to  the  microfuge  tubes 
containing the lysed lymphocytes so that the entire cell lysate was present in 1 mL Trizol 
reagent.  
For intestinal epithelial cells the supernatant was discarded and 500µL of Trizol was added 
and after agitation the solution transferred to a fresh microfuge tube. A further 500µL of 
Trizol was then added to ensure collection of all cells and the final solution was again 1ml. 
   
Following that 400 µL chloroform was added to each microfuge tube, and mixed for 15 
seconds using a vortex mixer till the samples were thoroughly mixed. The samples were 
then centrifuged  at 14  000 rpm (20 817 g) for 10 minutes at 4 °C to allow for phase 
separation.  The  upper  or  RNA-containing  aqueous  phase  was  removed  by  careful 
aspiration, taking care to avoid the protein interface, and transferred to fresh tubes. An 
equal volume of isopropanol was then added to each tube. After mixing the contents, the 
sample was incubated at -20°C for 30 minutes to allow for RNA precipitation. Next, the 
tubes were centrifuged at 14 000 rpm (20 817 g) for 15 minutes at 4 °C to collect the RNA 
pellet. The supernatant was then discarded and the RNA pellet was washed in 500 µL 70%   47 
ethanol and the tubes were centrifuged again at 14 000 rpm (20 817 g) for 10 minutes at 
4°C. After discarding the supernatant, the RNA pellet was air dried and resuspended in 22 
µL nuclease-free water. 20 µL of RNA solution was used for cDNA synthesis, and 2 µL of 
solution used to quantify and assess RNA integrity by spectrophotometry and agarose gel 
electrophoresis.  
 
 
 
 
 
 
 
 
 
 
 
2.2.4 Synthesis of cDNA 
 
Reagents: 
1.  Oligo(dT)12-18 primer (0.5 µg/µL; Invitrogen Life Technologies) 
2.  10 mM dNTP 
3.  5X First Strand Buffer [250 mM Tris-HCl (pH 8.30, 375 mM KCl, 15 mM MgCl2; 
Invitrogen Life Technologies] 
4.  Moloney  Murine  Leukaemia  Virus  Reverse  Transcriptase  (M-MLV  RT)  (200 
units/µL; Invitrogen Life Technologies) 
5.  Nuclease-free water 
 
Method: 
For cDNA synthesis, 2 µg of total RNA, in 20 µl of nuclease-free water, and 0.5 µg oligo 
(dT) primer (Life Technologies Ltd), were heated to 65° C for 5 minutes to dispose the 2° 
structure and then rapidly cooled on ice. Reverse transcription was performed at 37.0°C for 
2hours, in a 50 µl reaction volume, according to the following protocol: 
Figure 2.1 – Example of agarose gel electrophoresis on RNA extracted from PBMC    48 
RNA (2 µg)      20 µL 
Oligo (dT) primer      1 µL 
10 mM dNTP       2.5 µL 
5X First Strand buffer   10 µL 
MMLV-RT        2 µL 
Nuclease-free water    14.5 µL 
Reaction volume    50.0 µL 
 
Synthesised cDNA was stored at -20°C 
 
2.2.5  Primer Design  
 
Primers were designed after visually examining the nucleotide sequences that are accessible 
on  PubMed,  a  service  provided  by  the  United  States  National  Library  of  Medicine 
(http://www.ncbi.nlm.nih.gov/entrez/query.fcgi). They were designed to be intron spanning 
to  distinguish  mRNA  from  possible  contamination  from  genomic  DNA.  They  were  20 
nucleotide bases in length and designed to anneal at 60°C during PCR amplification. All 
oligonucleotide  DNA  primers  were  synthesised  and  purified  by  reverse-phase  High 
Pressure Liquid Chromatography (HPLC) by Thermo Electron GmbH, Germany. Primers 
were synthesised to a scale of 0.02 µmoles, and shipped in a dry or lyophilised form. The 
oligonucleotide primers were reconstituted in nuclease-free water to 100 µM concentration, 
and stored at -20 °C. Amplicons were diluted to a final concentration of 10 µM for use in 
PCR  amplification.  Table  2.1  lists  the  oligonucleotide  primers  used  in  RT-PCR  and 
quantitative RT-PCR reactions.  
 
2.2.6 Quantitative Real Time Polymerase Chain Reaction (q-PCR) 
 
Reagents: 
 
1.  10  µM  sense  and  anti-sense  primers  (Primers  synthesised  by  Thermo  Electron 
GmbH, Germany) 
2.  25 mM MgCl2   49 
3.  10 mM deoxynucleotide triphosphate (dNTP) mix (containing 10 mM dATP, 10 
mM dTTP, 10 mM dCTP and 10 mM dGTP) 
4.  10X Qiagen PCR Buffer (Contains Tris-Cl, KCl, (NH4)2SO4, 15 mM MgCl2; pH 
8.7. Manufacturer does not disclose information regarding concentrations) 
5.  Q-Solution (Qiagen; manufacturer does not disclose details of composition) 
6.  Taq polymerase (5U/ µL; Qiagen) 
7.  SYBR green (Biogene) 
8.  DEPC-treated water 
 
Method 
 
Quantitative  real-time  PCR  was  performed  using  the  Rotor-Gene  amplification  system 
(Biogene, Kimbolton, UK). RT-PCR was performed, in a 20 µL reaction volume, according 
to the following protocol.  Each 20µl PCR reaction contained 5.25µl of RNAse free water, 
3µl of cDNA, 1µM of sense and anti-sense primer, 1.5mM MgCl2, 1µl of dNTP’s (5mM 
each of dATP, dTTP, dCTP and dGTP) 1 µL SYBR green (Biogene; final concentration 
1:60 000), 2µl 10X Qiagen PCR Buffer (Qiagen, Crawley, UK), 4µl of Q-solution (Qiagen) 
and 0.25U Taq polymerase (Qiagen) according to the following protocol. 
 
Protocol 
 
Intron-spanning primer pairs were used to amplify each cDNA   
cDNA         3 µL 
  10 µM primers (sense + anti-sense)   2 µL 
  25 mM MgCl        1.5 µL 
  10 mM d NTP mix      1 µL 
  Taq polymerase (5U/ µL)    0.25 µL 
  10x PCR Buffer solution    2 µL 
  Q-Solution        4 µL 
  SYBR green        1 µL 
  DEPC-treated water      5.25 µL 
  Reaction volume      20.0 µL   50 
 
Synthesised cDNA was initially denatured at 94 °C for 3 minutes, and amplified using 40 
cycles of denaturation at 94 °C, annealing at 60 °C for 30 seconds, and extension at 72°C 
for 60 seconds. The data were expressed as the ratio of NOD2 to GAPDH. Specificity of 
the desired PCR products was determined by  melting curve analysis  and confirmed by 
agarose gel electrophoresis and ethidium bromide staining. 
 
2.2.7  Gel electrophoresis 
 
The  size  of  all  PCR  products  was  verified  by  agarose  gel  electrophoresis  and  UV 
transillumination. A 1% agarose gel was prepared by dissolving 0.6g agarose in 60 mL 
water. This solution was heated, using a microwave oven (for 3 minutes using the low 
power setting), and then poured into an electrophoresis box that was specifically used for 
either RNA or DNA analysis respectively. The gel was allowed to set at room temperature 
and, once polymerised, was covered with nuclease free water. The cDNA samples were 
loaded and the gel was run for 25minutes at 65 V (5 V/ cm) prior to UV transillumination. 
 
 
 
 
Figure 2.2 – Example of melt curve produced-peripheral blood monocytes 
stimulated by bacterial ligands: TNFα α α α, IL1βand GAPDH expression   51 
Table 2.1 Oligonucleotide primers 
 
 
 
 
F: forward primer; R: reverse primer. All primers pairs were designed to span introns, and 
the  expected  genomic  DNA  and  mRNA  sizes  (number  of  nucleotide  base  pairs)  is 
indicated.  All  numbers  indicate  the  starting  nucleotide  position  of  the  primer,  listed 
according to the GenBank accession number.  
 
Primer  5’ – 3’ sequence 
IL-8 2878F  CTT TCT GAT GGA AGA GAG CTC 
IL-8 3968R  GTC CTC ACA ACA TCA CTG TG 
IL1b 5724F  GGT GTT CTC CAT GTC CTT TG 
IL1b 6779 R  GGA AGA CAC AAA TTG CAT GG 
HD6 1471F  CCA CTC CAA GCT GAG GAT G 
HD6 2697R  TAG GAC ACA CGA CAG TTT CC 
NOD2 115520F   GCG CGA TAA CAA TAT CTC AGA 
NOD2 122313R   CAG AGT TCT TCT AGC ATG ACG 
GAPDH 3543F   CGA GAT CCC TCC AAA ATC AAG 
GAPDH 4610R   G AGC TTG ACA AAG TGG TCG 
Lysozyme 4353F   GCT GCA AGA TAA CAT CGC TG 
Lysozyme 5417R   ACC TTT CAC TTA ATT CCT ACT CCC 
TGFß 1740F  ACA TTG ACT TCC GCA AGG AC  
TGFß 2269R  AAG GAA TAG TGC AGA CAG GC 
TNFα 1814F  GAG TGA CAA GCC TGT AGC CC 
TNFα 2380R  TGG CAG AGA GGA GGT TGA CC   52 
2.2.8 Cell culture 
 
Reagents: 
1.  100x Antibiotic antimycotic solution: 10 000 U penicillin, 10 mg streptomycin, and 
25 µg amphotericin B per mL) 
2.  10x Trypsin-EDTA solution: 5.0 g porcine trypsin, 2.0 g EDTA⋅4 Na in 0.9% NaCl; 
cell culture tested 
3.  Trypsin solution: 1 mL 10x Trypsin-EDTA solution and 9 ml Dulbecco PBS 
4.  Dulbecco PBS 
5.  Dulbecco’s modified Eagle medium (DMEM) 
6.  DMEM/F12 medium 
7.  10% foetal calf serum 
8.  200 mM L-Glutamine 
9.  HT-29 intestinal epithelial cells (ATCC Number HTB-38) 
10. SW480 intestinal epithelial cells (ATCC Number CCL-228) 
 
 
HT29  intestinal  epithelial  cells  were  obtained  from  Dr.  A  Bromfield  (Department  of 
Medicine, Royal Free and University College Medical School, London). This investigator 
had originally purchased the cells from LCG Promochem, the European distribution partner 
for  American  Type  Culture  Collection  (ATCC)  products.  SW480  cells  were  purchased 
directly from LCG Promochem.  
 
2.2.8.1    Propagation of intestinal epithelial cell lines   
 
 
 
Human colon cancer cell line HT29 (American Type Culture Collection, Manassas, USA) 
was  cultured  in  Dulbecco’s  modified  Eagle  medium  (DMEM)  supplemented  with  10% 
foetal calf serum, 2mM L-Glutamine, 1 U/mL penicillin, 1 µg/mL streptomycin and 2.5 
ng/mL amphotericin B, at 37°C in a 95% air/ 5% CO2 atmosphere. SW480 cells were 
cultured  in  DMEM/F12  medium  supplemented  with  10%  foetal  calf  serum,  1  U/mL 
penicillin, 1 µg/ml streptomycin and 2.5 ng/mL amphotericin B, at 37°C in a 95% air/ 5%   53 
CO2 atmosphere. All reagents used for cell culture were purchased from Sigma Chemical 
Company, Poole, UK. 
Cell lines were propagated after reaching 80-90% confluence in T75 flasks (usually after 
one week of culture). The growth medium was poured from the flask, and the cells were 
twice washed with 10 mL Dulbecco PBS. After pouring out the PBS, 5 mL of trypsin 
solution  was  added  to  the  flask.  After  1  minute,  approximately  4.5  mL  of  the  trypsin 
solution  was  removed  from  the  flask,  and  the  flask  was  incubated  at  37.0°C  for 
approximately 10 minutes.  
 
Following  trypsinisation,  the  cells  were  visualised  under  a  microscope  to  confirm  cell 
detachment  from  the  plastic  walls  of  the  flask.  The  detached  cells  were  thoroughly 
resuspended in 8 mL of appropriate fresh culture medium. After calculating the cell count, 
using an improved Neubauer counting chamber, cells were seeded into fresh T75 culture 
flasks according to the following concentrations: 2-4 x 10
4 cells/ cm
2 for HT-29 cells, and 
10
4 cells/ cm
2 for SW480 cells. Fresh culture medium was added to the T75 flask so that 
cells  were  allowed  to  propagate  in  10  mL  growth  medium;  the  growth  medium  was 
replenished twice weekly.  
 
All  cell  lines  were  checked  and  found  to  be  free  from  mycoplasma  infection  by  Ms 
Demetra  Mavri  (Research  assistant,  Centre  for  Hepatology,  Royal  Free  and  University 
College Medical School, London).  
 
 
Table 2.3 Seeding concentrations used to propagate intestinal epithelial cells. 
Cell type  Seeding concentration 
(cells/ cm
2) 
Cell yield from trypsin-
treated confluent cells 
cultured in T75 flasks 
HT-29  2-4 x 10
4  2-3 x 10
7 
SW480  1 x 10
4  2-3 x 10
7 
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2.2.8.2    Bacterial stimulation of intestinal epithelial cell lines 
 
 
Reagents 
 
1  Muramyl diPeptide (MDP) N-acetylmuramyl-L-alanyl-D-isoglutamine  
2  Peptidoglycan (PGN) micrococcus luteus Sigma-Aldrich – category number 53243, 
staphylococcus aureus Sigma-Aldrich – category number 77140, bacillus subtilis  
Sigma-Aldrich – category number 69554 
3  Lipopolysaccharide (LPS)  
4  Lysozyme (LZM)  
5.  E.Coli LF82  
 
Cells were grown to 90% confluence and as before the growth medium was poured from 
the flask, and the cells were twice washed with 10mL Dulbecco PBS. 5 mL of trypsin 
solution was then added to the flask for 1 minute and then approximately 4.5 mL of the 
trypsin solution was removed from the flask. The flask was then incubated at 37.0°C for 
approximately  10  minutes.  Following  trypsinisation,  the  cells  were  visualised  under  a 
microscope to confirm cell detachment from the plastic walls of the flask. The detached 
cells were then thoroughly resuspended in 12 ml of fresh culture medium and plated 1 ml 
each  into  2  x  6  well  plates  each  well  already  containing  2ml  of  warmed  fresh  culture 
medium. They were incubated at 37°C in a 95% air/ 5% CO2 atmosphere for 24 hours. 
Once  they  had  reached  approximately  70%  confluence  in  each  well  the  medium  was 
removed, cells were washed with PBS and then stimulated with the correct concentration of 
bacterial stimulation and/or freshly diluted LZM in warmed fresh medium to make a total 
of 3 ml in each cell. LZM was freshly made for each experiment. The dose chosen was 
initially 100 times physiological levels – 64mg/ ml and then increased to 100mg/ml further 
for ease of experimental technique. They were then incubated for a further set time period 
before the RNA was extracted using Trizol reagent. 
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2.3  Clinical Data Collection 
 
I met all patients involved in this study personally through the Inflammatory Bowel Disease 
Clinic at The Royal Free Hospital London.  They were interviewed at time of venesection 
and I later reviewed each set of notes and recent haematology and biochemistry results to 
ensure correct clinical information was obtained. The project was previously approved by 
the joint Ethics Committee of the Royal Free Hampstead NHS Trust and Royal Free and 
University College Medical School (London, UK). 
 
2.3.1  NOD2 Genotyping 
 
Genomic DNA had previously been isolated from venous blood of 150 patients attending 
the Inflammatory Bowel Disease Clinic at the Royal Free Hospital, London. Using an 
allele-specific polymerase chain reaction, followed by agarose gel electrophoresis Dr 
Manisha Abeya, (MD student, Department of Medicine, Royal Free and University College 
Medical School, London) had determined the NOD2 status of each of these patients. All 
NOD2 mutant samples were confirmed by DNA sequencing. 
 
2.4  Statistical analysis 
Values in the text and figures are expressed as the mean ± S.E.M. (Standard error of the 
mean). Statistical differences between means were determined using Student’s t-test and 
considered  significant  if  p<0.05.  All  analyses  were  performed  using  GraphPad  Prism 
version 3.02 (25 April 2000) (GraphPad, San Diego, CA)  
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Chapter Three 
3.0 Determining the effect of direct bacterial stimulation on peripheral 
blood mononuclear cells (PBMC) cytokine expression  
3.1 Introduction 
 
Crohn’s Disease is an inflammatory condition which can affect the entire gastrointestinal 
tract and whose aetiology remains unclear but is thought to be due to an excessive response 
to  a  component  of  the  bacterial  flora  in  a  genetically  susceptible  host.  (Bouma  2003) 
Mutations  in  the  NOD2  gene  are  strongly  associated  with  Crohn’s  disease.  NOD2  is 
expressed  intracellularly  in  monocytic  cells  and  in  Paneth  cells  of  the  small  intestine. 
NOD2 has been shown to recognize MDP a component of bacterial cell wall peptidoglycan 
that is present in most bacteria. The challenge has been to understand how mutations in 
NOD2 gene are involved in the pathogenesis of Crohn’s disease. I therefore investigated 
peripheral blood mononuclear cells (PBMC) response to bacterial stimuli and the effect of 
inherited mutations in the NOD2 gene on that response. 
 
 
3.1.1 Bacterial Stimulation of PBMC from Healthy Controls – Initial Cytokine Studies 
 
Initial studies in two healthy individuals involved freshly isolated PBMC being stimulated 
in serum free media with either Muramyldipeptide (20µg/ml), PGN m.luteus (20µg/ml) or 
PGN  s.aureus  (20µg/ml)  for  2  hours.  After  extraction  of  RNA  and  cDNA  synthesis, 
quantitative real time PCR was performed looking at cytokine expression. Results were 
then normalised for Glutaraldehyde phosphate dehydrogenase (GAPDH) a house keeping 
gene. The cytokines we examined included TNFα,  IL-1β and IL-8. In Crohn’s disease, 
mucosal inflammation is mediated by an excessive T helper 1 (TH1)-cell response that is 
characterized by the cytokine tumour necrosis factor α (TNFα). Interleukin-1β (IL-1β) and 
interleukin-8 (IL-8) are cytokines involved in the immediate innate immune response. IL-8, 
a member of the CXC chemokine family, is an important activator and chemo-attractant for   57 
neutrophils  and  has  been  implicated  in  the  pathogenesis  of  a  variety  of  inflammatory 
diseases, including IBD, asthma and sepsis (Standiford 1990, Yoshimura 1987)  
 
Figure  3.1  shows  that  MDP  induced  minimal  upregulation  4.2  fold  of  TNFα  cytokine 
expression whilst PGN from both m.luteus and s.aureus induced a mean 24 and 22 fold 
increase in TNFα expression from normal PBMC. 
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Figure 3.1 – Stimulation of peripheral blood monocytes by bacterial ligands: 
TNFα α α α expression   58 
I  also  wanted  to  determine  the  effect  of  bacterial  stimulation  on  the  expression  of  the 
regulatory cytokine transforming growth factor β (TGFß) as well as NOD2 and lysozyme 
expression  (LZM).  TGFß  is  a  cytokine  produced  by  suppressor  T  cell  subsets,  which 
ameliorate TH1 mediated intestinal inflammation which are important in CD pathogenesis. 
There  was  no  significant  response  to  bacterial  stimuli  in terms  of  transforming  growth 
factor β (TGFβ), NOD2 or LZM expression in PBMC from healthy volunteers. Figure 3.2 
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Figure 3.2-Stimulation of peripheral blood monocytes by bacterial ligands: 
NOD2, LZM & TGFβ expression   59 
 
3.2 Bacterial Stimulation of PBMC - Dose Response  
3.2.1 Lipopolysaccharide (LPS) 
The doses of bacterial ligands to be studied were first optimised. Lipopolysaccharide (LPS) 
is  a  component  of  the  outer  membrane  of  Gram  negative  bacteria  and  specific  Gram 
positive bacteria (Listeria monocytogenes) which contributes to the bacteria’s structural 
integrity. LPS is also an endotoxin known to activate the innate immune system through 
Toll  like  receptor  4.  Fresh  PBMC  were  isolated  from  healthy  volunteers  as  previously 
described  and  concurrently  stimulated  in  serum  free  media  for  2  hours  with 
Lipopolysaccharide  (LPS)  at  one  of  the  following  doses  -1ng/ml,  10ng/ml,  50ng/ml, 
100ng/ml or 200ng/ml. After extraction of RNA and cDNA synthesis, quantitative real time 
PCR was performed looking at TNFα, IL-1β and IL-8 cytokine expression. Results were 
normalised for GAPDH expression  
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There is a linear increase in response to LPS from 1ng/ml to 100ng/ml where the effect is 
maximal  causing  a  41.1  fold  induction  in  TNFα  expression  and  29.5  and  22.5  fold 
induction  in  terms  of  IL-1β  &  IL-8  respectively.  The  effect  plateauxed  on  any  further 
increase in LPS. It was entirely on the basis of the results shown above in the experiments I 
had performed in the laboratory, that I thus elected to use 100ng/ml LPS for the further 
experiments. (Figure 3.3) 
Figure 3.3 – Dose response to LPS stimulation, TNFα, IL1β, IL8 expression   60 
3.2.2 Peptidoglycan (PGN) 
Peptidoglycan (PGN) as discussed previously is an essential component of virtually all 
bacteria that provides rigidity and structure. The amount, location and specific composition 
of PGN varies between species. Responses to Peptidoglycan (PGN) from the following 
species,  micrococcus  luteus  and  staphylococcal  aureus  and  sonicated  mycobacterium 
vaccae were examined.  They were concurrently stimulated for 2 hours at the following 
doses - 100ng/ml, 1µg/ml, 10µg/ml, 20µg/ml and 30µg/ml and then RNA extracted and 
analysed as previously described. Figure 3.4 
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Figure 3.4 – Dose response to PGN stimulation, TNFα, IL1β & IL8 expression   61 
 
There is a maximum response in terms of TNFα, IL-1β and IL-8 expression to PGN at 
20µg/ml. The response was consistent across PGN from each of the 3 species studied with 
a mean of 23.2 fold increases in the 3 proinflammatory cytokines studied.  
 
3.2.3 Muramyl dipeptide (MDP) 
 
Fresh PBMC were isolated from healthy volunteers and again concurrently stimulated in 
serum free media for 2 hours with Muramyldipeptide at the following doses - 100ng/ml, 
1µg/ml, 10µg/ml, 20µg/ml and 30µg/ml. After extraction of RNA and cDNA synthesis, 
quantitative real time PCR was performed looking at cytokine expression. Results were 
normalised for GAPDH expression and are shown in Figure 3.5 
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MDP at 100ng/ml caused a mean 7.1 fold induction in TNFα, IL-1β & IL-8 expression. 
Any further increase in MDP dose did not cause a resulting increase in cytokine expression. 
 
Figure 3.5 – Dose response to MDP stimulation, TNFα, IL1β, & IL8 expression   62 
3.2.4  Bacterial Stimulation of PBMC - Length of Stimulation 
 
To establish the time at which the maximum response from bacterial stimuli is seen fresh 
PBMC were again isolated from healthy volunteers and stimulated with MDP, PGN and 
LPS. Cells were harvested at 1 hour, 2 hours, 4 hours and 6 hours. After extraction of RNA 
and cDNA synthesis, quantitative real time PCR was performed looking at TNFα and IL-1β 
cytokine expression. Results were normalised for GAPDH expression. (Figure 3.6) 
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  Figure 3.6 – PBMC response to MDP, PGN & LPS stimulation over time in terms 
of TNFα and IL1β expression   63 
This demonstrated that LPS was a potent inducer of inflammatory cytokine response and by 
two hours this response was maximal causing a mean 49.2 fold induction in TNFα and 56.8 
fold induction in IL-1β. There was no further increase in induction and a plateuxing effect 
to 6 hours. PGN and MDP caused a more modest induction in TNFα & IL1β expression 
but this was also maximal at 2 hours. 2 hours of bacterial stimulation was therefore the time 
point used in future experiments. 
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3.3  Healthy control PBMC response to bacterial stimuli 
 
The  response  in  normal  PBMC  from  healthy  volunteers  to  various  stimuli  was  then 
examined more closely. Blood was obtained from 12 healthy volunteers and the PBMC 
then extracted. The NOD2 status on these healthy controls was not examined.  
Freshly isolated PBMC were stimulated in serum free media for 2 hours with either 
1.  Muramyldipeptide (20µg/ml) 
2.  Peptidoglycan (PGN) m.luteus (20µg/ml) 
3.  Lipopolysaccharide (LPS) (100ng/ml) 
After extraction of RNA and cDNA synthesis, quantitative real time PCR was performed 
looking at cytokine expression and results were normalised to expression of the house-
keeping gene, GAPDH. 
 
In freshly isolated PBMC from 12 healthy volunteers MDP causes only a mean 3.11 fold 
increase in TNFα expression (SEM 0.40) whilst PGN induces a mean 30.19 fold increase 
(SEM 0.40) whilst LPS is the most potent inducer of TNF expression with a 54.04 fold  
increase in expression (SEM-9.40). Figure 3.7 
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Figure 3.7-Stimulation of peripheral blood monocytes by bacterial ligands: TNFα 
expression   65 
I  then  went  on  to  examine  interleukin-1β  (IL-1β)  and  interleukin-8  (IL-8)  expression, 
cytokines involved in the immediate innate immune response.  Figure 3.8  
 
 
 
These cytokines demonstrated the same stimulatory hierarchy with MDP being the weakest 
stimulant of cytokine expression and LPS being the most powerful inducer causing a 59.48 
fold increase in IL1-β expression (SEM 18.21). Although the same hierarchy is seen in IL-8 
expression with MDP being the weakest, LPS the most potent and PGN intermediate, the 
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Figure 3.8 – Stimulation of peripheral blood monocytes by bacterial ligands: IL-1β 
and IL-8 expression   66 
relative fold induction is less pronounced with only an 11.6 fold increase in response to 
LPS stimulation and so following this I focussed primarily on TNFα and IL-1β expression.    
 
3.4  Clinical Characteristics of Crohn’s patients studied 
 
Having  established  the  effect  of  bacteria  on  healthy  control  PBMC  I  then  wanted  to 
compare the effect of bacterial stimulation on PBMC in patients with Crohn’s disease who 
were wild type, heterozygous or homozygous for the common disease causing mutations in 
the NOD2 gene. 28 patients with Crohn’s disease were recruited from the Inflammatory 
Bowel Disease clinic at the Royal Free Hospital, London between January 2004 and July 
2005.  There  is  potential  selection  bias  here  as  only  5  NOD2  homozygotes  have  been 
identified thus far from the IBD clinic and these were all asked to participate. There was a 
larger pool of patients from which to select the heterozygotes or wild type patients from 
and this was done on the basis of whom was attending the weekly clinic. This however 
increases  the  possibility  that  patients  who  were  clinically  well  were  less  likely  to  be 
attending the clinic, thus introducing bias. 
 
Clinical information including Vienna Classification, IBD treatment and disease activity at 
the time of venesection was collected and the results are shown in Tables 3.1, 3.2 and 3.3 
respectively.    Twelve  patients  were  wild  type  for  the  common  disease  causing  NOD2 
mutations, 7 male and 5 female with a mean age of 45.8yrs.  There were 11 patients who 
were heterozygous for the common disease causing mutations in the NOD2 gene -7 male 
and 4 female with a mean age of 41.0 yrs and 5 who were homozygous or compound 
heterozygotes, 2 male and 3 female with a mean age of 38.4yrs. The overall mean age of 
the Crohn’s patients studied was 42.6yrs (range 14-82 yrs) and the sex ratio was 1.33:1 
(M:F) There was no significant difference in age, sex or disease classification between 
groups. Other differences between the cohorts are discussed below. 
 
3.4.1  Disease Activity 
 
In terms of disease activity at time of venesection 2 out of 12 (16.7%) of the patients wild 
type for the common NOD2 mutations had active disease whereas 4 of the 11 heterozygotes   67 
(36.4%) and 3 out of the 5 homozygotes (60%) patients had active disease at time of the 
venesection. This may be of significance. 
 
3.4.2  Use of immunomodulator treatment  
 
Use  of  immunomodulator  treatment  including  azathioprine,  Mercaptopurine  or 
Methotrexate was common in all groups with a total of 12 of the 28 (42.9%) being on one 
of these second line agents. Use was highest proportionally amongst the wild type group 
where 7 of the 12 (58.3%) were currently taking a thiopurine or Methotrexate. 3 of the 11 
hetereozygotes (27.3%)  and 2 of the 5 (40%) homozygotes were using a thiopurine or 
Methotrexate at the time of venescetion.  The dose of oral thiopurine ranged between 75mg 
and 200mg but no data are available assessing the efficacy of the treatment in terms of 
Azathioprine metabolites. 
 
3.4.3  Infliximab use 
 
There were no current users of the TNF antibody Infliximab in either the wild type or 
hetereozygote group but 2 from each group (16.7% and 18.2% respectively) had previously 
(at least 12/12 ago) received it. Amongst the homozygote group there was only one patient 
(20%)  who  had  received  Infliximab  and  was  receiving  ongoing  maintenance  treatment 
every 8 weeks at the time of venesection.  
 
3.4.4  Smoking Status 
 
The rate of smoking in our cohort was lower than expected with only 4 of the 28 (14.3%) 
being current smokers. These were again equally distributed with 2 each amongst the wild 
type and heterozygote groups. There were a further 2 ex-smokers, (defined as not smoked 
for over 6 months) one wild type and one heterozygote for the common disease causing 
mutations in the NOD2 gene. None of the patients who were homozygous for the common 
disease  causing  mutations  in  the  NOD2  gene  were  either  current  or  ex-smokers. 
6
8
 
 
S
u
b
j
e
c
t
 
N
O
D
2
 
s
t
a
t
u
s
 
S
e
x
 
A
g
e
 
C
o
m
o
r
b
i
d
i
t
y
 
S
m
o
k
e
r
 
I
B
D
 
D
r
u
g
s
 
D
i
s
e
a
s
e
 
A
c
t
i
v
i
t
y
 
I
n
f
l
i
x
i
m
a
b
 
U
s
e
 
D
i
s
e
a
s
e
 
C
l
a
s
s
i
f
i
c
a
t
i
o
n
1
 
M
M
 
w
t
/
w
t
 
M
a
l
e
 
4
1
 
N
i
l
 
S
m
o
k
e
r
 
A
z
a
t
h
i
o
p
r
i
n
e
 
1
0
0
m
g
 
O
D
,
 
P
e
n
t
a
s
a
 
2
g
 
B
D
 
A
c
t
i
v
e
 
N
e
v
e
r
 
A
1
,
 
L
3
,
 
B
2
 
 
O
W
 
w
t
/
w
t
 
M
a
l
e
 
2
6
 
N
i
l
 
S
m
o
k
e
r
 
P
e
n
t
a
s
a
 
1
g
 
B
D
 
Q
u
i
e
s
c
e
n
t
 
N
e
v
e
r
 
A
1
,
 
L
3
,
 
B
1
 
D
E
 
w
t
/
w
t
 
F
e
m
a
l
e
 
2
1
 
N
i
l
 
N
S
 
A
s
a
c
o
l
 
1
2
0
0
m
g
 
B
D
 
A
z
a
t
h
i
o
p
r
i
n
e
 
1
5
0
 
m
g
 
O
D
 
Q
u
i
e
s
c
e
n
t
 
N
e
v
e
r
 
A
1
,
 
L
2
,
 
B
1
 
I
B
 
w
t
/
w
t
 
F
e
m
a
l
e
 
4
9
 
N
i
l
 
N
S
 
M
e
t
h
o
t
r
e
x
a
t
e
 
1
5
m
g
 
o
/
w
k
,
 
P
e
n
t
a
s
a
 
1
g
 
B
D
,
 
P
r
e
d
 
7
m
g
 
O
D
 
A
c
t
i
v
e
 
P
r
e
v
i
o
u
s
 
(
2
0
0
2
)
 
A
1
,
 
L
3
,
 
B
1
 
 
R
B
 
w
t
/
w
t
 
M
a
l
e
 
6
4
 
N
i
l
 
N
S
 
A
z
a
t
h
i
o
p
r
i
n
e
 
1
0
0
m
g
 
O
D
 
P
e
n
t
a
s
a
 
1
g
 
B
D
 
Q
u
i
e
s
c
e
n
t
 
N
e
v
e
r
 
A
2
,
 
L
4
,
 
B
1
 
A
B
 
w
t
/
w
t
 
M
a
l
e
 
4
4
 
N
i
l
 
N
S
 
M
e
r
c
a
p
t
o
p
u
r
i
n
e
 
5
0
m
g
 
O
D
 
Q
u
i
e
s
c
e
n
t
 
N
e
v
e
r
 
A
1
,
 
L
4
,
 
B
2
 
J
M
 
w
t
/
w
t
 
F
e
m
a
l
e
 
7
6
 
I
H
D
,
 
N
I
D
D
M
 
S
a
r
c
o
i
d
 
E
x
 
s
m
o
k
e
r
 
N
i
l
 
Q
u
i
e
s
c
e
n
t
 
N
e
v
e
r
 
 
A
2
,
 
L
4
,
 
B
1
 
R
M
 
w
t
/
w
t
 
M
a
l
e
 
4
5
 
N
i
l
 
N
S
 
A
z
a
t
h
i
o
p
r
i
n
e
 
2
0
0
m
g
 
O
D
,
 
P
e
n
t
a
s
a
 
1
g
 
B
D
 
Q
u
i
e
s
c
e
n
t
 
P
r
e
v
i
o
u
s
 
(
2
0
0
0
)
 
 
A
1
,
 
L
3
,
 
B
2
 
M
C
 
w
t
/
w
t
 
F
e
m
a
l
e
 
6
2
 
N
i
l
 
N
S
 
N
i
l
 
Q
u
i
e
s
c
e
n
t
 
N
e
v
e
r
 
A
2
,
 
L
1
,
 
B
1
 
E
S
 
w
t
/
w
t
 
F
e
m
a
l
e
 
 
N
i
l
 
N
S
 
N
i
l
 
Q
u
i
e
s
c
e
n
t
 
N
e
v
e
r
 
A
1
,
 
L
2
,
 
B
1
 
D
I
 
w
t
/
w
t
 
M
a
l
e
 
2
1
 
N
i
l
 
N
S
 
P
e
n
t
a
s
a
 
1
g
 
B
D
 
Q
u
i
e
s
c
e
n
t
 
N
e
v
e
r
 
A
1
,
 
L
2
,
 
B
1
 
P
U
 
w
t
/
w
t
 
M
a
l
e
 
5
9
 
I
H
D
 
N
S
 
M
e
r
c
a
p
t
o
p
u
r
i
n
e
 
7
5
m
g
 
O
D
,
 
A
s
a
c
o
l
 
8
0
0
m
g
 
B
D
 
Q
u
i
e
s
c
e
n
t
 
 
N
e
v
e
r
 
A
2
,
 
L
3
,
 
B
1
 
 
1
 
A
c
c
o
r
d
i
n
g
 
t
o
 
V
i
e
n
n
a
 
C
l
a
s
s
i
f
i
c
a
t
i
o
n
 
–
 
s
e
e
 
A
p
p
e
n
d
i
x
 
B
.
 
T
a
b
l
e
 
3
.
1
 
C
l
i
n
i
c
a
l
 
C
h
a
r
a
c
t
e
r
i
s
t
i
c
s
 
o
f
 
P
a
t
i
e
n
t
s
 
S
t
u
d
i
e
d
 
–
 
N
O
D
2
 
+
/
+
 
-
-
-
-
-
-
-
-
A
t
 
t
i
m
e
 
o
f
 
v
e
n
e
s
e
c
t
i
o
n
-
-
-
-
-
-
-
-
-
  
6
9
 
 
S
u
b
j
e
c
t
 
N
O
D
2
 
s
t
a
t
u
s
 
S
e
x
 
A
g
e
 
C
o
m
o
r
b
i
d
i
t
y
 
S
m
o
k
e
r
 
I
B
D
 
D
r
u
g
s
 
D
i
s
e
a
s
e
 
A
c
t
i
v
i
t
y
 
I
n
f
l
i
x
i
m
a
b
 
U
s
e
 
D
i
s
e
a
s
e
 
C
l
a
s
s
i
f
i
c
a
t
i
o
n
 
A
C
 
1
3
+
/
-
 
M
a
l
e
 
3
1
 
N
i
l
 
N
S
 
P
e
n
t
a
s
a
 
1
g
 
B
D
 
A
c
t
i
v
e
 
N
e
v
e
r
 
A
1
,
 
L
3
,
 
B
1
 
L
O
S
 
1
2
+
/
-
 
F
e
m
a
l
e
 
8
2
 
H
y
p
e
r
t
e
n
s
i
o
n
 
N
S
 
N
i
l
 
Q
u
i
e
s
c
e
n
t
 
N
e
v
e
r
 
A
1
,
 
L
3
,
 
B
3
 
S
O
 
8
+
/
-
 
M
a
l
e
 
1
9
 
G
e
n
d
e
r
 
R
e
a
s
s
i
g
n
m
e
n
t
 
N
S
 
A
z
a
t
h
i
o
p
r
i
n
e
 
1
5
0
m
g
 
O
D
,
 
P
e
n
t
a
s
a
 
1
g
 
B
D
 
Q
u
i
e
s
c
e
n
t
 
N
e
v
e
r
 
A
1
,
 
L
3
,
 
B
1
 
S
M
 
1
2
+
/
-
 
F
e
m
a
l
e
 
4
0
 
N
i
l
 
E
x
 
s
m
o
k
e
r
 
A
z
a
t
h
i
o
p
r
i
n
e
 
1
0
0
m
g
 
O
D
 
A
c
t
i
v
e
 
P
r
e
v
i
o
u
s
 
(
2
0
0
0
)
 
A
1
,
 
L
3
,
 
B
3
 
D
H
 
1
3
+
/
-
 
M
a
l
e
 
2
7
 
N
i
l
 
N
S
 
P
e
n
t
a
s
a
 
1
g
 
B
D
 
Q
u
i
e
s
c
e
n
t
 
N
e
v
e
r
 
A
1
,
 
L
3
,
 
B
3
 
S
S
 
8
+
/
-
 
M
a
l
e
 
4
9
 
N
i
l
 
N
S
 
N
i
l
 
Q
u
i
e
s
c
e
n
t
 
N
e
v
e
r
 
A
2
,
 
L
1
,
 
B
1
 
H
C
 
8
+
/
-
 
F
e
m
a
l
e
 
2
1
 
N
i
l
 
N
S
 
A
s
a
c
o
l
 
1
2
0
0
m
g
B
D
 
Q
u
i
e
s
c
e
n
t
 
N
e
v
e
r
 
A
1
,
 
L
3
,
 
B
1
 
M
G
 
8
+
/
-
 
M
a
l
e
 
7
0
 
N
i
l
 
N
S
 
P
e
n
t
a
s
a
 
1
g
 
B
D
 
Q
u
i
e
s
c
e
n
t
 
N
e
v
e
r
 
A
2
,
 
L
3
,
 
B
1
 
L
S
 
8
+
/
-
 
F
e
m
a
l
e
 
1
9
 
N
i
l
 
S
m
o
k
e
r
 
A
z
a
t
h
i
o
p
r
i
n
e
 
1
0
0
m
g
 
O
D
,
 
B
u
d
e
s
o
n
i
d
e
 
9
m
g
 
O
D
 
A
c
t
i
v
e
 
P
r
e
v
i
o
u
s
 
 
A
1
,
 
L
4
,
 
B
3
 
A
D
 
1
3
+
/
-
 
M
a
l
e
 
1
9
 
N
i
l
 
S
m
o
k
e
r
 
N
i
l
 
Q
u
i
e
s
c
e
n
t
 
N
e
v
e
r
 
A
1
,
 
L
1
,
 
B
1
 
F
P
 
8
+
/
-
 
M
a
l
e
 
 
7
4
 
H
y
p
e
r
t
e
n
s
i
o
n
 
N
S
 
P
e
n
t
a
s
a
 
1
g
 
B
D
 
A
c
t
i
v
e
 
N
e
v
e
r
 
A
2
,
 
L
1
,
B
1
 
 
1
 
A
c
c
o
r
d
i
n
g
 
t
o
 
V
i
e
n
n
a
 
C
l
a
s
s
i
f
i
c
a
t
i
o
n
 
–
 
s
e
e
 
A
p
p
e
n
d
i
x
 
B
 
-
-
-
-
-
-
-
-
-
-
A
t
 
t
i
m
e
 
o
f
 
v
e
n
e
s
e
c
t
i
o
n
-
-
-
-
-
-
-
-
-
 
T
a
b
l
e
 
3
.
2
 
C
l
i
n
i
c
a
l
 
C
h
a
r
a
c
t
e
r
i
s
t
i
c
s
 
o
f
 
P
a
t
i
e
n
t
s
 
S
t
u
d
i
e
d
 
–
 
N
O
D
2
+
/
-
  
7
0
 
 
S
u
b
j
e
c
t
 
N
O
D
2
 
s
t
a
t
u
s
 
S
e
x
 
A
g
e
 
C
o
m
o
r
b
i
d
i
t
y
 
S
m
o
k
e
r
 
I
B
D
 
D
r
u
g
s
 
D
i
s
e
a
s
e
 
A
c
t
i
v
i
t
y
 
I
n
f
l
i
x
i
m
a
b
 
U
s
e
 
D
i
s
e
a
s
e
 
C
l
a
s
s
i
f
i
c
a
t
i
o
n
1
 
L
C
 
1
2
-
/
8
-
 
M
a
l
e
 
7
2
 
C
h
r
o
n
i
c
 
L
y
m
p
h
y
o
c
y
t
i
c
 
l
e
u
k
a
e
m
i
a
 
–
s
t
a
g
e
 
A
 
N
S
 
N
i
l
 
Q
u
i
e
s
c
e
n
t
 
N
e
v
e
r
 
A
2
,
 
L
4
,
 
B
1
 
P
B
 
1
3
-
/
-
 
F
e
m
a
l
e
 
2
9
 
N
i
l
 
N
S
 
A
z
a
t
h
i
o
p
r
i
n
e
 
1
0
0
m
g
 
O
D
,
 
P
e
n
t
a
s
a
 
1
g
 
B
D
 
A
c
t
i
v
e
 
P
r
e
v
i
o
u
s
 
 
A
1
,
 
L
4
,
 
B
3
 
A
E
 
8
-
/
-
 
M
a
l
e
 
1
4
 
N
i
l
 
N
S
 
P
e
n
t
a
s
a
 
2
g
 
B
D
 
A
c
t
i
v
e
 
N
e
v
e
r
 
A
1
,
 
L
3
,
 
B
1
 
S
S
 
1
2
-
/
8
-
 
F
e
m
a
l
e
 
5
0
 
N
i
l
 
N
S
 
M
e
t
h
o
t
r
e
x
a
t
e
 
1
0
m
g
 
/
w
k
,
 
P
e
n
t
a
s
a
 
5
0
0
m
g
 
T
D
S
 
A
c
t
i
v
e
 
N
e
v
e
r
 
 
A
1
,
 
L
4
,
 
B
3
 
J
H
 
1
3
-
/
-
 
F
e
m
a
l
e
 
2
7
 
N
i
l
 
N
S
 
I
n
f
l
i
x
i
m
a
b
 
M
a
i
n
t
e
n
a
n
c
e
 
A
c
t
i
v
e
 
C
u
r
r
e
n
t
 
A
1
,
 
L
3
,
 
B
1
 
 
1
 
A
c
c
o
r
d
i
n
g
 
t
o
 
V
i
e
n
n
a
 
C
l
a
s
s
i
f
i
c
a
t
i
o
n
 
–
 
s
e
e
 
A
p
p
e
n
d
i
x
 
B
 
 
 
 
 
 
 
 
-
-
-
-
-
-
-
-
A
t
 
t
i
m
e
 
o
f
 
v
e
n
e
s
e
c
t
i
o
n
-
-
-
-
-
-
-
-
 
T
a
b
l
e
 
3
.
3
 
C
l
i
n
i
c
a
l
 
C
h
a
r
a
c
t
e
r
i
s
t
i
c
s
 
o
f
 
P
a
t
i
e
n
t
s
 
S
t
u
d
i
e
d
 
–
 
N
O
D
2
 
-
/
-
   71 
3.5  Bacterial stimulation of PBMC in Patients with Crohn’s Disease  
 
Fresh PBMC were collected and stimulated with bacterial ligands as described in section 
3.3. The results for TNFα and IL-1 β cytokine expression were determined and results for 
TNFα shown in Figure 3.9 in comparison to healthy controls. In patients with Crohn’s 
Disease (n=28), PBMC respond to bacterial stimuli with the same hierarchical activity as in 
healthy individuals. (IL-1β data in Figure 3.11) LPS was again the most potent stimulator 
causing a mean 46.97 fold increase in TNFα expression (SEM 5.75). This compares to 
54.04 fold induction in PBMC from healthy controls. PGN caused a 29.63 fold induction in 
TNFα expression (SEM 5.51) which is similar to healthy controls (30.19 fold increase) 
MDP was the weakest stimulator causing a mean of 2.64 fold induction (SEM 0.37) in 
TNFα  from  PBMC  from  Crohn’s  patients  compared  to  3.11  in  PBMC  from  healthy 
controls. 
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Figure 3.9 - Response of PBMC to bacterial stimuli from Crohn’s patients 
compared to healthy controls -TNFα expression   72 
3.6  Bacterial stimulation of PBMC across NOD2 genotypes 
 
I then went onto examine whether the NOD2 genotype affected how PBMC responded to 
bacterial stimulation. The results are shown in Figure 3.10 for TNFα expression and in 
Figure  3.11  for  IL-1β  gene  expression.  The  same  hierarchical  activity  was  seen  in  all 
patients regardless of the NOD2 genotypes. LPS was the most potent inducer causing a 54 
fold, 41 fold, 55.6 fold or 41.54 fold increase in TNFα expression in healthy controls, wild 
type, heterozygotes and homozygotes respectively. MDP was a weak stimulant inducing 
between a 2.58 to 3.45 fold increase in TNFα expression. 
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Figure 3.10- Response of PBMC to bacterial stimuli across the NOD2 genotypes -
TNFα expression   73 
 
 
 
 
This hierarchical effect was the same when examining IL-1β expression. MDP was a weak 
inducer across all the genotypes, ranging between a mean of 4.9 and 8.83 induction in IL-
1β expression. LPS was the most potent inducer again causing between a 59.47 and 72.74 
fold induction in IL-1β expression. (Figure 3.11) 
 
To help determine whether my healthy samples represent a normal Gaussian Distribution 
population I performed a Kolmogorov-Smirnov (KS) test. When examining results from 
LPS, PGN and MDP stimulated PBMC the P value obtained was >0.10 in each thereby 
passing the normality test. (KS distance 0.118) It is hard to verify completely however that 
the samples are normally distributed due to the small sample size (n=12). 
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Figure 3.11 – Response of PBMC to bacterial stimuli across the NOD2 genotypes – 
IL1β expression   74 
3.6.1  Stimulation of PBMC by LPS across genotypes 
 
To further clarify the effect of bacterial stimulation I then compared the effect of each of 
the bacterial ligands on PBMC from healthy controls and those Crohn’s patients carrying 0, 
1  or  2  NOD2  disease  causing  mutations.  LPS,  an  amphiphilic  material  in  the  outer 
membrane of both gram positive and gram negative bacteria is a well known activator of 
macrophages and is sensed through TLR 4.  
Effect of LPS across genotypes
Healthy
NOD2 +/+
NOD2 +/-
NOD2 -/-
0
10
20
30
40
50
60
70
Healthy
NOD2 +/+
NOD2 +/-
NOD2 -/-
R
e
l
a
t
i
v
e
 
T
N
F
α
 
m
R
N
A
 
e
x
p
r
e
s
s
i
o
n
(
n
o
r
m
a
l
i
s
e
d
 
t
o
 
G
A
P
D
H
)
 
 
 
 
Toll like receptors (TLR’s) are a family of pattern recognition receptors that sense motifs 
found in microbial pathogens and initiate immune defense against such pathogens. TLR are 
found  in  PBMC  but  are  membrane  bound  in  contrast  to  NOD2  which  lies  within  the 
cytoplasm. This showed (Figure 3.12) that LPS caused a mean 49.08 fold induction in 
TNFα expression (SEM 4.87) in PBMC and there was no significant  difference in the 
cytokine response between patients and healthy controls and across the NOD2 genotypes. 
This was as expected as LPS is sensed through TLR 4 which is present in all PBMC and 
therefore the NOD2 status should not be relevant. 
Figure 3.12 – Effect of LPS on PBMC from healthy controls & across NOD2 
genotypes 
n=12  n=12  n=11  n=5   75 
 
3.6.2  Stimulation of PBMC by PGN across genotypes 
 
 
 
Effect of PGN across genotypes
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PGN induced a mean 30.19 fold increase in TNFα expression in healthy controls and 30.21 
and 25.73 fold increase in TNFα expression in PBMC from wild type and heterozygotes. In 
homozygotes  PGN  still  caused  an  increase  in  TNFα  expression  but  this  was  relatively 
reduced to 15.97 fold increase. This does not reach statistical significance but a possible 
explanation for this is that PGN is sensed through both toll like receptor 2 which should be 
similar in PBMC from all genotypes and also through its breakdown product MDP which 
may be reduced in the PBMC carrying two NOD2 mutations.  
 
 
 
 
Figure 3.13 – Effect of PGN on PBMC from healthy controls & across NOD2 
genotypes 
n=12  n=12  n=11  n=5   76 
3.6.3  Stimulation of PBMC by MDP across genotypes 
 
 
 
 
Examining the response to MDP shows that the response is minimal even in healthy PBMC 
causing only a 3.11 fold induction in TNFα expression. The effect of MDP on PBMC wild 
type  and  heterozygote  for  the  NOD2  mutations  is  reduced  -2.58  fold  and  2.45  fold 
respectively. When studying the homozygotes the response is further reduced but not at a 
statistically significant level. The response of the PBMC who were homozygote for the 
frameshift mutations (n=2) was then examined separately and this demonstrated a further 
reduced response to MDP. This compares with the previous published data (Li 2004, Ogura 
2001, Inohara 2003) that demonstrated that the frameshift mutation caused reduced NFkB 
activation. 
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Figure 3.14 – Stimulation with MDP – Response across NOD2 genotypes 
n=12  n=12  n=11  n=5 
n=2   77 
3.6.4  TGFß,  LZM  and  NOD2  expression  in  Crohn’s  PBMC  stimulated  with 
bacterial ligands 
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I previously demonstrated that normal PBMC from healthy volunteers  when stimulated 
with bacteria did not respond by altering LZM, TGFβ or NOD2 expression (Figure 3.2). I 
Figure 3.15 – NOD2, LZM and TGFβ expression unchanged across genotypes   78 
therefore wanted to ensure that this was unchanged in PBMC from Crohn’s patients with or 
without  a  NOD2  mutation.  I  therefore  directly  compared  in  a  single  experiment  fresh 
PBMC  from  a  healthy  control,  and  two  Crohn’s  patients  who  were  wild  type  or 
homozygous for the common NOD2 disease causing mutations. PBMC were stimulated 
with MDP, PGN m.lut and PGN s .aureus for  2 hours and RNA extracted and  cDNA 
synthesized as per protocol. LZM, TGFβ and NOD2 expression remained unchanged in 
each of the PBMC regardless of stimulation. (Figure 3.15) 
 
Contrary  to  these  initial  experiments  Netea  and  colleagues  (Netea  2004)  subsequently 
published their work which also examined the cytokine response of PBMC to bacterial 
stimulation. They examined PBMC from 8 healthy controls and 8 patients with Crohn’s 
disease (4 double frameshift mutation, 4 wild type) and demonstrated that the frameshift 
mutation resulted in defective release of the anti inflammatory cytokines TGFβ and IL-10 
rather than of the proinflammatory cytokine TNFα from cells stimulated with the TLR2 
ligand PGN.  They suggest that the reduced anti inflammatory cytokines production results 
in a pro inflammatory cytokine bias and they suggest this could be the basis of mechanism 
of NOD2 associated CD. These results have not been replicated. 
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3.7  Differential response across bacteria - Do mycobacteria depend on 
NOD2 for sensing? 
 
Mycobacteria,  particularly  Mycobacteria  paratuberculosis  remains  a  putative,  though 
controversial cause of Crohn’s disease as discussed previously. (Chpater1.3.4.2)  Mutations 
in the NOD2 gene are strongly associated with Crohn’s disease. Furthermore an increased 
incidence  of  Mycobateria  paratuberculosis  has  been  reported  in  patients  with  Crohn’s 
Disease who carry NOD2 gene mutations (Behr 2004). More recently an in vitro study 
suggests that NOD2 is an essential recognition molecule for Mycobacterium tuberculosis 
(MTB)  and  pronounced  cellular  activation  is  noted  in  NOD2–transfected  cells  that  are 
stimulated with heat–killed MTB preparations. (Ferwerda 2005) 
   
We  therefore  hypothesised  whether  mutant  NOD2  proteins  would  influence  cellular 
activation in response to mycobacterial antigen stimulation. We used two different strains 
of mycobacteria to assess whether different mycobacteria would illicit different response. 
Sonicated forms of Mycobacterium vaccae (MV) and Mycobacterium tuberculosis (MTB) 
were the mycobacteria species tested. 
 
Blood  was  extracted  from  twelve  Crohn’s  patients  attending  the  Inflammatory  Bowel 
Disease clinic at the Royal Free Hospital, London. Five patients were wild type for the 
common  NOD2  mutations,  four  patients  carried  one  disease  causing  NOD2  mutation 
(heterozygote) and three patients had two disease causing NOD2 mutations– one of whom 
was  homozygous  for  the  Leu1007fsinsC  mutation.    Fresh  PBMC  were  isolated  and 
prepared as previously described at a cell concentration of 4x10
6 cells / well in 6 well 
plates.  They were then stimulated in serum free media for 2 hours with either:-  
1.  Muramyldipeptide (20µg/ml) 
2.  Mycobacterium vaccae (MV) (Strain NCTC 11659) 
3.  Mycobacterium tuberculosis (MTB) (Strain H37RV) 
4.  Lipopolysaccharide (LPS) (100ng/ml) 
After 2 hours incubation RNA was extracted, cDNA was synthesised, quantitative real time 
PCR  was  performed  looking  at  cytokine  expression  and  results  were  normalised  to   80 
expression of the house keeping gene GAPDH. The response to MDP and LPS was used as 
the experimental positive control.  
 
3.7.1  Stimulation of PBMC by MDP across NOD2 genotypes 
 
The response of PBMC to MDP stimulation is seen in Figure 3.16. As expected MDP was a 
weak stimulant causing a mean 4.5 fold increase in TNFα expression and 7.1 fold increase 
in IL-1β expression. There was no significant difference across the NOD2 genotypes but as 
expected the patient homozygous for the Leu1007fsinsC mutation had a reduced response 
to MDP.  
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Effect of stimulation with M DP across
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Figure 3.16 – TNFα and IL-1β cytokine response to MDP stimulation by PBMC 
across genotypes   81 
3.7.2  Effect of Mycobacterium Tuberculosis on PBMC across NOD2 
genotypes
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The inflammatory response by PBMC to Mycobacterium tuberculosis was more potent than 
the  response  to  MDP  but  again  less  pronounced  than  the  response  to  LPS.  Firstly  the 
cytokine response in PBMC from Crohn’s patient’s wild type for the NOD2 mutations was 
similar  to  that  seen  in  healthy  controls  (data  not  shown.).  Mycobacterium  tuberculosis 
induced a mean 15.1 fold increase in TNFα expression and 26.8 fold increase in IL-1β 
n=5  n=4  n=3 
n=5  n=4  n=3  n=1 
n=1 
Figure 3.17 – TNFα and IL-1β cytokine response to Mycobacteria tuberculosis 
stimulation by PBMC across NOD2 genotypes   82 
expression  in  PBMC  from  Crohn’s  patients.  Furthermore  there  was  no  significant 
difference between the Crohn’s patients regardless of their NOD2 status. 
 
3.7.3  Effect of Mycobacterium Vaccae on PBMC across NOD2 genotypes 
The effect of Mycobacterium vaccae on PBMC can be seen in Figure 3.18. Mycobacterium 
vaccae is also a modest inducer of pro inflammatory cytokines causing a mean 11.7 fold 
induction in TNFα expression and 20.2 fold induction in IL-1β expression in PBMC. Again 
there was no significant difference across the patients carrying one or two disease causing 
NOD2 mutations or when specifically looking at PBMC with double frameshift mutation. 
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Figure 3.18 – TNFα and IL-1β cytokine response to Mycobacteria vaccae stimulation by 
PBMC across NOD2 genotypes   83 
3.8  Conclusion 
 
I have demonstrated that PBMC from healthy controls respond to bacteria in a predictable 
stimulatory hierarchy when stimulated with MDP, PGN and LPS. LPS is the most potent 
stimulator where it causes a 54 fold increase in TNFα expression and a 59 fold increase in 
IL-1β  expression.  No  effect  on  the  antinflammtory  cytokine  TGFß  expression  was 
demonstrated. 
 
PBMC from patients with Crohn’s Disease also responded in a similar pattern to bacterial 
stimulation with LPS being the most potent inducer of inflammatory cytokines and MDP 
being the most modest.  The effect of LPS on PBMC is unaffected whether you have no, 
one or two disease causing NOD2 mutations. This is for the reason that LPS is sensed 
through the surface receptor TLR4.  
 
MPD is a modest stimulator of PBMC where it causes a mean 3.11 fold induction in TNFα 
expression in healthy controls and 2.64 fold induction in patients with Crohn’s disease. In 
patients carrying two NOD2 mutations the stimulatory effect is reduced further particularly 
in  PBMC  homozygote  for  the  frameshift  mutation.  This  confirms  the  findings  of  the 
transfection studies (Inohara 2003, Girardin 2003) and also of Li (2004) who subsequently 
published  their  comprehensive  studies  of  primary  mononuclear  cells  in  CD  patients 
comparing the functional effects of the individual disease-associated mutations. They too 
demonstrated a decreased transcriptional response to MDP of the frameshift mutation. 
 
Furthermore this data does not support the hypothesis that Mycobacteria depend on NOD2 
for sensing. The stimulatory response of freshly extracted PBMC to Mycobacterium vaccae 
and Mycobacterium tuberculosis was modest when examining TNFα and IL-1β cytokine 
expression and was not dependent on NOD2 status. This is in apparent contrast with the 
results of Ferweda (2005) and colleagues who demonstrated decreased TNFα protein in 
PBMC expressing mutant NOD2 proteins (encoded by the frameshift mutation) which were 
stimulated by sonicated MTB preparations. Possible reasons  for the differences  will be 
discussed in Chapter 4 
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Chapter Four 
4.0  Determining  the  effect  of  MDP  priming  on  PBMC  response  to 
bacterial stimulation. 
4.1 Introduction 
 
Muramyldipeptide is a weak agonist inducing TNFα and IL1β expression in PBMC. In 
PBMC  expressing  mutant  NOD2  proteins,  this  response  is  further  reduced:  this  is 
particularly so in PBMC expressing mutant NOD2 proteins encoded  by the  L3020insC 
frameshift mutation in the NOD2 gene (Inohara 2003, Li 2004). In the previous chapter 
(Chapter  3),  I  have  shown  similar  results  in  freshly  extracted  human  peripheral  blood 
monocytes. Nonetheless, these results present an apparent paradox as Crohn’s Disease is 
characterized by increased NFκB activity and Th1 cytokine responses that are characterized 
by elevated levels of TNFα and IL1β.  
 
In mice, the combination of MDP and LPS induces greater inflammatory responses than 
either component used alone. Simultaneous intravenous injection of LPS and MDP results 
in marked lethality  in  guinea pigs  and mice (Ribi 1979, Takada 1987). Ribi et al  first 
observed that the administration of intravenous LPS and MDP induced early shock, which 
was sometimes lethal, in guinea pigs; animals receiving either LPS or MDP alone did not 
have such a reaction (Ribi 1979) 
 
Similarly, Takada and colleagues showed that simultaneous administration of MDP and 
LPS was lethal to mice whereas administration of either MDP or LPS alone was not. They 
then  went  on  to  examine  the  optimal  time  interval  between  MDP  and  LPS  injection 
required to sensitize mice for lethal toxicity of LPS. Takada demonstrated that pretreatment 
of 4 hours with MDP was more effective than either simultaneous administration or 2 hours 
pretreatment  and  after  4  hours  pretreatment  with  MDP,  LPS  also  caused  an  early 
anaphylactoid  reaction  which  was  absent  in  the  other  time  periods.  For  this  reason  an 
interval  of  4  hours  between  the  MDP  treatment  and  subsequent  LPS  treatment  was 
observed in my experiments. (Takada 1987)   85 
Furthermore the same group has shown that MDP priming is also effective for inducing 
increased  inflammatory  cytokines  in  mice  in  response  to  other  bacterial  components, 
including lipotechoic acid (LTA). (Monodane 1997) 
 
MDP also appears to prime inflammatory responses in human monocytic cells. Yang and 
colleagues studied the effects of MDP in human monocytic cell lines THP-1 and U937 and 
demonstrated  that  MDP  by  itself  exhibited  only  a  weak  ability  to  induce  secretion  of 
inflammatory cytokines such as IL-8 but showed marked synergistic effect with both LPS 
and LTA. They also found that cells primed with MDP exhibited enhanced production of 
IL-8 upon stimulation with LPS, while the cells primed with LPS showed no change in 
production upon stimulation with MDP. (Yang 2001) 
 
In 2004, Uehara and colleagues showed that NOD2 is responsible for the synergistic effects 
of MDP and TLR agonists in monocytic cell lines. Their results suggested that combinatory 
dual  signaling  through  extracellular  TLR’s  and  intracellular  NODs  might  lead  to  the 
synergistic activation of host innate immune responses to invading bacteria. (Uehara 2004) 
 
Having  recognized  this  phenomenon  in  both  animal  models  and  monocytic  cell  lines  I 
wanted to determine whether MDP modulated immune responses to bacterial antigens in 
human PBMC expressing wild-type and mutant NOD2 proteins. I hypothesized that MDP 
by itself is a weak agonist of inflammatory responses in monocytes but that MDP priming 
enhances subsequent inflammatory responses to bacterial ligands. I chose to ‘prime’ or pre 
treat the PBMC for 4 hours before subsequent LPS treatment on the basis of Takada’s 
experiments which showed that 4 hours pretreatment with MDP is more effective than 
either simultaneous administration or 2 hours pretreatment. (Takada 1987) 
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4.2  MDP Priming of PBMC in healthy controls  
Peripheral  blood  monocytes  from  twelve  healthy  controls  were  freshly  isolated  and 
prepared (as previously described) at a cell concentration of 4x10
6 cells/well in serum free 
media. They were then incubated concurrently for 4 hours with or without MDP – priming 
– before being stimulated with LPS for a further 2 hours. The doses used were  
•  Muramyl dipeptide (20µg/ml) 
•  Lipopolysaccharide (LPS) (100ng/ml); these doses were unchanged  
All  cells  were  then  harvested,  RNA  extracted  and  cDNA  synthesized  as  previously 
described. Quantitative  PCR looking at TNFα  and  IL1β  expression was performed  and 
results normalised for GAPDH expression 
 
Figure 4.1-MDP modulation of TNFα and IL1β mRNA expression in healthy 
PBMC 
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The effect of LPS on PBMC with or without priming with four hours of MDP is seen in 
Figure 4.1. The effect of LPS alone is consistent with that shown previously, causing a 
mean 51.7 fold induction in both TNFα and IL-1β mRNA expression but, to our surprise 
cells primed for 4 hours with MDP had a reduced response to the subsequent LPS. LPS 
alone caused a mean 52.4 fold induction of TNFα expression but this was reduced to 40.9 
fold if the cells had been primed with MDP and in terms of IL-1β expression induction was 
reduced from a mean of 51.3 to 44.8 fold induction. 
 
As expected using human PBMC there was considerable interpersonal variation so to allow 
us to compare results between patients I elected to set the effect of LPS alone at 100% and 
any changes are shown in relation to that. Figure 4.2 shows the same data re-analysed with 
the induction level caused by LPS alone set at 100%. We found that, priming with MDP 
significantly reduced the subsequent response of healthy monocytes to LPS from 100% to a 
mean of 77% in TNFα mRNA expression. This is statistically significant (p<0.05). IL-1β 
expression was also significantly down regulated after MDP priming from 100% to 82.4% 
(p<0.05). 
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Figure 4.2-MDP modulation of TNFα and IL1β in mRNA expression in healthy 
PBMC (n=12) 
*p < 0.05 
*p < 0.05   89 
4.2.1  PGN Priming of PBMC in healthy controls  
Prior to this and as part of my pilot studies I also however examined the effect of PGN 
‘priming’  on  monocytes  subsequent  response  to  LPS.  I  used  the  same  experimental 
technique. I hypothesised that PGN would have its effect on monocytes via the breakdown 
product muropeptides and this may be sensed by NOD2. After performing the experiment 
on 5 healthy controls the ‘priming’ effect was seen with PGN but was more pronounced 
with MDP and thereafter I concentrated on MDP and used this in all NOD2 mutants. 
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Figure 4.3 - MDP & PGN modulation of TNFα and IL1β in mRNA expression in 
healthy PBMC (n=5)   90 
4.3  MDP Priming of PBMC from Patients with Crohn’s Disease 
 
I then went on to examine the effect of MDP priming on PBMC from patients with Crohn’s 
disease who were wild type, heterozygous or homozygous for the common disease causing 
mutations in the NOD2 gene. Freshly extracted PBMC from twenty-eight patients with 
Crohn’s  disease  who  attend  the  Inflammatory  Bowel  Disease  clinic  at  the  Royal  Free 
Hospital, London were examined to determine whether the same phenomenon occurred. 
The clinical characteristics of the patients with Crohn’s disease examined are previously 
described in Tables 3.1-3.3.  
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  Figure 4.4 - MDP modulation of TNFα and IL-1β mRNA expression in PBMC 
from Crohn’s patients (n=28)   91 
The same protocol as described in section 4.2 was followed with freshly extracted PBMC 
being stimulated with LPS for 2 hours after 4 hours priming either with or without MDP. 
All  cells  were  then  harvested,  RNA  extracted  and  cDNA  synthesized  as  previously 
described. Quantitative PCR was performed looking at TNFα and IL-1β expression. The 
response to LPS alone was set at 100% and any changes are shown in relation to that. The 
results are seen in Figure 4.4. 
 
Whereas in healthy PBMC, 4 hours MDP pretreatment reduced the subsequent response to 
LPS from 100% to 77%, in PBMC from patients with Crohn’s disease MDP pretreatment 
caused minimal change to the subsequent response to LPS -100% to 97% in terms of TNFα 
expression and 100% to 85% when measuring IL-1β expression. It therefore appeared that 
MDP did not have the same down regulatory affect previously demonstrated in healthy 
PBMC in PBMC from patients with Crohn’s disease.  
 
As MDP is the minimal structural motif  recognized by  NOD2 we therefore speculated 
whether this priming effect may be modified by carrying mutations in the NOD2 gene and 
whether  this  was  the  explanation  of  the  differing  results  between  PBMC  from  healthy 
controls  and  Crohn’s  patients.  We  therefore  looked  at  the  effect  of  MDP  priming  on 
Crohn’s  patients  separately  who  were  wild  type,  heterozygous  or  homozygous  for  the 
common disease causing mutations in the NOD2 gene. There are as before 12 wild type 
Crohn’s patients, 11 Heterozygote and 5 homozygote or compound heterozygote Crohn’s 
patients. 
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4.4  MDP Priming of PBMC across NOD2 genotypes 
4.4.1  MDP Priming of NOD2 +/+ PBMC 
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Figure 4.5 demonstrates that in patients’ wild type for the common disease causing NOD2 
mutations MDP priming does cause a subsequent significantly reduced response to LPS 
stimulation similar to that seen in PBMC from healthy controls. MDP priming caused a 
reduction  in  TNFα  expression  from  100%  to  76%  and  IL-1β  mRNA  expression  was 
reduced from 100% to 72%. These are both statistically significant.  
Figure 4.5-MDP modulation of TNFα and IL1β in mRNA expression in PBMC 
from NOD2 +/+ Crohn’s patients (n=12) 
*p < 0.05 
*p < 0.05   93 
4.4.2  MDP Priming of NOD2 +/- PBMC 
 
Examining  patients  who  are  heterozygous  for  NOD2  mutations  the  down  regulatory 
modulatory response caused by 4 hours pretreatment with MDP is still present. The effect 
of  LPS  is  reduced  from  100%  to  79%  after  MDP  priming  when  measuring  TNFα 
expression and from 100% to 75.7% when measuring IL-1β mRNA expression.  
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*p<0.05 
Figure 4.6-MDP modulation of TNFα and IL-1β in mRNA expression in PBMC 
from NOD2 +/- Crohn’s patients (n=11)   94 
4.4.3.  MDP Priming of NOD2 -/- PBMC 
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When examining patients carrying two disease causing mutations in the NOD2 gene the 
down  regulatory  effect  caused  by  MDP  priming  is  lost  and  indeed  the  response  to 
subsequent LPS is actually increased. TNFα mRNA expression was increased from 100% 
to a mean of 129.5% and IL-1β from 100% to 122.8% It should be emphasised that this 
effect observed is greater than the additive effects of MDP and LPS.  
Figure 4.7-MDP modulation of TNFα and IL1β in mRNA expression in PBMC 
from NOD2 -/- Crohn’s patients (n=5)   95 
4.4.4  MDP Priming compared across genotypes 
 
Whilst this apparent reversal of effect in patients who were homozygous is exciting the data 
must be taken with caution as when we look at the same data as individuals on the scatter 
graph in Figure 4.8 there is significant inter individual variation although the trend is still 
clear. 
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Figure 4.8-MDP modulation of TNFα and IL-1β in mRNA expression in PBMC 
from across NOD2 genotypes   96 
4.4.5  Summary 
In PBMC from healthy controls and patients’ wild type for the common disease causing 
NOD2 mutations, MDP priming for four hours causes a subsequent significantly reduced 
response to LPS and TLR4 mediated immune stimulation in terms of TNFα and IL-1β 
mRNA expression. In Crohn’s disease patients homozygous for NOD2 mutations this down 
regulatory effect of MDP stimulation of NOD2 is lost and indeed the subsequent response 
to LPS is increased. It will be important to confirm these findings in the future in a larger 
patient cohort who are homozygous both in the frameshift mutation and point mutations. 
 
4.5   Discussion 
4.5.1  Human Studies 
 
Since I started my research a synergistic response between NOD2 stimulation by MDP and 
various TLRs has been published both in human and mouse models. These results appear to 
contrast  with  my  own,  and  I  will  discuss  possible  reasons  that  may  account  for  these 
differences. Whilst all confirm that MDP modulates the response to TLR stimulation, some 
show  decreased  cellular  activation  (i.e.  loss  of  function)  whilst  others  show  increased 
cellular activation (i.e. gain of function). I will discuss the mouse models later (Chapter 6) 
but to compare my results with the published human findings (van Heel 2005 & 2005a) I 
will first discuss the differences in experimental technique here between them 
 
The first report of synergistic enhancement of LPS responses by MDP, the NOD2 ligand 
was reported in monocytes by Traub. (Traub 2004) They initially hypothesised that this 
was  due  to  cross  talk  between  extracellular  TLR  signalling  pathways  and  intracellular 
NOD2. 
 
Following this van Heel and colleagues published two papers in 2005 analysing firstly, the 
cytokine  response  of  PBMC  to  varying  doses  of  MDP  and  secondly  the  effect  of  co-
incubating  MDP  with  different  toll  like  receptor  ligands  (van  Heel  2005).  Using 
cryopreserved cells from seven healthy controls wild type for NOD2 and nineteen NOD2 
double mutant genotypes, PBMC were incubated for 22 hours with MDP and either TLR 
2,4,5  or  6  ligands  before  analyzing  cytokine  protein  secretion  using  ELISA-based   97 
techniques. They showed that MDP alone induced little TNFα or IL-1β protein secretion 
(3.9% and 2.3% of amount induced by LPS) but strong IL-8 protein secretion after 22 hours 
incubation (33.6% of the response to LPS). They also confirmed previous findings that the 
response to MDP is reduced in NOD2 double mutants. This was particularly evident at low 
MDP concentrations and in the frameshift mutations. Van Heel et al then demonstrated that 
co-administration of MDP and each of the TLR ligands significantly increased TNFα and 
IL-1β protein secretion. This upregulatory effect was abolished in cells carrying two NOD2 
disease causing mutations 
In  their  second  paper  van  Heel  and  colleagues  specifically  examined  the  effect  of  the 
interaction of TLR9 ligand (CpG DNA) with MDP (van Heel 2005a). Again they used 
cryopreserved PBMC and examined protein cytokine expression by ELISA from 7 healthy 
controls and 19 Crohn’s patients who carried the NOD2 double mutant genotype. They 
showed that concomitant MDP and TLR 9 stimulation caused a marked increase in TNFα 
(2.1 fold) and IL-8 (3.7 fold) protein secretion. This effect was also abolished in the double 
NOD2 mutant genotype.  
 
Van Heel concluded that NOD2 activation by MDP causes an amplification of the innate 
immune response to other pathogens via the TLR system and proposed that the absence of 
this in NOD2 associated Crohn’s disease causes failure of the early pathogen clearance and 
thus an abnormal adaptive immune response. 
 
4.5.2  Possible Confounding factors  
 
 
My data show that MDP priming modulates cellular response to LPS, and that this effect is 
likely to be mediated by the NOD2 protein: MDP-primed PBMC expressing the mutant 
NOD2 proteins encoded by a homozygous mutation in the NOD2 gene increase mRNA 
transcription of TNFα and IL-1β after LPS stimulation. Although I did not measure protein 
secretion in my experiments (due to financial and time constraints) my results contrast with 
those  reported  by  van  Heel  and  colleagues.(van  Heel  2005  &  2005a)  It  is  therefore 
imperative to exclude possible confounding factors, examine differences and to ensure that 
the only predictive difference is in the patients NOD2 status.  I will therefore discuss the 
differences and possible confounding factors in my study here.    98 
4.5.3  MDP concentrations 
 
The concentration of MDP which is relevant both in bacterial infection and bacterial health 
in humans is not known and varying doses have been used. In 2004 Traub demonstrated 
synergy between muropeptides and LPS in human whole blood both at the translational and 
transcriptional level. This was particularly evident at nanomolar concentrations of MDP 
where they showed that as little as 10ng/ml MDP increased the TNFα releasing capacity of 
LPS  4-fold.  They  also  examined  IL-1β,  IL-6  and  IL-10  and  showed  the  effect  was 
consistent though less pronounced in these other cytokines. 
Li  and  colleagues  (Li  2004)  in  their  paper  showed  varying  responses  to  MDP  across 
genotypes and doses. In wild type individuals, MDP-induced IL-8 protein expression with a 
greater response to high dose (1mcg/ml) compared with low dose (10ng/ml) MDP. At low 
MDP doses, in all homozygotes they observed no induction of IL-8 protein. With higher 
doses of MDP only the Leu1007fsins C mutation did not respond.  
 
Van Heel in their studies demonstrated that the differences between homozygote cells and 
wild type cells in terms of IL-8 secretion after stimulation with MDP alone was particularly 
pronounced at low nano molar concentrations of MDP (10ng/ml) but the difference was 
still present though smaller, at higher concentrations. This suggests a change in sensitivity 
rather than an all or nothing effect. Thereafter van Heel used MDP at a dose of 10ng/ml as 
the  maximal  difference  between  wild  type  and  double  mutant  cells  was  seen  at  this 
concentration  and  went  on  to  show  that  MDP  at  this  dose  substantially  up  regulated 
secretion of TNFα and IL-1β induced by TLR ligands and that this effect was abolished in 
cells carrying two NOD2 disease causing mutations.  
 
MDP because of its low molecular weight and water solubility is rapidly excreted from the 
body. After intravenous injection of MDP at 1.5mg/kg into rats, plasma levels immediately 
start to decline (Fosset 2003) such as at thirty minutes after injection the plasma levels fall 
from 27µg/ml to 4µg/ml and MDP was no longer detectable after 2 hours.  
 
In summary the concentrations of MDP which may be relevant both in bacterial infection 
and bacterial health in humans is not known and how these varying doses affect cellular 
responses is not clarified. The concentrations of MDP we used were considerably higher   99 
compared to van Heel and colleagues and may be a factor to explain the difference between 
the results. 
 
4.5.4  Clinical Aspects 
 
As stated previously my results differ from other published human data on the modulatory 
effect of MDP on PBMC responses and another possible difference are the clinical aspects 
of the patients studied. 
 
4.5.4.1  Presence of Disease 
 
Van Heel compared healthy controls, with normal NOD2 with Crohn’s disease patients 
with  double  NOD2  mutants.  They  did  not  examine  patients  with  Crohn’s  with  normal 
NOD2 function so theoretically the differing result between the two groups may be due to 
the presence of Crohn’s disease itself and the NOD2 status is irrelevant. This is unlikely 
however as they report that the PBMC from both groups had similar responses to LPS 
alone (unpublished data)  
 
Li  et  al  in  their  study  (Li  2004)  of  the  effect  of  MDP  mediated  activation  of  PBMC 
demonstrated varying sensitivity of the Crohn’s disease associated NOD2 mutations in their 
response  to  MDP.  However  they  also  demonstrated  that  the  absolute  levels  of  IL-8 
secretion were significantly higher in wild type Crohn’s individuals compared to wild type 
healthy controls suggesting the presence of the disease is a factor in how PBMC respond to 
MDP.  
 
4.5.4.2  Disease Activity 
 
It  is  also  important  to  exclude  whether  the  presence  of  active  inflammation  may  be  a 
confounding  factor  in  our  results  particularly  as  van  Heel  in  his  papers  had  compared 
healthy controls against Crohn’s disease patients with double NOD2 mutants and stated 
that the patients had predominantly quiescent disease. In our cohort it is noted that there 
were many patients with active disease at the time of venesection particularly in the NOD2   100 
homozygote cohort as compared to either the wild type or heterozygote groups.  60% (3/5) 
of the patients carrying 2 NOD2 mutants had active disease compared with only 2 of the 12 
(16.7%) patients wild type for the common disease causing NOD2 mutations and 4 of the 
12 heterozygote (33%) for the common NOD2 mutations. However when examining the 
results of these individual patients in my experiment the presence or not of active disease 
did  not  predict  the  response  to  MDP  priming.  It  remains  possible  however  that  the 
differences may be due in part to the confounding effect of inflammation. One possible 
explanation  for  this  discrepancy  is  that  after  prolonged  exposure  to  high  levels  of 
proinflammatory cytokines and bacterial products in the circulation, these monocytes may 
have become refractory to further stimulation. 
 
4.5.4.3 Treatment 
 
Another  possible  explanation  of  the  differences  is  the  confounding  effect  of  medical 
treatments  particularly  immunosuppressant  therapy.  Amongst  my  cohort 
immunosuppressant  use  with  thiopurines  or  methotrexate  was  proportionally  higher 
amongst patients’ wild type  for NOD2 mutations. 58.3% of patient’s wild type for the 
common  NOD2  mutations  were  on  immunosuppressive  treatment  at  the  time  of 
venesection compared to 40% of patient’s homozygote for NOD2 mutations and 33% of 
heterozygote patients but again looking at individuals their use did not predict response to 
MDP priming. Van Heel commented that there was no difference between the response in 
patients on or off immunosuppressive treatment (van Heel 2005). 
 
There were was only one current user of  Infliximab and they were in the homozygote 
group.  There  were  2  from  each  of  the  heterozygote  and  wild  type  groups  who  had 
previously been exposed to Infliximab and again despite inter individual variation this did 
not enable us to predict the response. 
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4.5.5  Transcriptional / translational level  
 
Traub (Traub 2004) demonstrated synergy between LPS and MDP at both the translational 
and  transcriptional  level  in  PBMC.  Wolfert  (Wolfert  2002)  also  studied  the  effect  of 
synergy examining it in the human monocytic cell line MonoMac 6 cells. Interestingly they 
showed that stimulating MonoMac 6 cells with MDP alone induced a 10 fold induction of 
TNFα mRNA but this did not result in increased TNFα protein expression. Therefore the 
majority of TNFα mRNA induced by MDP is not translated into protein. They suggest that 
MDP induces TNFα gene expression specifically without TNFα translation. They went on 
to demonstrate synergy in the MonoMac 6 cells and reported an increased transcription of 
LPS induced TNFα mRNA when MDP was co-incubated with LPS.  They suggest that the 
apparent synergy between LPS and MDP is due to the removal of the block in translation in 
the presence of LPS. 
 
Li (Li 2004) and colleagues as stated previously demonstrated that MDP induces a broad 
array  of  transcripts  including  IL-1β,  TNFα  and  IL-8  and  that  in  PBMC  with  double 
Leu1007fsinsC mutation there is reduced response to MDP. Furthermore they demonstrated 
that in Leu1007fsinsC homozygotes there was a profound defect in IL-1β protein secretion 
despite a marked induction of IL-1β mRNA after being stimulated with MDP and TNFα 
and  suggested  that  this  would  indicate  that  the  NOD2  pathway  is  involved  in  post 
transcriptional induction of IL-1β expression 
 
Van Heel et al in their studies demonstrated synergy in the cytokine response at the protein 
level after 22 hours of coincubation rather than examining the RNA level. Another key 
difference therefore is that we examined the mRNA level rather than the protein level. It is 
possible  therefore  that  in  our  experiments  TNFα  and  IL-1β  gene  expression  was 
specifically induced without translation into protein as Wolfert has previously suggested. 
(Wolfert  2002)  It  would  be  crucial  and  very  interesting  to  examine  the  supernatants 
collected from my experiments to see if the induction and ‘priming’ effect is seen at the 
protein level. 
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4.5.6    NOD2 mutations 
4.5.6.1    ? True recessive disease 
 
 
We  examined  healthy  controls  and  Crohn’s  disease-affected  patient’s  wild  type, 
heterozygote and homozygote for the common NOD2 mutations whereas van Heel in his 
study only compared healthy controls with 19 Crohn’s patients that were homozygous for 
the  NOD2  mutants.  They  elected  not  to  examine  patient’s  heterozygote  for  NOD2 
mutations for two reasons. Firstly heterozygotes cannot be confidently identified due to the 
presence  of  rare  variants  which  are  known  to  comprise  24%  of  NOD2  homozygotes. 
(Lesage 2002) Secondly Li et al (2004) had reported no difference between wild type and 
heterozygous individuals in MDP stimulated PBMC IL-8 secretion and hypothesised that 
the genetic and biological data are consistent with an entirely recessive model of disease 
with no true heterozygote. They went onto suggest that hetereozygous NOD2 carriers are 
actually  misclassified  double  mutants  carriers,  carrying  a  second  unidentified  disease 
associated mutation.  
 
In our cohort only the 3 common disease causing mutations Leu1007fsinsC, G908R and 
R702W have been identified. This may indeed underestimate the number of homozygotes 
and could have an effect on the results obtained in our heterozygote group. 
 
4.5.6.2    Varying NOD2 mutations 
 
In contrast to wild type and hetereozygotes Li (Li 2004) showed there was an impaired 
response in the NOD2 double mutants or homozygotes to MDP which was most significant 
in the double dose Leu1007fsinsC mutation. In G908R and R702W homozygotes there was 
impairment  of  NF-ĸB  activity  but  this  was  more  modest.  Despite  this  varying  MDP 
sensitivity they demonstrated in vivo each of the three risk alleles had comparable allele 
frequency and genetic risk. Van Heel however although showing that PBMC with NOD2 
double mutants had impaired response to MDP compared to wild type PBMC, commented 
that there was no difference between the 5 different NOD2 double mutant types.    
 
Further subdivision of the double mutants in our cohort into the Leu1007sinsC frameshift 
or  point  mutations  also  did  not  predict  how  PBMC  responded  to  MDP  priming  and   103 
subsequent  LPS  stimulation.  Of  our  cohort  we  have  two  patients  homozygote  for  the 
Leu1007sinsC  frameshift  mutation,  one  homozygote  for  the  R702W  mutation  and  two 
compound heterozygotes but again this did not enable us to predict whether the response 
would be up or down regulatory in terms of MDP priming.  
 
4.5.7    Blood  
 
Peripheral  blood  mononuclear  cells  are  heterogenous  including  B  cells,  T  cells  and 
monocytes. The synergistic effect could be dependent not only on a bystander effect from 
other blood cells but also from serum components. Traub and colleagues examined this and 
demonstrated that synergism was dependent purely on the monocytes (Traub 2004). Van 
Heel (2005a) and colleagues analysed the separate components by immunomagnetic beads 
in their study of peripheral blood mononuclear cells and found no significant difference 
between cell types.  
 
A further difference is that we used freshly extracted PBMC whereas van Heel et al used 
cryopreserved cells. They state (van Heel 2005) that the cryopreservation was according to 
a method reported by Kreher to yield similar results in overnight cytokine assays to fresh 
cells (Kreher 2003). They confirmed this finding in their lab (unpublished). I performed 
their method of cryopreservation and repeated my experimental protocol with concurrent 
fresh  and  previously  cryopreserved  cells  for  1  healthy  control,  1  wild  type  and  1 
homozygote and there was no difference in the pattern or trend but the absolute levels were 
lower  in  the  cryopreserved  cells.  All  other  variables  were  kept  constant.  This  factor 
therefore  appears  to  be  unlikely  to  explain  the  differing  results  but  does  suggest  that 
cryopreservation of PBMC may be a useful strategy to perform future studies. 
 
4.5.8  Technical Issues 
 
Technical issues which were considered include the following. We were careful to use pure 
synthetic ligands (LPS, PGN and MDP) to avoid the risk of contamination by biologically 
active impurities and also eliminate variation in bacterial preparations  
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Another possible explanation is that the LPS was contaminated with MDP and so the effect 
we noted was due to the natural downward curve over time of stimulation with LPS but this 
is not the case as the effect of MDP alone was examined concurrently and had the expected 
minimal pro inflammatory effect.  
 
Another clear difference is that there was concurrent stimulation of PBMC by van Heel’s 
group versus ‘priming’ with MDP alone then subsequent stimulation in our experimental 
protocol.  In vivo it is not known how innate immune pattern recognition receptors are 
triggered as there are many TLR and NOD ligand motifs present on a microbial pathogen. 
 
4.6  Conclusion 
 
In PBMC from healthy controls and patients’ wild type for the common disease causing 
NOD2 mutations MDP priming for four hours causes a subsequent significantly reduced 
response to LPS stimulation in terms of TNFα and IL-1β mRNA expression. In PBMC with 
double NOD2 mutant this down regulatory effect of MDP stimulation of NOD2 is lost and 
indeed the subsequent response to LPS is increased.  
 
Van Heel has published other human data examining TLR and NOD2 stimulation in PBMC 
and they too show that MDP modulates the response to other pathogenic components via 
the  toll–like  receptor  system,  however  whereas  their  data  show  a  functioning  NOD2 
normally enhances the innate immune responses to TLR and this is lost in Crohn’s disease 
patients  homozygous  for  NOD2  mutations  our  data  suggests  the  opposite.  How  this 
translates to the in vivo situation is as yet unclear as it is likely that innate immune pattern 
recognition  receptors  are  not  triggered  one  by  one  but  rather  that  there  is  complex 
activation of multiple receptors taking place concurrently due to the many TLR and NOD 
ligand motifs present on a microbial pathogen. 
 
 
 
   105 
Chapter Five 
5.0  Stimulation of Intestinal Epithelial cells by bacterial ligands  
5.1  Introduction 
Mutations  of  the  NOD2  protein  are  associated  with  increased  susceptibility  to  Crohn’s 
disease. The NOD2 protein is expressed in monocytes and Paneth cells and in previous 
chapters I have shown the results of work examining the response of monocytes carrying 
mutations in the NOD2 gene to bacterial products.  With the more recent exciting discovery 
of NOD2 expression in Paneth cells and with emerging evidence that Paneth cell products 
may be regulated in NOD2 associated Crohn’s disease (Wehkamp 2003) I would have liked 
to examine the effect of NOD2 mutations on Paneth cells function particularly in response 
to  bacteria.  Unfortunately  this  effect  is  more  difficult  to  examine  as  Paneth  cells  from 
human tissues are difficult to obtain and there is no Paneth cell –like cell line. 
 
Paneth cells express both the NOD2 protein and secrete lysozyme. I speculated therefore 
that Paneth cells may play another role in the development of intestinal inflammation that is 
mediated  through  the  actions  of  the  secreted  antimicrobial  product  lysozyme.  Muramyl 
dipeptide  (MDP)  is  the  minimally  active  component  of  peptidoglycan  that  stimulates 
NOD2-mediated cellular responses and it is a synthetic component. In biological systems, 
muropeptides (of which MDP is a commercially available example) are generated by the 
enzymatic action of lysozyme on the peptidoglycan component of the bacterial cell wall. 
Paneth cells are strategically located at the bases of the crypts of Lieberkuhn and secrete 
lysozyme  in  response  to  intestinal  bacteria,  an  action  that  is  likely  to  generate  the 
production of muropeptides.  
 
In  this  chapter  I  therefore  examine  the  effect  of  lysozyme  and  lysozyme  generated 
muropeptides on cellular responses in intestinal epithelial cells.  
5.1.1  Lysozyme 
 
Lysozyme (LZM) is an antibacterial enzyme originally described in 1922 by Alexander 
Fleming.  Lysozyme  is  found  at  significant  concentrations  in  many  human  secretions   106 
including tears, breast milk, saliva and gastric and small intestinal secretions. (Elphick & 
Mahida, 2005)  It is expressed in the intestinal tract by gastric and pyloric glands, duodenal 
Brunners glands, mononuclear cells and granulocytes but most strongly by Paneth cells. 
(Stamp 1992) Lysozyme is a 14kDa cationic enzyme which cleaves the glycosidic bonds 
that  connects  N-acetyl  muramic  acid  with  N-acetylglucosamine  and  which  stabilises 
peptidoglycan, thereby resulting in bacterial lysis. Peptidoglycan (PGN) is the exoskeletal 
component of bacterial cell walls that provide bacteria with shape & mechanical rigidity. 
Lysozyme  is  predominantly  active  against  Gram  positive  bacteria  as  Gram  negative 
bacteria have an outer membrane which makes them relatively resistant to lysozyme. (See 
also Chapter 1.5.3.2.1) 
 
5.1.2  Lysozyme as a Bactericidal Effector 
 
Alexander Fleming also discovered and named a bacterial species now called Micrococcus 
Luteus which was highly susceptible to LZM mediated killing. He proposed that M.luteus 
and certain other bacteria are non pathogenic directly because they are readily destroyed by 
LZM. However lysozyme has also been reported to have a bactericidal activity independent 
of its enzymatic activity and its importance in innate immunity is suggested by the finding 
of reduced lysozyme protein staining in Paneth Cells in newborn infants with necrotising 
enterocolitis, a severe inflammatory intestinal disease that is often fatal. (Coutinho 1998) 
These authors suggest a deficiency of lysozyme, may render the intestine more susceptible 
to bacterial infection and bacterial translocation across the mucosa.  
 
The  role  of  LZM  as  a  bactericidal  effector  has  also  been  suggested  by  Akinbi  and 
colleagues  (Akinbi  2000)  who  studied  mice  transgenic  for  rat  LZM.  The  increased 
production of lysozyme in the respiratory epithelial cells of the transgenic mice, compared 
to control mice enhanced bacterial killing in the lung in vivo, and was associated with 
decreased systemic dissemination of pathogen and increased survival following infection 
with Group B Streptococcus and Pseudomonas aeuroginosa. 
 
Furthermore  Ganz  and  colleagues  (Ganz  2003)  examined  transgenic  mice  deficient  in 
LZM-M.  Unlike  humans  who  have  a  single  LZM  gene,  mice  have  two,  one  encoding 
lysozyme M found in leukocytes and another encoding lysozyme P, normally expressed in   107 
Paneth  cells.  After  challenge  with  the  normally  non  pathogenic  and  highly  lysozyme-
sensitive  bacterium  Micrococcus  luteus  they  demonstrated  more  severe  and  extensive 
lesions in the lysozyme-M deficient mice than in the wild type mice. They proposed that 
the tissue injury was due to the failure of lysozyme–M deficient mice to inactivate PGN 
resulting  in  a  prolonged  and  more  severe  inflammatory  response  and  they  proposed 
therefore that in healthy normal tissues, injury is normally limited by prompt degradation of 
the bacterial macromolecules that trigger innate immunity and inflammation.  
 
Defects in innate immunity may contribute to the development of Crohn’s disease, and as 
lysozyme  has  been  implicated  in  innate  immune  responses  (Ganz  2003)  I  wanted  to 
examine the effects of lysozyme on inflammatory responses in intestinal epithelial cells. 
 
5.2  Aims  
The  biologic  function  of  lysozyme  is  not  fully  defined,  an  apparent  paradox  given  its 
abundance and ubiquitous distribution in animal tissues. Paneth cells secrete lysozyme and 
it  is  very  likely  in  vivo  that  lysozyme  breaks  down  intestinal  bacteria  to  generate 
muropeptides. To mimic this situation in vitro I used lysozyme to generate muropeptides 
and then used these to stimulate intestinal epithelial cells and thus explore the effect both 
lysozyme and lysozyme generated muropeptide stimulation has on inflammatory signaling 
in intestinal epithelial cells. 
 
I  furthermore  wanted  to  determine  whether  lysozyme  induced-inflammatory  responses 
varied from different bacterial species as lysozyme may generate muropeptides that are 
specific to a particular bacterial species or strain.  
 
Ideally, I would like to have examined these responses in Paneth cells but primary Paneth 
cells are difficult to obtain from human tissue and maintain in culture and there is no Paneth 
cell-like cell line. I therefore used an intestinal epithelial cell line SW480 as a surrogate. 
This cell line was chosen because our laboratory has shown that it has the highest level of 
NOD2 mRNA expression compared to other cell lines such as Caco-2 and HT29 cells, and 
also expresses human defensin 5 as measured by PCR. (Ogura 2003) All results obtained 
were analysed using students t- test. 
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5.3  Effect of LZM on SW480 responses to whole bacteria 
I sought to determine the effect LZM had on the response of SW480 cells to bacterial 
stimuli. SW480 cells were propogated in T75 flasks and once 90% confluent were washed 
and transferred to 6 well plates in fresh culture medium and incubated for 16 hours at 37
oc 
overnight. The SW480 cells were then stimulated with whole M.luteus 5 mg/ml either with 
or without LZM 100 mg/ml for 2-8 hours in a 37
oC incubator. 
 
The cells were then harvested at the end time point, RNA extracted and cDNA synthesized.  
qPCR was performed looking at gene expression. Results were normalized for GAPDH 
expression and an ethidium bromide gel was run to examine the size of the PCR products 
and  to  confirm  the  specificity  of  the  reaction.  The  inflammatory  cytokines  examined 
initially  were  IL-8  and  TNFα.  Results  shown  are  the  results  of  at  least  triplicate 
experiments.
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  Figure 5.1 - Effect of micrococcus luteus +/- Lysozyme on IL-8 and TNFα mRNA 
expression in SW480 cells – Time course  
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The  first  result  noted  was  that  LZM  alone  has  no  effect  on  TNFα  or  IL-8  cytokine 
induction. The levels of these proinflammatory cytokines is the same as in the controls at 
all time points over an eight hour period. Whole M.luteus on SW80 cells induces IL-8 
mRNA expression 2.5 fold after 4 hours before plateuxing over the following 4 hours. The 
addition of LZM increases 2 fold the transcription of IL-8 mRNA but not TNFα at both 2 
and 4 hours compared to stimulation with whole bacteria alone. 
 
 
5.3.1  Effect of LZM on SW480 responses to whole bacteria – Dose response 
 
Having established a time course and showing maximal difference at 4 hours I used the 
same method to establish a dose response effect. (Figure 5.2) This shows that the addition 
of  LZM  to  M.luteus  increases  the  transcription  of  IL-8  mRNA  but  not  TNFα  mRNA 
expression compared to stimulation with whole bacteria alone. The results also confirm that 
LZM alone has no effect on inducing IL-8 or TNFα mRNA expression in SW480 cells. 
M.luteus alone induces IL-8 mRNA and TNFα mRNA expression in increasing amounts 
relative to the dose of M.luteus but this proinflammatory effect was weak. 
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Based on these transcription mRNA results that lysozyme may affect IL-8 and other pro-
inflammatory signaling cytokines I wanted to minimise the role of other possible bacterial 
antigens such as LPS and thus used commercially available PGN, the substrate on which 
lysozyme has its effect to determine the specificity of the cellular responses induced by 
lysozyme. 
 
Figure 5.2 - Effect of micrococcus luteus +/- Lysozyme on IL-8 and TNFα mRNA 
expression in SW480 cells – Dose response 
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5.4  Effect of LZM on SW480 responses to PGN Staph.aureus 
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I also wanted to determine whether LZM acting on PGN from different bacterial species 
would produce different muropeptides and thus a different inflammatory response from 
SW480 cells and so we compared PGN from different species. PGN from staphlycoccus 
aureus (a gram positive cocci), and bacillus subtilis (a gram positive rod) were initially 
compared. The same experimental protocol was followed and again the results shown are 
the results of a minimum of 3 experiments 
 
SW480’s were incubated with PGN at a dose of 10µcg /ml with or without LZM at a dose 
of 100mg/ml.  The cells were then harvested, RNA extracted and cDNA synthesized. qPCR 
was  performed  looking  at  gene  expression.  Results  were  normalized  for  GAPDH 
expression and specificity confirmed by ethidium bromide gel visualization. 
Figure 5.3 Effect of PGN s.aureus +/- Lysozyme on IL-8 mRNA expression in 
SW480 cells – Time course 
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The  results  of  stimulation  with  PGN  from  S.aureus  showed  that  LZM  alone  has  no 
inflammatory response but PGN from S.aureus causes a 10 fold induction in IL-8 mRNA 
expression which is maximal at 4 hours and this effect is multiplied by a factor of four with 
the  addition  of  LZM  (Figure  5.3).  This  is  statistically  significant  p<0.05  at  4  hours 
(p=0.027)  but  does  not  reach  significance  at  2  or  6  hours  and  by  8  hours  the 
proinflammatory effect was diminished.  
 
We also looked at the expression of TNFα and Human β defensin 2 (HbD2) and the results 
can be seen in Figures 5.4 & 5.5. LZM alone had no effect on TNFα expression throughout 
the time period studied. PGN S.aureus induced a mean 13 fold induction in TNFα at 4 
hours and this was increased to 18 fold with the addition of LZM.  
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I also examined the expression of Human β defensin 2 (HbD2) after stimulation with PGN 
S.aureus as I wanted to determine whether LZM acting on PGN induced the transcription 
of  other  genes,  apart  from  inflammatory  cytokines,  that  are  directly  involved  in  the 
Figure 5.4 - Effect of PGN s.aureus +/- Lysozyme on TNFα mRNA 
expression in SW480 cells – Time course 
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generation  of  antimicrobial  molecules  such  as  the  defensins.  When  examining  HbD2 
expression the increase with LZM was more pronounced at 4 hours from 20 fold to 80 fold 
induction. At 4 hours this reached statistical significance (p<0.05) but at all other time 
points it did not. Again LZM alone had no inflammatory activity at any time point. 
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Figure 5.5 - Effect of PGN s.aureus +/- Lysozyme on HBD2 mRNA expression in 
SW480 cells – Time course 
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5.5  Effect of LZM on SW480 response to PGN Bacillus Subtilis 
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When  examining  PGN  from  B.subtilis  a  gram  negative  rod  this  bacteria  was  again  a 
powerful stimulant of IL-8 expression and marker of NF-ĸB activity in SW480 cells. At 2 
hours there was a mean 56 fold induction in IL-8 expression which was augmented to 122 
Figure 5.6 - Effect of PGN B.subtilis +/- Lysozyme on IL-8 and TNF α mRNA 
expression in SW480 cells – Time course 
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fold induction with the addition of LZM. At 4 hours the effect is still marked with a 21 fold 
induction being increased to 91 fold with the addition of LZM.  The effect of LZM on 
TNFα is more modest and is only seen at 2 hours. There is a 28 fold induction in TNFα 
expression which is increased to 50 fold with the addition of LZM. By 4 hours there is no 
difference between the cells given LZM or not. (Figure 5.6) 
 
In summary when comparing the results of the effect of muropeptides derived from LZM 
acting on PGN from S.aureus and B.subtilis in terms of IL-8 and TNFα mRNA I have 
shown that PGN alone induces an inflammatory response and that this response is enhanced 
by  lysozyme.  Furthermore  there  are  differences  in  different  bacterial  species  derived 
muropeptides.  
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5.6  Effect of LZM on SW480 response to E.coli LF82 
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I also examined the effect of E.coli LF82 on SW480 but the results from this are obviously 
complicated by the fact that it was not pure a pure synthesised PGN and thus the bacteria 
could trigger the inflammatory pathway by a variety of TLRs including TLR2, TLR 4 and 
CD14 as well as through PGN breakdown products. I examined E. Coli LF82 because as 
discussed earlier (Ch1.3.4.3) adherent invasive Escherichia coli have been proposed as a 
Figure 5.8 - Effect of E.Coli LF82+/- Lysozyme on IL-8 and TNF α mRNA 
expression in SW480 cells – Time course 
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causative role in the initiation of Crohn’s disease. Strain LF82 was isolated from a chronic 
lesion of a Crohn's disease patient and has previously been extensively studied (Martin 
2004, Darfeuille-Michaud 2004) 
 
Accepting these limitations the results show (Figure 5.8) that E.coli LF82 is a powerful 
inducer of IL-8 causing a mean 161 fold induction at 2 hours. The effect of LZM does 
increase this response to a mean 204 fold induction at 2 hours whereas again LZM alone 
has no proinflammatory activity. At 4 hours onwards the response has reduced and there is 
no difference elicited by the addition of LZM. When examining TNFα mRNA expression 
this is again maximal at 2 hours but considerably less. At 2 hours there is a mean 50 fold 
induction  in  TNFα  expression  by  E.Coli  alone  and  the  addition  of  LZM  causes  this 
induction to be non significantly higher at 55 fold. 
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5.7  Effect of LZM on SW480 responses to whole bacteria –other 
cytokines
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I studied other cytokines to see if the effect of LZM was a general phenomenon or specific 
to certain cytokines. Angiogenesis-promoting cytokines have been suggested to play an 
important role in inflammatory bowel disease (IBD) since they promote inflammation by 
increasing  vascular  permeability  and  mediate  tissue  repair  by  activating  fibroblasts. 
(Hooper  2003)  Serum  angiogenin  a  protein  with  both  angiogenic  and  ribonucleolytic 
activity is elevated in patients with IBD. (Koutroubakis 2004) We looked at Angiogenin, 
RNAse4 and Human Defensin 6 expression to see if these were induced by either whole 
m.luteus,  LZM  or  in  combination.  Figure  5.9  shows  there  was  no  increase  in  mRNA 
Figure 5.9 - Effect of micrococcus luteus +/- Lysozyme on Angiogenin, RNAse4 
and HD6 mRNA expression in SW480 cells 
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expression after stimulation with m.luteus and this was unchanged with the addition of 
LZM over an 8 hour period. I did not examine them further. 
 
5.8   Conclusion 
 
I  have  shown  that  LZM,  possibly  through  the  generation  of  bacterial  muropeptides 
enhances  inflammatory  signalling  in  the  intestinal  epithelial  cell  line  SW480.  LZM 
enhanced whole M.luteus induced IL-8 mRNA transcription from SW480cells and LZM 
also enhanced PGN S.aureus and B.subtilis induced IL-8 mRNA transcription. I have also 
shown that lysozyme alone has no proinflammatory effect on SW480 cells. 
 
My results suggest that cellular inflammatory responses may be dependent on the specific 
muropeptides derived from different bacterial species. The different PGN studied, S.aureus 
and  B.subtilis,  produced  different  responses  in  terms  of  magnitude  of  IL-8  mRNA 
transcription  and  differing  responses  in  terms  of  the  other  proinflammatory  cytokines 
examined.  
 
LZM acting on PGN S.aureus induced significant response in terms of IL-8 and HbD2 
mRNA transcription from SW480 cells and the effect of LZM increased this 4 fold whereas 
the response in terms of TNFα was only doubled with the addition of LZM. This effect was 
maximal at 4 hours. The response of PGN B. subtilis was most marked at 2 hours and the 
addition of LZM increased the response 2 fold in terms of IL-8 and TNFα but without 
having any effect on HbD2 expression (figure not shown) 
 
E.Coli LF82 alone induced high levels of TNFα mRNA. Although this was increased by 
the addition of LZM the effect was less pronounced. This may be relevant as it is possible 
that this strain is pathogenic in Crohn’s disease and LZM may not be so important in terms 
of the proinflammatory response.   
 
To answer the question does lysozyme allow cells to distinguish between different bacterial 
species it would be useful to examine all cytokines preferably by micro array and also the 
response to PGN from a wide variety of Gram negative cocci and rod. I also only measured   120 
mRNA levels not protein levels by ELISA due to cost and time constraints. In future it 
would be useful to look at both the transcription and translational levels.  
 
PGN alone is known to be sensed through Toll like receptor 2 whereas its breakdown 
product, after the addition of lysozyme, muropeptide has been demonstrated to be NOD2. It 
therefore would be crucial and interesting to block Toll like receptor 2 and thereby limit the 
response of the SW480 to the muropeptide induced response alone. I would expect this to 
have no effect on the results obtained. We attempted to do this but were unable to entirely 
block TLR-2. For completeness it would be good to also inhibit TLR 4 and CD14 and show 
that the response is entirely due to lysozyme mediated breakdown product of PGN and not 
any other bacterial impurities.  
 
The  response  of  SW480  cells  to  PGN  is  augmented  by  the  addition  of  LZM  which 
presumably breaks down the PGN to produce muropeptides which may be recognized by 
the NOD2 protein. I could not study the effect of NOD2 in this system but in future it 
would also be interesting to determine whether the response depended on NOD2. It would 
be interesting to examine the effect of LZM on bacterial signalling in an intestinal cell line 
which did not express NOD2 such as HT29 cells and then transfect NOD2 in and then 
repeat the experiments stimulating them with PGN with or without lysozyme. 
   121 
Chapter Six 
6.0  Discussion 
6.1  NOD2 and Crohn's disease 
A  paradox  which  has  become  central  to  understanding  the  role  of  NOD2  in  the 
pathogenesis  of  Crohn’s  disease  is  that  in  transfection  studies,  NOD2  mutations, 
particularly the frameshift mutation are associated with reduced NF-ĸB activation in 
response to MDP stimulation (Inohara 2003, Giardin 2003) whereas Crohn’s disease is 
characterised  by  increased  NF-ĸB  activation  and  subsequent  downstream  effects  on 
cytokine production and immunoregulation (Chamaillard 2003, Podolsky 2002).  
 
Using both experimental animal and human studies several groups, including ourselves 
have  therefore  sought  to  illuminate  the  mechanism  whereby  NOD2  mutations 
predispose to Crohn’s disease. Thus far they have not resolved the paradox and the data 
remains discrepant.  
 
The data I have presented here adds to this.  
 
The results from examining the murine studies reveal the complexity of understanding 
NOD2  function  and  its  role  in  the  pathogenesis  of  Crohn's  disease.  Several  of  the 
hypotheses that have been given to explain the observations in the murine studies can be 
divided conceptually into those suggesting that mutant NOD2 is defective in performing 
critical  functions  required  for  limiting  inflammation  -  “loss-of-function”,  and  those 
proposing that mutant NOD2 proteins activate pro-inflammatory pathways - “gain-of-
function”. However, these hypotheses are not mutually exclusive and it may be that to 
categorise  the  NOD2  mutation  as  a  loss  or  gain  of  function  may  be  an 
oversimplification of mechanisms in vivo. 
 
6.2  NOD2 Loss of Function or Gain of Function - Murine studies 
 
There have been three reports of NOD2 and TLR function studied in murine models 
where the NOD2 gene has been modified. Two ‘knock-out’ murine models have been 
developed (Pauleu 2003 and Kobayashi 2005) and one murine model with a targeted 
defect  similar  to  the  human  Leu1007fsinsC  mutation  (Maeda  2005)  has  also  been   122 
developed. In all models the mice appear to be healthy and fertile, indicating that the 
protein has no critical developmental functions.  
 
Watanabe and colleagues (Watanabe 2004) using the NOD2 ‘knock-out’ mouse model, 
showed that the NOD2 protein acts as an important regulator of NF-ĸB activation in 
response  to  the  TLR2  activation  system.  They  showed  that  MDP  suppressed  TLR2 
induced NF-ĸB activation in wild type cells.  However in the NOD2 ‘knock-out’ mouse, 
this  down  regulatory  process  did  not  occur  and  proinflammatory  cytokines  were 
produced with a TH1 profile similar to that found in Crohn’s disease. This suggests that 
MDP acting via NOD2 normally inhibits PGN mediated TH1 responses via TLR2. 
 
Subsequently  Maeda  and  colleagues  (Maeda  2005)  generated  mice  with  a  targeted 
defect  similar  to  the  human  Leu1007fsinsC  mutation  and  outwardly  they  were  also 
healthy and fertile. Firstly, in contrast to transfection studies, they showed that in bone 
marrow derived macrophages (BMDM) isolated from control and NOD2 mutant mice, 
MDP induced greater NF-κB activation and IL-1β secretion in the mutant mice. They 
then looked at combined TLR2 and NOD2 activation with PGN and MDP and found no 
inhibitory  function  of  NOD2  thus  not  replicating  Watanabe’s  findings.  These 
investigators went on to assess the response to dextran sodium sulphate and showed 
increased  intestinal  inflammation,  increased  IL-1β  secretion  and  increased  mortality 
rates in the NOD2 mutant mice in comparison to the wild-type mice. These results 
suggest that the frameshift mutation is a gain-of-function allele and are the opposite of 
those found in most published human studies. 
 
In  contrast however  Kobayashi  generated NOD2  ‘knock-out’  mice  which  were also 
outwardly healthy with no evidence of intestinal inflammation after six months and they 
stimulated BMDM with TLR2, 3 and 4 ligands (Pam3CS, RNA and LPS respectively) 
with or without MDP. They showed increased IL-6 and IL-12 secretion in wild type but 
not mutant mice stimulated with TLR ligands and MDP. They also went on to examine 
the  effect  of  MDP  pre-treatment  on  the  mouse  prior  to  endotoxic  shock  by  LPS 
injection and showed that pre-treatment with MDP then subsequent LPS was fatal to 
wild type mice but knock out mice were protected and resistant to LPS challenge. LPS 
alone showed similar effect and survival in both groups. 
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They then went on to investigate the role of NOD2 in the innate immune response 
against  bacterial  infection.  NOD2  -/-  mice  were  more  susceptible  to  oral  but  not 
systemic infection with the enteric bacterial pathogen Listeria monocytogenes. This was 
paralleled by decreased expression of the Paneth cell α-defensin, similar to the human 
findings  by  Wehkamp  (Wehkamp  2004)  suggesting  that  NOD2  plays  a  pivotal  and 
specific role in protecting against bacterial infections in the intestine. 
 
They conclude by suggesting that mutations in NOD2 may promote Crohn’s disease 
through defective regulation of  responses  to commensal and or pathogenic bacteria, 
rather than as an initiating factor for disease. 
 
6.3  NOD2 Loss of Function or Gain of Function - Human studies 
 
The synergistic effects between MDP and TLR’s demonstrated by Kobayashi in NOD2 
‘knock-out’ mice have also been demonstrated in human studies. (Yang 2001, Uehara 
2004 & van Heel 2005). Yang (2001) showed that MDP alone exhibited a weak ability 
to induce secretion of inflammatory cytokines but a marked synergistic effect with LPS 
and LTA was demonstrated in human monocytic THP-1 cells. Uehara (2004) went on to 
demonstrate that MDP exhibited significant synergistic effects with TLR2, TLR4 and 
TLRP9  agonists  to  induce  the  production  of  proinflammatory  cytokines  in  human 
monocytic  cells.  They  also  showed  that  NOD2  was  responsible  for  the  synergistic 
effects.  Van  Heel,  as  previously  discussed  in  Chapter  4,  showed  in  cryopreserved 
monocytes that MDP upregulated secretion of TNFα and IL-1β induced by TLR ligands 
in wild type cells but that this effect was abolished in NOD2 homozygotes.  
 
The results I show here contribute more data; my results are not definitive but indicate 
that the mechanisms whereby NOD2 gene mutations contribute to Crohn’s disease are 
likely to be complex. I have shown that cellular activation is reduced in MDP stimulated 
PBMC expressing mutant NOD2 proteins and these results are consistent with other 
reports (Ogura 2001, Inohara 2003 & Li 2004). I have, however, also shown that there 
are  conditions  whereby  mutant  NOD2  proteins  predispose  to  the  development  of 
enhanced inflammatory  responses  in PBMC primed by  MDP.  I  have  shown that in 
PBMC not expressing the common NOD2 gene mutations, MDP inhibits the subsequent 
response to TLR4 activation by LPS; however, in PBMC expressing 2 mutant NOD2 
alleles, this effect is reversed. This is the first human data which supports the findings of   124 
Watanabe and colleagues who also demonstrated that mutant NOD2 lacks an inhibitory 
function.  Within  the  intestinal  milieu,  it  is  likely  that  bacterial  antigens  continually 
stimulate immune responses, and I speculate that priming may well be an important 
phenomenon that determines inflammatory and immune response. 
 
It adds to the theory that intracellular activation of NOD2 by MDP modulates the innate 
immune  response  to  other  pathogens  via  the  extracellular  TLR  system.  Possible 
explanations for the marked difference between studies (discussed in chapter 4) may be 
the different cell types used, the variable concentrations of ligands particularly MDP 
used, or the use of NOD2 expression ‘knock-out’ mice or over expressing transfected 
cells rather than the more subtle human mutations. 
 
6.4  NOD2 modulates the TLR system 
 
Although traditionally our understanding has been that TLR recognition triggers the 
innate immune system leading to an inflammatory response, a protective role of TLR 
activation by intestinal commensal bacteria has been demonstrated. (Rakoff-Nahoum 
2004) Under steady state conditions activation of TLRs by commensal microflora was 
critical for tissue repair and protection against intestinal injury and associated mortality. 
Furthermore in vivo it is likely that innate immune pattern recognition receptors are not 
triggered by single ligands but rather that complex activation of multiple receptors takes 
place concurrently due to the many TLR and NOD ligand motifs present on a microbial 
pathogen. (Sansonetti 2004, Philpott 2004)  
 
I postulate that dual signalling via both TLR and NOD pathways may be necessary for 
efficient innate immune responses and that in the presence of abnormal NOD2 this 
process is compromised resulting in an abnormal initial defense against commensal and 
pathogenic  bacteria  or  an  abnormal  tolerance  mechanism  which  is  critical  in 
maintaining controlled activation of the immune system in the intestine.  
 
6.5  Mechanism of interaction with TLR system 
The hypothesis that extracellular TLR and intracellular NOD2 participate together as 
pattern recognition receptors in regulating the mucosal immune responses to intestinal   125 
microbes is an attractive one; however, the mechanism of interaction between the TLR 
system and NOD2 activation by MDP is as yet unclear. 
It has been demonstrated that NOD2 interacts with RICK to activate NF-ĸB activation. 
Kobayashi showed using mouse cells deficient in RICK reduced cytokine production 
after stimulation with LPS and PGN but not bacterial CpGDNA indicating that RICK is 
downstream of TLR2 and 4 but not TLR9 (Kobayashi 2002). Van Heel’s human data 
showing  synergistic  enhancement  of  CpGDNA  with  MDP  would  also  suggest  a 
mechanism  other  than  via  RICK.  There  have  been  recent  papers  describing  other 
components  of  the  innate  immune  pathway  which  interact  with  and  modify  NOD2 
function – RIP2 and NEMO (Abbott 2004) NALP3 (Martinon 2004) and GRIM 19 
(Barnich  2005)  all  of  which  are  involved  with  PAMP  recognition  and  have  a 
downstream effect on NF-ĸB activation and which may be implicated in the future.  
 
6.6  The Future 
 
Since 2001 and the discovery of NOD2, a new technique has been developed which has 
accelerated genetic research. Following the completion of the human genome sequence 
it  has  been  possible  to  perform  genome  wide  association  studies  (GWAS)  which 
provide  systematic  assessment  of  the  contribution  of  common  variation  to  disease 
pathogenesis. These GWAS have resulted in the identification of many novel loci which 
all confer risk to Crohn’s disease. They have also further highlighted the importance of 
the innate immune system and implicated other new pathogenic pathways. 
.  
In 2006 the North American IBD Genetics Consortium provided strong evidence for an 
association  between  ileal  Crohn's  disease  and  the  IL23R  gene  using  genome-wide 
association studies (Duerr 2006) and this was replicated in a British population in 2007 
(Tremelling 2007).  IL23 is a critical cytokine in the differentiation of T-helper cells 
especially their differentiation into Th17 T cells (Steinman 2007). In animal models it 
has been shown that Th17 Tcell subset mediates chronic inflammatory conditions and 
furthermore that IL23 is essential for the development of intestinal disease (Hue 2006).  
 
A  subsequent  GWA  reported  a  SNP  in  ATG16L1  on  chromosome  2,  a  gene 
homologous  to  the  essential  yeast  autophagy  gene  ATG16,  to  be  associated  with 
Crohn’s disease. (Hampe 2007) This was subsequently replicated in the UK. (Prescott   126 
2007) The ATG16L1 protein is expressed in the colon, small intestine and leukocytes 
and is involved in the autophagy pathway. This is a cellular pathway involved in protein 
and  organelle  degradation  and  mediates  resistance  to  intracellular  pathogens. 
Interestingly autophagy is critical in inhibiting Mycobacterium tuberculosis survival in 
macrophages. (Gutierrez 2004) Increased susceptibility to Crohn’s disease secondary to 
a defective autophagy mechanism (in the case of mutation in ATG16L1) strengthens the 
hypothesis previously explored that interactions with the intestinal microflora play a 
significant role in the pathogenesis of Crohn’s. 
 
Recently exciting studies by Cadwell and Saitoh have provided further insight into this 
mechanism by demonstrating the effect the autophagy pathway has on the biology of 
Paneth cells. (Cadwell 2008, Saitoh 2008)  Cadwell and colleagues generated mice with 
reduced ATG16L1 protein expression and elegantly demonstrated a striking reduction 
in  the  secretion  of  Paneth  cell  antimicrobial  granules  into  the  intestinal  lumen.  In 
addition  microarray  analysis  showed  that  there  was  up  regulation  of  certain  genes 
associated with the inflammatory response in autophagy deficient Paneth cells. They 
went on to show in Crohn’s disease patients who were homozygous for the ATG16L1 
risk allele that they too had similar abnormal Paneth cell granule secretion.  
Saitoh demonstrated in mice that ATG16L1 is an essential component of the autophagic 
machinery  responsible  for  control  of  the  endotoxin-induced  inflammatory  immune 
response.  (Saitoh  2008)  Following  stimulation  with  lipopolysaccharide,  ATG16L1-
deficient macrophages produced high amounts of the inflammatory cytokines IL-1β and 
IL-18. Furthermore mice lacking ATG16L1 were highly susceptible to dextran sulphate 
sodium-induced acute colitis, which was then alleviated by injection of anti- IL-1β and 
IL-18  antibodies  thus  indicating  the  importance  of  ATG16L1  in  the  suppression  of 
intestinal inflammation. 
The last few years have been exciting times in the search for the aetiology of Crohn’s 
disease. The loci identified all encode for genes involved in a variety of mechanisms 
which  give  insight  into  the  pathophysiology  of  Crohn’s:–  NOD2  which  I  studied  - 
pathogen  recognition,  ATG16L1  -  autophagy,  IL23R  -  the  differentiation  of  Th17 
lymphocytes. The identification of all these loci is however the first step and further 
studies are needed into their functional implications and also the relative contribution of 
each pathway to the pathophysiology of Crohn’s disease.    127 
Despite these developments the association of the three common NOD2 mutations and 
Crohn’s  disease  remains  the  most  important  genetic  susceptibility  factor  thus  far 
identified. The function of the NOD2 protein as already discussed however is not yet 
definitively established and the pathogenic mechanisms whereby mutant NOD2 proteins 
lead to the development of Crohn’s disease remains to be defined. The mucosal immune 
system is the central effector of intestinal inflammation and injury and the evidence 
indicates that there is dysregulation of mucosal immunity in Crohn’s. Under normal 
situations, the intestinal mucosa is in a state of "controlled" inflammation regulated by a 
delicate balance of proinflammatory (TNFα,  IL1β IL-6, IL-12) and anti-inflammatory 
cytokines (IL-4, IL-10, IL-1) As the mucosal immune system is continually responding 
to commensal bacteria and rarely activates the systemic immune system, experiments 
which have thus far been done in both transfected cell lines and human PBMC may be 
of limited relevance to how NOD2 causes intestinal inflammation. 
Until very recently, the function of Paneth cells, first described over 100 years ago, had 
remained  obscure.  Recently,  however,  the  importance  of  these  cells  has  been 
highlighted firstly with  the identification of  NOD2 in them  and more recently with 
ATG16L1. Further studies are  needed therefore into the relative  contribution  of the 
effect of mutations in both NOD2 and ATG16L1 on Paneth cell function and I think 
will be critical to our understanding of the pathophysiology of Crohn’s.  
The other critical unanswered question is how the environment, for example smoking 
interacts with the genetic make up to determine Crohn’s susceptibility and this will be 
imperative to clarify. 
Finally it is worth remembering that despite the great advances in the understanding of 
the pathophysiology of Crohn’s there has been limited impact on either the diagnosis, 
management  or  treatment  of  Crohn’s  disease.  Newer  therapeutic  targets  have  been 
identified (such as IL23) but the transition from the lab bench to the clinical setting has 
yet  to  be  made.  The  most  likely  first  impact  on  patient’s  lives  will  be  of  tailoring 
treatment strategies to the individual’s genetic make up. 
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Appendix B: The Vienna Classification of Crohn's disease 
 
Age at diagnosis
1:   A1, <40 years 
  A2, ≥40 years 
 
Location
2:   L1, Terminal ileum
3 
  L2, Colon
4 
  L3, Ileo-colon
5 
  L4, Upper gastrointestinal
6 
 
Behavior:  B1, Non-stricturing non-penetrating (i.e. 
inflammatory)
7  
  B2, Stricturing
8 
  B3, Penetrating
9 
1. The age when diagnosis of Crohn's disease was first definitively established by radiology, 
endoscopy, pathology or surgery. 
2. The maximum extent of disease involvement at any time before the first resection. 
Minimum involvement for a location is defined as any aphthous lesion or ulceration. 
Mucosal erythema and oedema are insufficient. For classification, at least both a small 
bowel and large bowel examination are required. 
3. Disease limited to the terminal ileum (the lower third of the small bowel) with or without 
spill over into caecum. 
4. Any colonic location between caecum and rectum with no small bowel or upper 
gastrointestinal (GI) involvement. 
5. Disease of the terminal ileum with or without spill over into caecum and any location 
between ascending colon and rectum. 
6. Any disease location proximal to the terminal ileum (excluding the mouth) regardless of 
additional involvement of the terminal ileum or colon. 
7. Inflammatory disease which never has been complicated at any time in the course of 
disease. Also known as ‘uncomplicated’ or ‘inflammatory’ 
8.Stricturing disease is defined as the occurrence of constant luminal narrowing 
demonstrated by radiologic, endoscopic or surgical-pathologic methods with prestenotic 
dilatation or obstructive signs/ symptoms without presence of penetrating disease at any 
time in the course of disease.   148 
9. Penetrating disease is defined as the occurrence of intra-abdominal or perianal fistulas, 
inflammatory masses and/or abscesses at any time in the course of disease. Perianal ulcers 
are also included. Excluded are postoperative intra-abdominal complications and perianal 
skin tags.    149 
Appendix C: List of reagents and suppliers 
  Name of reagent  Supplier 
1  100x Antibiotic antimycotic solution: 10 000 U 
penicillin, 10 mg streptomycin, and 25 µg 
amphotericin B per mL  Sigma 
2.  10x Trypsin-EDTA solution: 5.0 g porcine trypsin, 
2.0 g EDTA⋅4 Na in 0.9% NaCl 
Sigma 
3.  5X First Strand Buffer [250 mM Tris-HCl (pH 8.30, 
375 mM KCl, 15 mM MgCl2]  Invitrogen 
4  Agarose  Sigma 
5  Chloroform  Sigma 
6  Deoxyadenosine triphosphate (dATP) 100 mM  Invitrogen 
7  Deoxycytidine triphosphate (dCTP) 100 mM  Invitrogen 
8.  Deoxyguanosine triphosphate (dGTP) 100 mM  Invitrogen 
.  Deoxythymidine triphosphate (dTTP) 100 mM  Invitrogen 
9.  Diethyl-pyrocarbonate (DEPC)  Sigma 
10.  DMEM/F12 medium  Sigma 
13.  Dulbecco’s modified Eagle medium (DMEM)  Sigma 
14.  EDTA (pH 8.0) Ethylenediaminetetraacetic acid  Sigma 
15.  Ethanol  VWR 
16.  Ethidium bromide  Sigma 
17.  Ficoll 400  Sigma 
18.  Hanks’ balanced salt solutions (HBSS)  Sigma 
19.  Histopaque® 1077  Sigma 
19.  Isopropanol  VWR 
20.  L-Glutamine, 200 mM  Sigma 
70.  Magnesium chloride (MgCl2)  Sigma 
21.  Moloney Murine Leukemia Virus Reverse 
Transcriptase (M-MLV RT) (200 units/ µL) 
Invitrogen 
22.  Nuclease-free water  Invitrogen 
23.  Oligo(dT)12-18 primer  Invitrogen 
24.  Phosphate Buffered Solution (PBS)  Sigma 
90.  Q Solution  Qiagen   150 
  Sense and antisense primers   Thermo Electron 
GmbH 
  SYBR green  Biogene 
25.  Trizol reagent  Invitrogen 
List of Suppliers: 
Amersham Biosciences UK Limited 
Amersham Place 
Little Chalfont 
Buckinghamshire 
HP7 9NA  
United Kingdom 
 
 
Eppendorf Scientific Incorporated 
One Cantiague Road 
P.O. Box 1019 
Westbury 
New York 
11590-0207 
USA 
Phone: 00 1 800-421-9988 
Fax: 00 1 516-876-8599 
Email: eppendorf@eppendorfsi.com 
UK distributor: VWR International 
 
Invitrogen Limited 
3 Fountain Drive 
Inchinnan Business Park 
Paisley 
PA4 9RF 
United Kingdom 
Phone: 0141 814 6100 
Fax: 0141 814 6260 
 
LCG Promochem 
Queen's Road 
Teddington 
Middlesex 
TW11 0LY 
London 
United Kingdom 
Phone: 020 8943 7000 
 
Qiagen Limited 
Qiagen House 
Fleming Way 
Crawley 
West Sussex   151 
RH10 9NQ 
United Kingdom 
Phone: 01293 422 911 
Fax: 01293 422 922 
 
Sigma-Aldrich Company Limited 
The Old Brickyard 
New Road 
Gillingham 
Dorset 
SP8 4XT 
United Kingdom 
Phone: 0800 717181 
Fax: 0800 378785 
Email: ukorders@europe.sial.com 
 
Thermo Electron GmbH 
Sedanstrasse 18 
89077 Ulm 
Germany 
Phone: +49-(0)731-935 79 290 
Fax: +49-(0)731-935 79 291 
Email: sales.oligos@thermo.com 
 
VWR International Limited 
Merck House 
Poole 
Dorset 
BH15 1TD 
United Kingdom 
Phone: 01202 660 444  
 